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1 Summary 
The von Hippel-Lindau (VHL) tumour suppressor gene is biallelically inactivated in 70 - 90% of 
sporadic clear cell renal carcinomas (ccRCC). However, loss of pVHL function alone is not 
sufficient to cause tumour formation in human or mouse kidneys, indicating that additional 
cooperating mutations are likely to be involved in tumour initiation. The protein product of the 
VHL locus, pVHL, possesses numerous potential tumour suppressor functions, including 
regulation of the HIFα transcription factors. Nuŵeƌous ƌeĐeŶt studies haǀe suggested that HIFϭα 
iŶhiďits aŶd HIFϮα pƌoŵotes the pƌolifeƌatioŶ of estaďlished ĐĐRCCs, hoǁeǀeƌ the ƌoles of these 
proteins in the initiation of ccRCC remain unclear. We show that simultaneous deletion of Vhl 
and Hif1a or Vhl and Hif2a in mouse kidneys does not induce cyst or tumour formation, indicating 
that eitheƌ Hifϭα oƌ HifϮα staďilizatioŶ aloŶe does Ŷot ƌepƌeseŶt aŶ oŶĐogeŶiĐ eǀeŶt, eǀeŶ ǁheŶ 
combined with loss of the multiple tumour suppressor activities of pVHL. Cell culture studies, 
hoǁeǀeƌ, suppoƌt the ŶotioŶ that Hifϭα aĐtiǀatioŶ iŶhiďits Đellulaƌ pƌolifeƌatioŶ. AďlatioŶ of Vhl 
in primary mouse embryonic fibroblasts (pMEFs) causes Trp53-dependent senescence and is 
accompanied by changes in cellular metabolism that decrease O2 consumption and impair ATP 
production. These effects are rescued by the additional deletion of Hif1a, but not of Hif2a, 
iŵplǇiŶg that Hifϭα staďilizatioŶ iŶduĐes ŵetaďoliĐ stƌess that iŶhiďits Đellulaƌ pƌolifeƌatioŶ. 
Consistently, downregulation of Hif1a in Vhl/p53-deficient pMEFs accelerates proliferation of 
pMEFs and enhances the transformation capacity of primary kidney cells (PKCs), supporting the 
hǇpothesis that loss of Hifϭα aĐtiǀitǇ is ďeŶefiĐial foƌ ƌeŶal tuŵouƌ eǀolution. In contrast, loss of 
Hif1a prevents the formation of cysts and neoplasms in Vhl/Trp53 double mutant kidneys, 
demonstrating that Hif1a is necessary for the first stages of tumour formation in vivo. These 
findings suggest that HIFϭα is ŶeĐessaƌǇ foƌ tumour initiation but later acts as a tumour 
suppressor and inhibits the proliferation of established ccRCCs. 
Maintenance of the correct activity of the HIFα transcription factors is also important for the 
physiological function of various organs. In the second part of this thesis we aimed to understand 
the underlying mechanisms of a previously published hydronephrosis phenotype, which is 
induced by the deletion of Vhl in the renal epithelium. Hydronephrosis is characterized by the 
expansion of the renal pelvis and the collecting system and is the most frequently diagnosed 
prenatal abnormality, occurring in approximately 1% of all pregnancies. Untreated 
hydronephrosis causes chronic kidney insufficiency and end stage renal disease, however, the 
precise mechanism is not yet fully understood. Histological analysis of Vhl-deficient mouse 
kidneys at different time points revealed the formation of a bilateral non-obstructive 
hydronephrosis between postnatal days 10 and 14. Furthermore, adult Vhl-deficient mice display 
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severe polydipsia and polyuria, which is accompanied by decreased urine osmolality and reduced 
hematocrit and hemoglobin levels. Detailed analyses of kidney morphogenesis by RT-qPCR and 
immunohistochemistry revealed a decreased abundance of specific renal markers in the medulla 
and papilla, suggesting a shortening of the respective parts of the nephron, presumably as a 
secondary effect of polyuria and subsequent development of hydronephrosis. Intriguingly, Vhl-
deficient mice do not show any signs of renal failure and blood creatinine and electrolyte levels 
remain unchanged. Co-deletion of Hif1a, but not of Hif2a, fully restored kidney morphology and 
function, indicating that the activation of specific Hif1α-target genes in the renal epithelium 
causes polyuria and the subsequent formation of hydronephrosis. Gene expression analysis of 
kidney lysates demonstrated a Hif1a-dependent increase in Vegf-a expression, the major 
molecular mediator of angiogenesis. Consistently, Vhl-deficient and Vhl/Hif2a-deficient, but not 
Vhl/Hif1a deficient kidneys exhibit an increased medullary vascularization. We hypothesize that 
changes in medullary blood flow disrupts the osmotic gradient, washing out salt from the renal 
interstitium and thereby preventing urinary concentration and urine reabsorption. The excess 
production of urine causes a back pressure on the kidney, leading to the expansion of the renal 
pelvis. Taken together, our study characterizes a new mouse model for non-obstructive 
hydronephrosis and gives new insights in the physiological and pathophysiological effects of 
Hif1a stabilization in the kidney.  
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2 Zusammenfassung 
Der Tumorsuppressor von Hippel Lindau ist in 70-90% der nicht erblich bedingten klarzelligen 
Nierenzellkarzinome (kNK) inaktiviert. Der Verlust von pVHL, dem Proteinprodukt von VHL, ist 
allerdings alleine nicht ausreichend um das Wachstum von Tumoren auszulösen, was darauf 
hindeutet, dass dafür zusätzliche Mutationen notwendig sind. pVHL erfüllt zahlreiche potenzielle 
Tumorsuppressorfunktionen, wie zum Beispiel die Regulation der TranskriptioŶsfaktoƌeŶ HIFα. 
Oďǁohl uŶzählige “tudieŶ daƌauf hiŶǁeiseŶ, dass HIFϭα das WaĐhstuŵ ǀoŶ kNK ǀeƌŵiŶdeƌt 
wohingegen es ǀoŶ HIFϮα geföƌdeƌt ǁiƌd, ďleiďt die Rolle dieseƌ PƌoteiŶe iŶ deƌ TuŵoƌeŶtstehuŶg 
unklar. Unsere Studie zeigt, dass die gleichzeitige Inaktivierung von Vhl und Hif1a oder Vhl und 
Hif2a in der Mauseniere nicht zur Entstehung von Tumoren oder Zysten führt. Dies beweist, dass 
weder die “taďilisieƌuŶg ǀoŶ Hifϭα noch von HifϮα alleiŶe oder kombiniert mit dem Verlust der 
mannigfaltigen tumorverhindernden Aktivitäten von pVhl ein onkogenes Ereignis darstellt. Das 
Ausschalten von Vhl in primären embryonischen Fibroblasten von Mäusen (pMEFs) führt zur 
Seneszenz dieser Zellen, welche durch die Inaktivierung von Trp53 verhindert werden kann. 
Gleichzeitig verändert sich der Metabolismus dieser Zellen, was einen verminderten 
Sauerstoffverbrauch und eine tiefere ATP Produktion zur Folge hat. Diese Prozesse werden durch 
die zusätzliche Inaktivierung von Hif1a, jedoch nicht durch die Inaktivierung von Hif2a verhindert, 
was darauf hindeutet, dass die “taďilisieƌuŶg ǀoŶ Hifϭα eiŶeŶ metabolischen Stress verursacht, 
der die Zellvermehrung hemmt. Die Herabregulierung von Hif1a beschleunigt das Zellwachstum 
auch in pMEFs ohne  funktionellem Vhl und Trp53 und fördert die maligne Transformation von 
primären Nierenzellen. Diese Resultate unterstützen die Hypothese, dass die Inaktivierung von 
Hif1a die Tumorentstehung begünstigt. Allerdings scheint Hif1a im frühen Stadium der 
Krebsentstehung notwendig zu sein, da die Inaktivierung von Hif1a in Mausnieren die Entstehung 
von Zysten und Neoplasmen, die durch Mutationen in Vhl und Trp53 ausgelösten wurden, 
verhindert. Diese Resultate legen ein neues Model für die Entstehung von kNK nahe, in dem 
HIFϭα füƌ die IŶitiatioŶ deƌ Tuŵoƌe ŶotǁeŶdig ist, im weiteren Verlauf jedoch als 
Tumorsuppressor agiert und das Wachstum von etablierten kNK vermindert.  
Die korrekte Regulierung der HIFα TƌaŶskƌiptionsfaktoren ist auch für die Funktion 
unterschiedlicher Organe notwendig. Im zweiten Teil dieser Doktorarbeit wurde untersucht, wie 
die Inaktivierung von Vhl im Nierenepithel zur Expansion des Nierenbeckens und der 
Sammelrohre führt. Die sogenannte Hydronephrose ist mit rund einem Prozent aller 
Schwangerschaften die am häufigsten diagnostizierte pränatale Fehlentwicklung. Unbehandelt 
führt sie zu einer chronischen Niereninsuffizienz und zu Nierenversagen, allerdings ist der dafür 
verantwortliche Mechanismus noch nicht vollständig geklärt. Die histologische Analyse von 
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Maus-Nieren an unterschiedlichen Entwicklungs-Zeitpunkten zeigt, dass der Verlust von Vhl die 
Entstehung einer bilateralen, nicht-obstruktiven Hydronephrose zwischen dem zehnten und 14 
Tag nach der Geburt auslöst. Ausserdem weisen adulte Mäuse mit einer Mutation in Vhl eine 
starke Polydipsie und Polyurie auf, welche von niedrigen Hämatokrit- und Hämoglobinwerten 
und reduzierter Urinosmolalität begleitet werden. Die detaillierte Untersuchung der 
Nierenmorphogenese mit Hilfe von RT-qPCR und Immunohistochemie zeigt eine reduzierte 
Menge mehrerer Proteinen, die nur in bestimmten Nephronabschnitten im Nierenmark und 
Nierenbecken exprimiert werden. Dies deutet auf eine Verkürzung der Nephrone hin, 
möglicherweise infolge der übermässigen Urinentwicklung und der dadurch entstehenden 
Hydronephrose. Bemerkenswert ist, dass diese Mäuse keine Anzeichen von Nierenversagen 
aufweisen und auch die Blutwerte für Kreatinin und verschiedene Elektrolyte unverändert sind. 
Die zusätzliche Inaktivierung von Hif1a aber nicht von Hif2a führt zu einer vollständigen 
Wiederherstellung der Nierenfunktion und Nierenmorphologie. Dies beweist, dass die Aktivität 
eines oder mehrereƌ ǀoŶ Hifϭα ƌegulieƌteŶ GeŶe iŵ NieƌeŶepithel füƌ deŶ oďeŶ ďesĐhƌieďenen 
Phenotype verantwortlich ist. Die Analyse der Genexpression zeigt, dass die Stabilisierung von 
Hifϭα zu eiŶeŵ AŶstieg deƌ Vegf-a Synthese in der Niere führt, einem zentralen Regulator der 
Angiogenese. Damit übereinstimmend weisen Nieren ohne Vhl oder Vhl und Hif2a im Gegensatz 
zu Nieren mit Mutationen in Vhl und Hif1a eine erhöhte Gefässbildung im Nierenmark auf. Wir 
vermuten, dass der veränderte Blutfluss im Nierenmark die Aufrechterhaltung des osmotischen 
Gradienten stört, was zu einer tieferen Osmolalität im Niereninterstitium führt und dadurch die 
Wasserabsorption im Nephron beeinträchtigt. Die erhöhte Urinproduktion übt einen ständigen 
Druck auf die Nieren aus, wodurch sich das Nierenbecken erweitert. Zusammengefasst 
charakterisiert unsere Studie ein neues Mausmodel für die nicht-obstruktive Hydronephrose und 
giďt Ŷeue EiŶďliĐke iŶ phǇsiologisĐhe uŶd pathophǇsiologisĐhe FuŶktioŶeŶ ǀoŶ HIFα iŶ deƌ Nieƌe.  
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5 Abbreviations 
 
ANH        antenatally diagnosed hydronephrosis  
Aqp Aquaporin 
ATP Adenosine triphosphate 
AVP Arginine vasopressin, also known as antidiuretic hormone (ADH) 
BUN Blood urea nitrogen 
ccRCC clear cell renal cell carcinoma 
Epo erythropoietin 
Hct hematocrit 
Hifα Hypocia inducible transcription factor alpha 
NaPi-IIa Na/phosphate cotransporter 
NCC  Na/Cl co-transporter 
NDI nephrogenic diabetes insipidus 
NKCC2 sodium-potassium chloride co-transporter 
P53 transformation related protein 53 (mouse homologue) 
PKCs primary kidney cells 
pMEFs primary mouse embryo fibroblasts  
pVhl  von Hippel Lindau protein 
TAL thick ascending limb of Henle 
TP53 tumour protein 53 gene (human homologue) 
Trp53 transformation related protein 53 gene (mouse homologue) 
Vhl  von Hippel Lindau gene 
ROS reactive oxygen species 
MBL medullary blood flow 
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6 Introduction 
6.1 Kidney anatomy and function 
A broad range of genetic or acquired diseases including polycystic kidney disease, virus infections, 
exogenous stress (toxins, drugs, obesity) or kidney cancer are affecting kidney function, finally 
causing kidney insufficiency. The kidney is the main excretory organ in mammals and is 
responsible for various physiological processes such as osmoregulation, urine excretion, blood 
cell production and the regulation of the blood pressure and acid/base homeostasis. The precise 
regulation of these processes is very complex and many questions are still not fully answered. In 
this thesis, we focused on clear cell renal cell carcinoma (ccRCC) and hydronephrosis, on two 
common disorders of the kidney. We aimed to understand the underlying mechanisms that are 
involved in the formation of these diseases and how specific genetic deletions influence the 
function and structural integrity of the organ. The following paragraphs focus on the processes 
and mechanisms of kidney structure and function that are important for the understanding of 
the experimental goals of the work described in this thesis. 
The functional unit of the kidney is the nephron, a tubular epithelial structure composed of the 
glomerulus, proximal tubule (PT), descending and ascending loop of Henle, macula densa, distal 
tubule (DCT) and the connecting tubule (CT) (Fig. 6.1A) (Treuting and Kowalewska 2012). The 
connecting tubule leads into the collecting ducts, which converge into the renal papilla and finally 
extend in the pelvis, the funnel-like dilated part of ureter. The human kidney consists of around 
1 Mio nephrons, whereas there are approximately 14 000 nephrons in mice. Importantly, the 
nephron number does not change with age. Macroscopically, the kidney consists of two major 
regions, the cortex (outer region) and the medulla (inner region), the latter being further divided 
in an outer and inner part (Fig. 6.1B). In contrast to the mouse kidney, which is a unilobular organ, 
the human kidney consists of 7-9 papillae which form the renal calyxes and then open into the 
renal pelvis (Fig. 6.1C) (Treuting and Kowalewska 2012). The glomeruli, the proximal and the 
distal tubules are located in the cortex, whereas the loop of Henle and the collecting ducts reach 
into the medulla. Peritubular capillaries surround the tubules in the medulla, taking up the 
reabsorbed solutes from interstitial space (Fig. 6.2). Therefore, the capillaries are essential for 
the maintenance of the osmotic gradient, the driving force for renal reabsorption (see below) (W 
F Boron 2009). 
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Fig. 6.1: Schematic view of kidney anatomy. (A) The renal glomerulus is located in the renal cortex and 
gives rise to the tubular system that is reaching into the inner medulla of the kidney. Several connecting 
tubules fuse into a collecting duct which finally ends in the renal pelvis. Different tubular segments are 
depicted in corresponding colors. (B) The human kidney consists of several pyramids that fuse via the renal 
calyxes into the pelvis, whereas (C) the mouse kidney is a unilobar organ.  
The glomerulus consists of a network of capillaries and is surrounded by podocytes, modified 
epithelial tuďulaƌ Đells. Togetheƌ, theǇ Đƌeate the BoǁŵaŶ’s spaĐe, ǁhiĐh is the pƌoǆiŵal eŶd of 
the tubular lumen of the nephron. This unit is called the BoǁŵaŶ’s Đapsule. The ďaseŵeŶt 
membrane is located between endothelial cells and podocytes and in cooperation they represent 
the actual filter unit. Together, they prevent large solutes (molecular weight < 1 kDa) and large 
ŶegatiǀelǇ Đhaƌged solutes iŶ the ďlood fƌoŵ eŶteƌiŶg the BoǁŵaŶ’s spaĐe (W F Boron 2009). 
After filtration, the primary urine is transported along the nephron and specific molecules (ions, 
water) are reabsorbed by specialized nephron segments (S Silbernagl 2003). The proximal tubule 
reabsorbs NaCl, NaHCO3, nutrients (glucose, amino acids etc.), water and divalent ions (Ca2+, 
HPO42-, SO42-) and secretes NH4+ and other endogenous and exogenous solutes into the lumen. 
The loop of Henle is mainly responsible for water reabsorption and maintenance of the osmotic 
gradient. In the descending limb of Henle water crosses the membrane along the osmotic 
gradient, which is recreated by the thick ascending limb, where specialized ion transporters 
(NKCC2) actively pump NaCl in the medullary interstitial space to make it hypertonic. The distal 
tubules and the collecting duct are responsible for the fine tuning of NaCl uptake and water 
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absorption by hormone-dependent regulation of ion transporters and water channels (see 
below) (W F Boron 2009).  
 
  Fig, 6.2: Simplified view 
on renal capillary 
system. The renal 
arteries give rise to 
numerous afferent 
arterioles which 
subsequently form the 
glomerular capillaries. 
The efferent arterioles of 
the juxtamedullary 
glomeruli descend into 
the renal papillae and 
form hairpin-shaped 
vessels called the vasa 
recta, providing the 
capillary network for the 
medulla. However, the 
majority of the efferent 
arterioles give rise to the 
peritubular capillary 
network that supplies 
the cortex with 
nutrients and oxygen 
(superficial glomeruli). 
 
A broad range of distinct transporters is expressed in the apical and basolateral side of the renal 
tubular cells to enable water reabsorption and to prevent loss of important molecules or ions in 
the urine. Solutes can be transported through epithelial cells either passively along their electro-
chemical gradient or actively by different types of transporter (transcellular pathway). Finally, 
they are reabsorbed from the interstitial space by the capillaries. The sodium-potassium-chloride 
co-transporter (NKCC2) is an example of an apically coupled co-transporter expressed in the thick 
ascending limp of Henle (TAL), where the uptake of the ions by the cell is driven by downhill 
concentration gradients of Na+ and Cl-. On the basolateral side of the cell, the ATP-dependent Na-
K-pump, an antiporter, actively transports Na+ into the interstitial space, through which the Na+ 
gradient is maintained. On the other hand, sodium and chloride are transported by NCC, a Na/Cl 
co-transporter, into the distal convoluted tubule. In addition to the transcellular pathway, small 
solutes can also travel from the primary urine to the blood via a fully extracellular pathway 
through the tight junctions of cells (paracellular pathway). Water flows passively through 
different renal aquaporins due to the difference in the osmotic gradient in the medulla. Since Na+ 
is the most important contributor to the osmolality of the extracellular fluid, a common rule is: 
  Introduction 
15 
 
where Na+ goes, water follows. Importantly, there are no aquaporins expressed in the TAL 
(Verkman 2008), which therefore enables the reconstitution of the osmotic gradient by NKCC2. 
Increased plasma osmolality causes the secretion of arginine vasopressin (AVP, also called 
antidiuretic hormone (ADH)) from the posterior pituitary that in turn binds to their receptors at 
the basolateral side of target cells, leading to increased absorption of water by several 
mechanisms. In the collecting duct, AVP stimulation causes the translocation of AQP2 (Aquaporin 
2) to the apical membrane and NKCC2 and K+ channels are stimulated in the TAL (W F Boron 
2009). Furthermore, the kidney is crucial for the control of plasma levels of solutes like 
phosphate, calcium, magnesium and amino acids that are only present at low concentrations. 
Interestingly, some molecules including urea or HCO3- are not only reabsorbed but can also be 
secreted by the kidney (W F Boron 2009).  
Some renal transporters are often used as markers for specific tubular segments, due to their 
very distinct expression patter. In this thesis, we used NCC as a marker for distal tubules, NKCC2 
for the TAL (Kaplan et al. 1996) and AQP2 for collecting ducts. Additionally, NaPi-IIa 
(Na/phosphate cotransporter), SGLT1, Cubulin, Pendrin, Tamm-Horsfall and ATP V1B1 were used. 
NaPI-IIa, SGLT1 and Cubulin are all markers for proximal tubules. NaPi-IIa is the most abundant 
phosphate transporter in humans and specifically expressed in proximal tubules, where 80% of 
the filtered phosphate is reabsorbed (Berndt and Knox 1992). SGLT1 is expressed in the later part 
of the proximal tubule and is responsible for the apical glucose uptake, whereas Cubulin binds 
albumin in the urine and hence mediates its endocytosis (Sahali et al. 1988; Birn et al. 2000; 
Wright et al. 2007). ATPV1B is the B1 subunit of the vacuolar proton-pumping ATPase (V-ATPase) 
and used as a marker for distal tubules and collecting ducts (Paunescu et al. 2007). Pendrin is a 
chloride iodide transporter that is expressed in the proximal tubules and the cortical collecting 
duct (Scott et al. 1999; Soleimani et al. 2001). Mutations in these genes cause the Pendred 
syndrome, a recessively inherited disorder characterized by congenital deafness (Everett et al. 
1997). Similarly, mutations in ATPV1B1 can also lead to loss of hearing (Yashima et al. 2010). 
(Paunescu et al. 2007). Tamm-Horsfall protein (also called uromodulin) is a glycoprotein 
expressed in the thick ascending limb and presumably in a part of the distal tubules. Although it 
has been shown to be involved in several pathways and human disorders, its precise function is 
still not fully understood (Hoyer et al. 1979; Sikri et al. 1981; Mao et al. 2014) 
Finally, the kidney also functions as an endocrine organ. At the macula densa the kidney senses 
the amount of fluid and NaCl passing through the nephron and regulates the glomerular filtration 
rate accordingly. Furthermore, the macula densa also controls the pressure of afferent arterioles 
by induction of renin excretion into the circulation by granular cells of the juxtaglomerular 
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apparatus (JGA) (W F Boron 2009). Another endocrine function of the kidney is the regulation of 
erythrocyte production in adults. When renal oxygen content drops, erythropoietin (EPO)-
producing, fibroblast-like cells are recruited to the border of the subcapsular tissue, elevating 
EPO secretion in the blood (Koury et al. 1989; Eckardt et al. 1993). In the bone marrow, Epo 
stimulates erythropoiesis and therefore enables increased oxygen transport in the body (Wenger 
and Hoogewijs 2010).   
6.2 Kidney development 
In amniotes nephrogenesis consists of 3 phases, each of them marked by the formation of a more 
advanced kidney (Gilbert 2003). In the first phase, the pronephros is formed from the 
intermediate mesoderm in the neck region of the embryo, forming the pronephric ducts and 
pronephric tubules which open into the cloacae. In mammals, the pronephros does not fulfil any 
excretory function and regresses again. The most caudal part, however, persists as the nephric 
duct (also known as Wolffian duct) and participates in the formation of the male reproduction 
organs (Gilbert 2003; Joseph et al. 2009). Subsequently, the formation of the mesonepheros is 
induced from the adjacent mesenchyme. The mesonephros is a large, tubular structure that 
consists of primitive glomeruli and functions as an interim kidney in some mammalian species 
until the metanephros has developed (Saxén L 1987; Gilbert 2003). Whereas the mesonephros 
does not function as a kidney in rodents, its contribution to fetal blood filtration remains 
unknown (Gilbert 2003). Next, the nephric duct starts to evaginate at day E10.5 in mice (fifth 
week of gestation in humans) and forms an uretic bud at its caudal end that invades the 
metanephric mesenchyme (Costantini and Kopan 2010; Song and Yosypiv 2012). After invading 
the metanephric mesenchyme the uretic bud starts extending and branching repeatedly (Fig. 
6.3A-G) (Srinivas et al. 1999). The metanephric mesenchyme condenses around the ureteric bud 
tips, undergoes mesenchymal-epithelial transition and forms the renal vesicles. Subsequently, 
the vesicles fuse with the ureteric stalk, creating the so-called S-shaped bodies. The most 
proximal part of the S-shaped body will give rise to the future glomerulus and most of the renal 
tubules, whereas the very distal end of the S-shaped body and the ureteric bud will form the 
collecting ducts (Dressler 2009).  At this stage, the different parts of the S-shaped body show a 
distinct gene expression pattern presumably reflecting the regionalization into the different 
segments (Georgas et al. 2009). However, the detailed mechanism of subdivision of the nephron 
is not fully understood yet.  Eventually, renal medulla becomes identifiable at E15.5 and expands 
longitudinally to increase in size. Importantly, nephrogenesis is not completed at birth in rodents. 
For instance, the medulla of newborn rats is not separated into an outer and inner zone yet. In 
the first 2 weeks after birth, the immature thick limbs of Henle are transformed by a series of 
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apoptotic deletions and growth of the segment (Song and Yosypiv 2012).  Very recent data shows 
that tubulogenesis continuous in the adult mouse kidney. Linage-tracing experiments indicate 
that a subset of adult epithelial cells keep dividing, thus leading to a complete renewal of the 
renal epithelium approximately every 6 weeks (Rinkevich et al. 2014).  
 
Fig. 6.3: Development of the adult kidney (Pronephros): (A-B) Mesenchymal cells condense at the uretic 
bud, (C) subsequently forming the renal vessels, (D-E) comma-and S-shaped body, (F) finally giving rise to 
the tubular system. (G) The ŵost pƌoǆiŵal Đells assoĐiate ǁith eŶdothelial Đells to ďuild up the BoǁŵaŶ’s 
capsule.  
Nephrogenesis is synchronized with kidney vascularization. Although it is believed that kidney 
vascularization is mainly achieved by angiogenesis (sprouting from existing vessels), 
vasculogenesis (de novo synthesis from endothelial progenitor cells) has also been postulated 
(Saxén L 1987). Hence, endothelial cells may sprout from pre-existing vessels in the surrounding 
tissue of the mesenchyme or could alternatively differentiate in situ from mesenchymal or 
epithelial cells within the S-shaped body (Gomez et al. 1997). During kidney organogenesis a 
ďƌoad speĐtƌuŵ of gƌoǁth faĐtoƌs suĐh as VEGF, TGFα, PDGF, IGF etc. are secreted, presumably 
also supporting development of the vascular system (Gomez et al. 1997). For instance, Kitamoto 
et al. show that correct VEGF signalling is important for the correct formation of vascular 
morphology and glomeruli (Kitamoto et al. 1997). Additionally, VEGF is crucial for the 
maintenance of glomeruli in adults indicating a crosstalk between epithelial and endothelial cells 
(Kitamoto et al. 1997).  
Finally, the renal interstitium and the renal nerves have to develop. The adult cortical and 
medullary interstitium arises from two distinct populations of metanephric stroma cells. The 
knowledge of the role of renal neuronal cells in metanephric development is still very limited, 
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although it has been shown that sympathetic nerves follow the track of blood vessels while 
growing into the embryonic kidney (Song and Yosypiv 2012). These two processes are not further 
discussed in the context of this thesis.   
Various signalling pathways are involved in renal organogenesis, including integrins or Wnt, 
Notch and Pi3K signalling pathways (Costantini and Kopan 2010). Mutations of these pathways 
can lead to severe malformations (see 6.4) (Schedl 2007; Wu et al. 2009). Furthermore, the 
hypoxia-iŶduĐiďle faĐtoƌs α, tƌaŶsĐƌiptioŶ faĐtoƌs iŶduĐed upoŶ loǁ oǆǇgeŶ teŶsioŶ aƌe esseŶtial 
foƌ iŶtaĐt kidŶeǇ deǀelopŵeŶt ;see ďeloǁ foƌ a detailed disĐussioŶ of Hifα sigŶalling). In new born 
mice Hif1a and Hif2a mRNA is highly expressed in the renal medulla, especially in the medullary 
collecting ducts (Freeburg and Abrahamson 2003). Moreover VEGF mRNA, a Hifα taƌget geŶe, 
was found in the medulla from rat kidneys at day 14 and inhibition of VEGF activity in developing 
mouse kidneys cause renal malformations (Kitamoto et al. 1997; Madsen et al. 2010) .  
IŶ this thesis ǁe eǆaŵiŶed the effeĐts of HIFα dǇsƌegulatioŶ iŶ the ƌeŶal epitheliuŵ oŶ ƌeŶal 
function and on the formation of clear cell renal carcinoma (ccRCC). We used the Cre/LoxP system 
to induce tissue-specific gene deletions in transgenic mice. The Ksp1.3-Cre transgene induces the 
expression of a Cre-recombinase in the ureteric bud, the Wolffian and Müllerian ducts, the 
developing ureter and in the developing tubules in the mesonephros and the metanephros and 
thereby causes gene deletions by homologous recombination in the epithelium of the uterus, 
epididymis, vesicular glands and in the renal nephron. Furthermore, the use of a tamoxifen-
inducible variation of the Cre-recombinase (Ksp1.3-Cre-ERT2) enabled us to cause gene deletion 
only in adult mice, circumventing any effects caused by changes in early development. Since the 
Ksp.1.3 promoter is only transiently active in the Wolffian and Müllerian ducts, this transgene 
causes gene recombination only in the renal epithelium (Shao et al., 2002a; Shao et al., 2002b; 
Patel et al., 2008). 
6.3 Renal cell carcinoma (RCC) 
6.3.1 Inherited and sporadic forms of RCC 
Renal cell carcinoma (RCC) is the general term for a group of cancers arising from the renal tubular 
epithelium. Currently these diseases represent the eighth leading cause of cancer-related death 
in the United States of America (Hakimi et al. 2013). Clear cell RCC (ccRCC) is the most common 
subtype with approximately 65% of all reported cases, followed by papillary RCC (pRCC, type 1 
and 2) accounting for 15-20% and chromophobe RCC with 5% of all RCC patients. Moreover, a 
few very rare carcinomas including MiTF-TFE translocations and spindle cell carcinomas are also 
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accounted to RCC (Jonasch et al. 2012). The different types of RCC are distinguished by 
morphology, prognosis and their underlying genetics. Similar to other types of cancer, RCCs occur 
in sporadic and hereditary forms, the latter accounting for 4% of all cases. Several familiar cancer 
syndromes predispose to different types of hereditary RCC. For instance, ccRCC often occurs in 
patients suffering from the von Hippel-Lindau (VHL) syndrome, which is characterized by 
germline mutations of VHL, a gene coding for pVHL, the recognition component of a ubiquitin 
ligase (Latif et al. 1993). Additionally, ccRCC is sometimes found in patients with the Tuberous 
Sclerosis syndrome, caused by germline mutations in the tuberous sclerosis complex (TSC) 1 and 
2 genes. Mutations in the MET genes cause hereditary papillary renal carcinoma and increase the 
risk for type 1 pRCC (Zbar et al. 1994; Schmidt et al. 1997). In contrast, fumarate hydratase (FH) 
mutations occur in hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) and 
predispose for pRCC type 2 (Tomlinson et al. 2002). The Birt-Hogg-Dubé syndrome is associated 
with mutations in the folliculin (FLCN) gene which predisposes to the development of 
chromophobe RCC (Nickerson et al. 2002). Finally, mutations in the succinate dehydrogenase 
subunit B (SDHB) give rise to the paraganglioma syndrome and these patients display an 
increased risk of developing multiple types of RCC. The genetic events that cause tumourigenesis 
in sporadic cases of RCC are less well understood. VHL is somatically mutated or silenced in up to 
92% of patients with ccRCC, indicating that loss of VHL function is a crucial step in the 
development of the cancer (Sato et al. 2013). In contrast, MET or FLCN mutations only occur in a 
small fraction of patients with sporadic pRCC or chromophobe RCC, respectively (Schmidt et al. 
1997; Kiuru et al. 2002). Similarly, to date no mutations in SDHB or TSC1/2 have been found in 
sporadic RCC (Parry et al. 2001). 
The goal of this thesis was to better understand the initial events in kidney cancer formation, 
focusing on ccRCC. To address this question, we developed different mouse models harbouring 
epithelium-specific deletions of the most common genetic alterations occurring in ccRCC. This 
system allowed us to investigate the cooperative effects of gene deletion directly in the murine 
kidney as well as in different cell culture models.  
6.3.2 Treatment of RCC 
The 5-year survival for patients with RCC largely depends on the stage of the disease. Whereas 
stage I RCC ;tuŵouƌ ч ϳ Đŵ, liŵited to the kidney) has an overall survival rate of 88%, stage II 
;tuŵouƌ ш ϳ Đŵ, liŵited to the kidney) and stage III disease (expansion into major veins, adrenal 
glands or perinephric fat) display a reduced survival rate of 63% and 65%, respectively. Only 15% 
of patieŶts suffeƌiŶg fƌoŵ stage IV disease ;iŶǀasioŶ ďeǇoŶd Geƌota’s fasĐia, >ϭ lǇŵph node 
metastasis or distant metastasis) are still alive 5 years after diagnosis (data from patients 
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diagnosed between 1964 and 1997) (Greene 2002; Sunela et al. 2009). In general, overall 
prognosis is rather poor since 30% of RCCs have already metastasized at the time of the first 
diagnosis and another 30% develop metastasis after initial resection of the primary tumour 
(Sandock et al. 1995; Mekhail et al. 2005).  
Currently, the most efficient treatment for ccRCC is surgery combined with targeted therapy 
using multiple anti-angiogenic agents, such as sorafenib (Raf kinase inhibitor (Bukowski et al. 
2007)), sunitinib (small-molecule tyrosine kinase inhibitor targeting VEGFR-2, PDGFR-B, FLT3 and 
KIT), bevacizumab (recombinant humanized monoclonal antibody against VEGF (Presta et al. 
1997)) and pazopanib (tyrosine-kinase inhibitor (Hutson et al. 2010)). Treatment of patients with 
metastatic ccRCC with the kinase inhibitors sorafenib and sunitinib have been shown to extend 
the overall survival to 28.8 months compared to only 10 months in patients treated with 
conventional chemotherapy (Motzer et al. 1999; Herrmann et al. 2011; Qian 2013). 
Unfortunately, patients undergoing anti-angiogenic therapy inevitably develop a resistance or 
already present primary resistance at the time of the treatment. Therefore, several novel agents 
are currently being tested as adjuvants in clinical trials. For instance, a phase II study of sunitinib 
plus trebananib, an angiopoietin peptibody disrupting the Ang/Tie-2 axis, has shown encouraging 
results with a progression-free survival of 16 months and a high overall response rate of 59% 
(Atkins 2012). Other promising newly developed agents are currently undergoing clinical trials 
such as cabozantinib (a small-molecule kinase inhibitor targeting MET receptor and VEGFR-2) and 
dalantercept (a soluble fusion protein of the extracellular domain of ALK-1 and human IgF1-Fc 
that binds BMP9 and BMP10, functioning as a ligand trap), both inhibiting angiogenesis by 
different mechanisms. Additionally, several other targets that have been associated with 
angiogenic resistance are currently being investigated in animal models, such as IL-8 neutralizing 
antibodies, HDM2/HDMX antagonists, improved mTOR inhibitors or the inhibition of the Hippo 
pathway. Direct inhibition of HIF2α, a transcription factor regulating VEGF expression, has also 
been proposed as potential potent therapeutic, however clinically applicable inhibitors have not 
yet been developed (Philips and Atkins 2014). Finally, recent studies have identified 
immunoregulatory pathways that protect tumour cells from the destruction by the immune 
system. Newly developed antibodies such as nivolumab blocking these immune checkpoints have 
been shown to exhibit anti-tumour activity in several cancers, including RCC and may be 
promising agents for new combination therapies. However, very recent clinical trials indicate an 
inacceptable dose-limiting toxicity for some patients and demonstrate the need of a suitable 
ccRCC mouse model that enables the development of new therapeutic agents that not only 
prolong a patieŶt’s life ďut eǀeŶtuallǇ Đuƌe the disease (Asim Amin 2014).    
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6.3.3 Von Hippel-Lindau (VHL) Disease  
Von Hippel-Lindau disease is an autosomal dominant disorder that is characterized by a germline 
mutation of the VHL gene, coded on chromosome 3p25 (see below) (Latif et al. 1993).  VHL 
patients are at high risk of developing ccRCC and various other benign and malignant tumours 
including pancreatic cysts and neuroendocrine tumours, pheochromocytoma (tumour of the 
adrenal gland (Santos et al. 2014)), retinal haemangioblastomas, central nervous system 
hemangioblastoma and endolymphatic sac tumours (tumour of the inner ear) (Linehan et al. 
2009). Tumours are initiated by the inactivation of the second allele of the VHL gene. VHL disease 
is divided into different subtypes, depending on the kind of inherited mutations in the VHL gene 
(missense, nonsense, deletions). Importantly, this genetic variability is also reflected by the 
clinical manifestation of the disorder. For instance, phaeochromocytoma is only a feature of type 
2 VHL diseases but not of type 1. Type 2 is further divided into 3 subtypes that differ in the risk 
of developing renal cancers. Type 2C is associated with a high risk of phaeochromocytoma, but a 
low risk of renal cell carcinoma and hemangioblastoma (Barontini and Dahia 2010). Genetic 
analyses of these patients reveal a specific missense mutation in the VHL gene that causes no or 
only very weak activation of the hypoxia-inducible transcription factor alpha (HIFα), a protein 
targeted for proteolytic degradation by VHL. This is in contrast to the mutations in other subtypes 
of the VHL disease that Đause high HIFα leǀels, correlating with a high risk for renal cancer and 
therefore indicating that HIF stabilization is an important step in the formation of ccRCC (Raval 
et al. 2005) 
VHL disease occurs with an incidence of 1 in 39 000 live births in England (Maher et al. 1991). 
Retinal haemangiomas or phaeochromocytomas are often the first manifestations of the 
syndrome in childhood or adolescence, presented by loss of visual acuity and visual field or severe 
hypertension and headaches, respectively. Central nervous system (CNS) haemangioblastomas 
are the most common lesion, occurring in 60-80% of all cases (Maher et al. 2011). These are highly 
vascularized benign tumours that cause important neurological deficits and are associated with 
a significant mortality rate. Furthermore, ccRCC or multiple renal cysts occur in 60-70% of 
patients depending on the subtype of VHL disease and are commonly diagnosed when patients 
reach the age of 40 years. ccRCC can arise from frequently observed multiple renal cysts or from 
non-cystic renal parenchyma and is a common cause of death in VHL patients (Maher et al. 2011). 
Additionally, 35-77% of patients develop pancreatic tumours or cysts. Whereas cysts are normally 
benign, tumours metastasize in 8-50% of the cases, commonly to the liver. Endolymphatic sac 
tumours can cause tinnitus, vertigo or irreversible loss of hearing in early adults (Barontini and 
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Dahia 2010). Finally, up to 60% of males with VHL disease develop epididymal cystadenomas, 
which are usually asymptomatic and do not require further treatment (Choyke et al. 1997).  
Treatment of patients depends on the manifestation of the disease. Children with a familiar 
history of VHL disease should be genetically screened for germline mutations in the VHL gene and 
clinical screening is recommended when mutations are identified (Johnston et al. 2001). 
However, 20% of VHL disease patients result from de novo mutations and are first identified by 
the manifestation of typical tumours found in VHL disease (Richards et al. 1995). Pancreatic and 
renal tumours are resected when larger than 3 cm in diameter. Also, early removal of 
endolymphatic sac tumours is recommended, possibly preventing or alleviating the neurological 
symptoms. Importantly, patients require life-long follow-ups due to the risk of recurrence 
(Barontini and Dahia 2010). Moreover, retinal angiomas mostly respond well to laser 
photocoagulation or cryotherapy. Several anti-angiogenic agents including small-molecule VEGF 
receptor inhibitors or anti-VEGF antibodies are currently used for the treatment of advanced 
tumours in clinics or in clinical trials, partially with good responses in some tumours (Barontini 
and Dahia 2010).  
Inherited VHL mutations can also cause Cuvash polycythaemia, an autosomal recessive disorder 
characterized by increased HIFα and EPO levels (Ang et al. 2002). These patients suffer from 
erythrocytosis but lack the typical tumoural phenotype of VHL disease, therefore Cuvash 
polycythaemia is categorized as a separate disorder. 
6.3.4 Clear cell renal cell Carcinoma (ccRCC) 
6.3.4.1 Origin of ccRCC 
Only 1% of ccRCC are caused by inherited VHL mutations (see 6.3.3) and the majority occur as 
sporadic cases (Neumann et al. 1998). The clear cell form of renal carcinoma is characterized by 
a high lipid and glycogen content and represents the most common and aggressive subtype 
(Linehan et al. 2009). ccRCC originates from the renal epithelium, however the type of tubular 
segment or segments that serves as the cell of origin of this tumour is still under debate.  
Examinations of pre-cancerous kidneys of VHL patients reveal that the majority of VHL-deficient 
proximal cells remain as single cells, whereas multicellular VHL null lesions almost exclusively 
arise from the distal tubules, possibly reflecting intrinsic differences in the response of the 
different segments to the loss of VHL function (Mandriota et al. 2002). Several studies with 
human ccRCC biopsies indicate that most tumours stain positively for proteins that are 
specifically expressed by the proximal tubules, while other studies suggest the distal tubules and 
collecting duct cells as the origin for ccRCC (Droz et al. 1990; Motzer et al. 1996; Paraf et al. 2000; 
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Mandriota et al. 2002; Straube et al. 2011). However, tubular cells may change their gene 
expression pattern during transformation possibly leading to up or down regulation of specific 
markers and therefore limiting the significance of these studies. Consistently, examination of 
kidneys from VHL patients show that clusters of VHL null cells lose the expression of epithelial 
markers such as E-cadherin and Tamm-Horsfall protein, yet they are positive for Vimentin, a 
mesenchymal marker for de-differentiation (Mandriota et al. 2002; Esteban et al. 2006). In 
summary, it appears that ccRCC most often arises from proximal tubular cells, but can also arise 
from epithelial cells of other nephron segments. 
For the generation of a ccRCC mouse model, we used the Ksp1.3 promoter, which specifically 
induces gene deletions in epithelial cells throughout the whole nephron, therefore targeting all 
segments that have been postulated as the origin of ccRCC. While the Cre-recombinase is only 
weakly expressed in the proximal tubules in comparison to expression levels in other nephron 
segments, our unpublished reporter studies, together with published data, show that 
approximately 5-10% of proximal tubular epithelial cells undergo Cre-mediated recombination 
(Shao et al. 2002a; Shao et al. 2002b; Frew et al. 2008b, Goncalves unpublished data). This 
observation suggests that the Ksp1.3-Cre mouse line is a good choice for the generation of ccRCC 
mouse models but also has implications for the physiological analyses that were carried out in 
this thesis.  
6.3.4.2 Common genetic alterations in ccRCC 
The most prominent mutation in ccRCC is the loss of function of pVHL, encoded by the VHL gene. 
Detailed molecular analysis has recently revealed that VHL is biallelically inactivated, either by 
loss of function mutations, DNA hypermethylation or loss of one copy of chromosome 3p in up 
to 92% of sporadic cases of ccRCC (Sato et al. 2013). This extremely high prevalence of genetic 
alterations in a specific gene indicates an important role of pVHL in tumourigenesis. This notion 
is further supported by the observation that 42% of the remaining cases of ccRCC that are wild 
type for pVHL harbour a biallelic inactivation of TCEB1 (encoding Elongin C) another member of 
the pVHL ubiquitin ligase complex (Kamura et al. 2000; Sato et al. 2013). However, examination 
of kidneys of VHL patients demonstrates that loss of pVHL function alone is not sufficient to 
induce tumour formation since kidneys exhibit a large number of VHL null cells but only a few 
finally develop into cysts or tumours. This notion indicates that additional oncogenic events have 
to occur to drive tumour formation (Mandriota et al. 2002; Montani et al. 2010)  
During the last years, whole-genome, whole-exome and transcriptome analyses have been 
performed using large collections of ccRCC samples, providing a deeper understanding of the 
underlying genetic alteration in ccRCC formation (Hakimi et al. 2013). These studies demonstrate 
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that loss of heterogocity (LOH) of chromosome 3p is a fundamental event in ccRCC pathogenesis, 
occurring in over 90% of the cases (The Cancer Genome Atlas Research 2013). On this 
chromosome segment the VHL, PBRM1, BAP1 and SETD2 genes are closely located. Further, these 
genes also belong to the top four mutated genes in ccRCC, hence leading to a lack of functional 
protein expression in a very high number of ccRCC cases. Together, these findings support the 
importance of pVHL inactivation in tumour formation and also indicate a fundamental role of 
epigenetic alteration in the formation of kidney cancer, as PBRM1, BAP1, and SETD2 are involved 
in chromatin remodelling (Sato et al. 2013). This goes in line with the findings in several other 
cancer types, where epigenetic changes are important drivers for tumour formation (Wilting and 
Dannenberg 2012).  
Genetic alteration in the tumour suppressor TP53 occurs in approximately 50% of all human 
cancers (Hollstein et al. 1994). In ccRCC, mutations in TP53 have been reported in 2.3-9% of the 
cases, representing only a minor fraction of tumours. However, when other members of the p53 
pathway such as ATM, MDM2 and CDKN2A and MYC are considered as well, 40% of the ccRCC 
tumours show disturbed p53 signalling, indicating an important function also in the formation of 
kidney cancers (Albers et al. 2013; Sato et al. 2013).  
Another frequent event in ccRCC is the deletion of chromosome 14q, which locates HIF1a 
(Hypoxia inducible transcription factor 1a) as well as SAV1 (Salvador 1) and FRMD6 (FERM 
domain-containing protein 6), two members of the Hippo pathway. This indicates a putative 
tumour suppressor activity for these genes (Shen et al. 2011). Moreover, investigations of 
phosphoinositide 3-kinase (PI3K)-Akt-mTOR signalling pathway show that approximately 27% of 
ccRCCs exhibit mutations in various members including PTEN, PI3K, Akt, TSC1, TSC2 and mTOR, 
leading to a constitutive activation of the pathway (Sato et al. 2013; The Cancer Genome Atlas 
Research 2013). The mTOR (mammalian target of rapamycin) signalling network serves as a 
global regulator of cell growth and cell proliferation. It senses the cellular energy and nutrient 
status and subsequently regulates several pro-proliferative processes such as transcription, 
translation, ribosome biogenesis, autophagy and cellular metabolism (Wullschleger et al. 2006). 
Constitutively active mTOR signalling is a common feature in various cancers, further supporting 
the relevance of these mutations in tumourigenesis. 
Despite these extensive studies, the interplay of the different genetic alterations and their 
contribution to tumour initiation and progression are poorly understood. Therefore, another goal 
of this thesis was to investigate the cooperative effects of the inactivation of Vhl, Hif1a and Trp53, 
representing some of the most common mutagenic alterations in ccRCC. 
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6.3.5 The Von Hippel Lindau protein (pVHL) 
As mentioned above, over 90% of ccRCC tumours exhibit loss of function of pVHL, demonstrating 
an essential role of this protein in tumourigenesis. The VHL locus is encoded on chromosome 3p 
and gives rise to a long and a short isoform (referred to as pVHL30 and pVHL19 in humans and 
pVHL25 and pVHL20 in mice) that are derived from alternate translational initiation sites (Iliopoulos 
et al. 1998; Blankenship et al. 1999). Studies in human cell lines show that the long form co-
localises predominantly with cytoplasmic microtubules, whereas in mice the short form localises 
mainly in the nucleus (Hergovich et al. 2003). Nevertheless, both isoforms can function separately 
as tumour suppressors, since reintroduction of pVHL30 as well as of pVHL19 in renal cancer cells 
inhibits tumour development in mouse xenografts (Blankenship et al. 1999). pVHL is a 
multipurpose adaptor protein involved in various cancer related processes. For instance, pVHL 
promotes the activity of the tumour suppressor p53 by suppressing the Mdm2-mediated 
ubiquitination and subsequent degradation of p53. pVHL is also associated with microtubules, 
inhibits their depolymerisation and regulates the orientation of the mitotic spindle and cellular 
division planes (Hergovich et al. 2003; Thoma et al. 2009; Hell et al. 2014). Consistently, pVHL is 
important for the maintenance of the primary cilium, a microtubule-based sensory organelle 
which is important for renal tubular integrity and suppression of renal epithelial cysts (Thoma et 
al. 2007). Furthermore, pVHL has been shown to bind to collagen and fibronectin and is therefore 
associated with the regulation of the extracellular matrix (ECM) (Ohh et al. 1998; Grosfeld et al. 
2007). pVHL also inhibits the NF-kB transcription factors, which are involved in the regulation of 
the immune system and promote cell survival and proliferation (Yang et al. 2007; Hayden and 
Ghosh 2008). pVHL supresses several cellular processes such as canonical Wnt signalling and 
cellular senescence (Chitalia et al. 2008; Young et al. 2008; Welford et al. 2010). Senescence is 
defined as irreversible growth arrest that occurs when cells encounter oncogenic stress and 
therefore is an important mechanism for preventing the proliferation of potential cancer cells 
(Rodier and Campisi 2011). Finally, pVHL serves as a recognition subunit of an E3 ubiquitin ligase 
complex consisting of Elongin B, Elongin C, Cullin 2 and Rbx-1 (VCB complex) (Pause et al. 1997; 
Lonergan et al. 1998; Lisztwan et al. 1999; Stebbins et al. 1999; Kamura et al. 2000). Under 
normoxic conditions this complex targets the HIFα transcription factors for oxygen-dependent 
proteolytic degradation (Maxwell et al. 1999). Under hypoxia, or in ccRCC cells where functional 
pVHL or Elongin B are missing, the HIFα tƌaŶsĐƌiptioŶ faĐtoƌs aƌe staďilized and induce the 
expression of target genes involved in glycolysis, proliferation, angiogenesis and other cellular 
processes, which have been shown to be important in tumourigenesis (see 6.3.6). The 
investigation of the role of dysregulation of Hif1α and Hif2α in Vhl null cells in the initiation of 
tumour formation was one of the major goals of this thesis. The pVHL ubiquitin ligase complex 
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also facilitates the proteosomal degradation of other proteins including certain isoforms of 
protein kinase C (PCK) and the large subunit of the RNA polymerase II complex (Rbp1) (Okuda et 
al. 2001; Kuznetsova et al. 2003).  
Although loss of pVHL is associated with several potential tumour-promoting pathways it remains 
unclear which of the distinct functions of pVHL contribute to its tumour suppressor activity. To 
address this question a broad range of different Vhl-deficient mouse models have been 
developed during the past years. In 1997, Gnarra et al. reported that the homozygous germ-line 
mutation of Vhl causes embryonic lethality due to a failure of the vascularization of the placenta 
(Gnarra et al. 1997). To circumvent this problem, several conditional mouse models have been 
developed using different segment specific promoters to induce gene deletions in the proximal 
tubule (Rankin et al. 2006), all nephron segments (Frew et al. 2008a; Schley et al. 2011; Mathia 
et al. 2013), the thick ascending loop of Henle or in the distal tubules and collecting ducts 
(Pritchett et al. 2014). Although some models led to fibrosis or mild cyst formation, Vhl-deletion 
in renal epithelium did not cause tumour growth in any of the mouse models.  
Together with the notion that only a few VHL null cells in VHL patients develop into tumours, 
these findings clearly show that the loss of pVHL alone is insufficient for the initiation of ccRCC 
and that additional alterations are necessary for the further transformation of VHL-deficient cells 
into tumour forming cells. Given that animal models for human cancers are an important tool for 
the development of efficient anti-cancer treatments, the main aim of this thesis was the 
generation of an autochthonous mouse model for ccRCC focusing on the specific role of Vhl, Hifα 
and Trp53.  
6.3.6 The hǇpoǆia induciďle factor α ;HIFαͿ transcription factor faŵilǇ 
The hypoxia inducible transcription factor (HIF) family consists of three members: HIFϭα, HIFϮα 
aŶd HIFϯα. HIFϭα aŶd HIFϮα ;also kŶoǁŶ as EPA“ϭͿ haƌďouƌ a tƌaŶsĐƌiptioŶ aĐtiǀatiŶg doŵaiŶ, 
ǁheƌeas the fuŶĐtioŶ of HIFϯα is still uŶĐleaƌ (Gu et al. 1998; Hara et al. 2001). HIFϭα is 
ubiquitously expressed, while HIFϮα is ƌestƌiĐted to eŶdothelial Đells, luŶg, kidŶeǇ, liǀeƌ aŶd 
tumours of various tissues (Semenza 2003; Wiesener et al. 2003). Under hypoxic conditions, 
HIFϭα aŶd HIFϮα ;ĐolleĐtiǀelǇ HIFαͿ tƌaŶsloĐate iŶto the ŶuĐleus ǁheƌe theǇ diŵeƌize ǁith the 
staďle β suďuŶit HIFϭβ ;also known as ARNT) and interact with the transcriptional co-activator 
p300/CBP and bind to a consensus hypoxia-responsive element (HRE) to induce the expression 
of a broad range of target genes (Fig. 6.4) (Banumathy and Cairns 2010). Under normoxic 
conditions a family of prolyl hydroxylases (PHD1-3) catalyses the hǇdƌoǆǇlatioŶ of HIFα using 
molecular oxygen and 2-oxoglutarate as substrates (Schofield and Ratcliffe 2004; Lofstedt et al. 
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2007). These modifications allow the binding of the VCB complex mediated by direct interaction 
between the pVHL protein and pƌolǇl hǇdƌoǆǇlated ƌesidues iŶ HIFα, resulting in the targeting of 
HIFα foƌ pƌoteasoŵal degƌadatioŶ (Maxwell et al. 1999; Ohh et al. 2000). Additionally, the factor 
iŶhiďitiŶg HIF ;FIHͿ hǇdƌoǆǇlates HIFα oŶ a speĐifiĐ aspaƌagiŶǇl ƌesidue, ďloĐkiŶg the iŶteƌaĐtioŶ 
of the transcription factor with the p300 co-activator and therefore preventing the induction of 
gene expression (Mahon et al. 2001). In a variety of tumours the E3 ubiquitin ligase hypoxia 
assoĐiated faĐtoƌ ;HAFͿ ŵediates the degƌadatioŶ of HIFϭα, ďut Ŷot of HIFϮα, iŶ aŶ oxygen-
dependent but pVHL-iŶdepeŶdeŶt ŵeĐhaŶisŵ. HAF also diƌeĐtlǇ ďiŶds to HIFϮα, theƌeďǇ 
promoting its transactivation activity without causing its degradation (Koh et al. 2008; Koh et al. 
2011).  
IŶ additioŶ to the ƌegulatioŶ of HIFα aĐtiǀitǇ ďǇ the aǀailaďilitǇ of oǆǇgeŶ, HIFα eǆpƌessioŶ is 
influenced by growth factors and diverse pathways that are commonly hyperactivated in human 
tumours (Bardos and Ashcroft 2004). For instance, activation of PI3K/Akt signalling under 
normoxia results iŶ iŶĐƌeased HIFα leǀels through upregulation of mTOR-depeŶdeŶt HIFα 
translation (Zundel et al. 2000). Interestingly, mTOR signalling also regulates the expression of 
HIFα. Expression of HIFϭα depeŶds oŶ the aĐtiǀitǇ of ŵTORCϭ aŶd ŵTORCϮ, ǁheƌeas HIFϮα 
expression is only induced by mTORC2 (Toschi et al. 2008). HIFα phosphoƌǇlatioŶ ďǇ the 
Ras/Raf/MAPK pathǁaǇ iŶĐƌeases the staďilitǇ of HIFα, though the ŵoleĐulaƌ ŵeĐhaŶisŵ is Ŷot 
yet clear (Bardos and Ashcroft 2004). Furthermore, PHDs can be inhibited by the Krebs cycle 
intermediates oxaloacetate, succinate and fumarate, ĐoŶŶeĐtiŶg HIFα ƌegulatioŶ to iŶtƌaĐellulaƌ 
metabolism (Sudarshan et al. 2007; Lisy and Peet 2008). 
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Fig. 6.4: Regulation of HIFα actiǀitǇ. Under normoxic conditions, PHD1-ϯ hǇdƌoǆǇlate HIFα, ǁhiĐh is 
recognized by pVHL, a member of a E3 ubiquitin ligase complex (VCB), and targeted for proteosomal 
degƌadatioŶ. IŶ hǇpoǆia, PHDs do Ŷot hǇdƌoǆǇlate HIFα esĐapes the hǇdƌoǆǇlatioŶ aŶd shuttles iŶto the 
ŶuĐleus, ǁheƌe it diŵeƌizes ǁith HIFβ aŶd the tƌaŶsĐƌiptioŶal ĐofaĐtoƌ pϯϬϬ. “uďseƋueŶtlǇ, this complex 
binds to the hypoxia-responsive element (HRE), leading to the expression of various target genes. Further, 
HIFα aĐtiǀitǇ is ƌegulated oŶ tƌaŶsĐƌiptioŶal oƌ tƌaŶslatioŶal leǀel ďǇ seǀeƌal additioŶal pathǁaǇs 
PhǇsiologiĐal HIFα staďilizatioŶ ƌesults in the cellular adaption to changed environmental 
condition by the regulation of the expression of target genes involved in numerous pathways. 
However, most these processes are also associated with tumour formation, including changes in 
energy metabolism (e.g. glucose transporter 1 (GLUT1), phosphoglycerate kinase (PKG) and 
lactose dehydrogenase A (LDHA)), angiogenesis (e.g. vascular endothelial growth factor (VEGF), 
erythropoiesis (erythropoietin (EPO)), epithelial-to-mesenchymal transition (EMT, cell survival 
(e.g. transforming growth factor-α ;TGF αͿͿ aŶd iŶǀasioŶ ;eg. MMPͿ (Gunaratnam et al. 2003; 
Higgins et al. 2007; Koh et al. 2011). In 2005, over 70 direct HIF target genes had been validated 
and numerous additional targets have been published since (Wenger et al. 2005). Importantly, 
Đell Đultuƌe eǆpeƌiŵeŶts haǀe shoǁŶ that HIFϭα aŶd HIFϮα ƌespoŶd diffeƌeŶtlǇ to eŶǀiƌoŶŵeŶtal 
cues. Experiments using different Đell liŶes deŵoŶstƌate that HIFϮα aĐĐuŵulates at ŵodeƌate O2 
concentration (2-ϱ%Ϳ, ǁheƌeas Hifϭα staďilizes oŶlǇ at loǁeƌ ĐoŶĐeŶtƌatioŶ ;Ϭ-2% O2) (Holmquist-
Mengelbier et al. 2006). AdditioŶallǇ, the HIFϭα ƌespoŶse is assoĐiated ǁith aĐute hǇpoǆia, oŶ 
the otheƌ haŶd HIFϮα ŵediates the cellular adaption to chronic hypoxia (Uchida et al. 2004). 
These functional differences are reflected by distinct expression profiles of the two isoforms. 
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Although they share a consensus sequence, HIFϭα preferably induces the expression of genes 
ƌegulatiŶg Đell ŵetaďolisŵ, ǁhile HIFϮα is assoĐiated ǁith the eǆpƌessioŶ of OCTϰ aŶd pƌo-
proliferative genes (Gordan et al. 2008; Keith et al. 2012). Furthermore, HIFϭα aŶd HIFϮα 
ƌeĐipƌoĐallǇ ƌegulate eaĐh otheƌ’s protein levels at least in renal cancer cell lines, since 
suppƌessioŶ of HIFϭα eŶhaŶĐes the eǆpƌessioŶ of HIFϮα aŶd ǀiĐe ǀeƌsa (Raval et al. 2005). In the 
following sections, the role of HIFα iŶ the ƌegulatioŶ of Đellulaƌ ŵetaďolisŵ aŶd pƌolifeƌatioŶ aƌe 
discussed in more detail.  
6.3.6.1 HIFα in the Warďurg effect 
Several studies characterize ccRCC as a metabolic disease (Linehan et al. 2010; Hakimi et al. 2013). 
For instance, mRNA expression and proteomic profiling by the TCGA study demonstrate a global 
metabolic shift in ccRCC, characterized by the decreased activity of AMPK and the TCA cycle, 
increased cellular glutamine transport and higher fatty acid production, as well as an increased 
dependence on the pentose phosphate shunt (The Cancer Genome Atlas Research 2013). HIFϭα 
controls the expression of a large panel of genes involved in cellular metabolism and is associated 
with the metabolic reprogramming of cancer cells. One important function of HIF1α is the 
adaptation of cellular metabolism under hypoxic conditions. In the presence of oxygen, quiescent 
cells mostly metabolize glucose to pyruvate, which then enters the tricarboxylic acid (TCA) cycle 
and is subsequently oxidized to CO2 by oxidative phosphorylation in the mitochondria, leading to 
the production of ATP, NADH (nicotinamide adenine dinucleotide) and NADPH  (Fig. 6.5) (Vander 
Heiden et al. 2009). In this process oxygen is required as final electron acceptor, therefore the 
cells have to reprogram their metabolism under hypoxia to avoid the production of reactive 
oxygen species (ROS) (Hamanaka and Chandel 2009). WheŶ oǆǇgeŶ is liŵited, HIFϭα iŶduĐes the 
transcription of a set of genes that cooperatively mediate the so-Đalled ͞ŵetaďoliĐ sǁitĐh͟. 
Elevated gene expression of the cellular glucose transporter 1 (Glut1) and several glycolytic genes 
(including hexokinases 1 and 2 (HK1/2), phosphofructokinases L (PFKL), aldolase A (ALDA), 
phosphoglycerate kinase (PGK) and enolase 1 (ENO1) and Pyruvate kinase M2 (PKM2)) 
accelerates glycolytic flux and enables the increased production of ATP (Semenza et al. 1994; Luo 
et al. 2011). Fuƌtheƌŵoƌe, the HIFϭα taƌget PDKϭ ;pǇƌuǀate dehydrogenase) inhibits the enzyme 
PDH (pyruvate dehydrogenase), which converts pyruvate to acetyl-CoA (Kim et al. 2006). In 
concert with LDHA (lactate dehydrogenase) PDK1 causes the preferential conversion of pyruvate 
to lactate, thereby diminishing energy production by oxidative phosphorylation and favouring 
aerobic glycolysis (Kim et al. 2006). Since these changes result in elevated lactate levels and 
laĐtate seĐƌetioŶ, the Đell iŶĐƌeases HIFϭα depeŶdeŶt eǆpƌessioŶ of NHE ϭ ;sodiuŵ-hydrogen 
exchanger 1), MCT-4 (monocarboxylate transporter 4) and CA9 (carbonic anhydrase 9) to 
maintain the alkaline intracellular pH and the acidic extracellular pH (Fang et al. 2008; Kroemer 
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and Pouyssegur 2008). AdditioŶallǇ, HIFϭα ŵodifies the aďuŶdaŶĐe of ŵitoĐhoŶdƌial pƌoteiŶs, 
resulting in impaired mitochondƌial aĐtiǀitǇ aŶd deĐƌeased RO“ pƌoduĐtioŶ. OŶ oŶe haŶd, HIFϭα 
regulates the composition of the cytochrome c oxidase (COX, electron transport complex IV) by 
the induction of COX4-2 and LON synthesis. COX4-2 replaces COX4-1 at complex IV, facilitating a 
more efficient mitochondrial respiration without ROS production. LON functions as a 
mitochondrial protease and is required for the degradation of COX4-1 (Fukuda et al. 2007). 
Moreover, the expression of the Complex 1 inhibitor NDUFA4L2 (NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex, 4-like 2) is also ƌegulated ďǇ HIFϭα, theƌeďǇ atteŶuatiŶg 
mitochondrial activity (Tello et al. 2011). On the other hand, Hif1a-dependent BNIP3 expression 
selectively triggers the autophagy of mitochondria (Zhang et al. 2008). FiŶallǇ, HIFϭα fuƌtheƌ 
reduces mitochondrial abundance by blocking the activity of the transcriptional coactivator PGC-
ϭβ ďǇ the ƌepƌessioŶ of MYC aĐtiǀitǇ via MXI-1 (see 6.3.6.2) (Liang and Ward 2006; Zhang et al. 
2007b) 
 
 
 
 
  Introduction 
31 
 
 
Fig. 6.5: Induction of the ŵetaďolic sǁitch ďǇ HIFα. AĐtiǀatioŶ of HIFα leads to aŶ iŶĐƌeased glǇĐolǇtiĐ flux 
by the elevated expression of glycolytic enzymes. Furthermore, mitochondrial activity is decreased by 
preventing the entry of pyruvate in the TCA cycle and simultaneous inhibition of specific complexes of the 
respiratory chain. The increased expression of acid and lactate transporters ensures the maintenance of 
Đellulaƌ pH leǀels. HIFϭα taƌget geŶes aƌe highlighted iŶ ƌed.  
Anaerobic glycolysis does not only serve as a protective mechanism for differentiated cells under 
hypoxic condition. Also proliferating cells metabolize 85% of their pyruvate to lactate under 
normoxia. Although aerobic glycolysis is less efficient than oxidative phosphorylation in terms of 
ATP production per glucose-derived carbon, proliferating cells benefit from the increased 
availability of intermediates for the production of nucleotides, amino acids and lipids that are 
required for further proliferation (Lehninger et al. 1993; Vander Heiden et al. 2009). Consistently, 
the metabolic reprogramming from oxidative phosphorylation to glycolysis is a common feature 
of cancer cells even in the presence of sufficient oxygen. This phenomenon is widely known as 
anaerobic glycolysis or Warburg effect and represents one of the hallmarks of cancer (Hanahan 
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and Weinberg 2000). Already in 1942 Otto Warburg observed a fundamental difference in the 
metabolism of cancer cells compared to normal tissues. He found that unlike most normal tissues 
cancer cells tend to metabolize glucose into lactate even in the presence of sufficient oxygen, 
indicating a shift from oxidative phosphorylation to glycolysis (Warburg, 1956). Since the function 
of mitochondria is not impaired in most cancer cells, these changes in cell metabolism enable the 
cell to employ aerobic glycolysis and oxidative phosphorylation to maximize the availability of 
energy (ATP), reducing equivalents (NADH, NADPH) and macromolecules for biogenesis (Vander 
Heiden et al. 2009).  
A big body of data based on tuŵouƌ ďiopsies aŶd ĐaŶĐeƌ Đells liŶes doĐuŵeŶt a HIFα-dependent 
metabolic reprogramming in ccRCC (Papandreou et al. 2006; Zhang et al. 2007a; Langbein et al. 
2008; Luo et al. 2011; The Cancer Genome Atlas Research 2013; Li et al. 2014). Consistently, a 
very recent study of 200 ccRCCs revealed the depletion of the fructose-1,6bisphosphatase 1 
(FBP1) in almost 100% of ccRCC tumours examined, leading to increased glycolytic flux and 
promotion of HIFα activity (Li et al. 2014), further arguing that there is a selection for enhanced 
glycolysis during the formation of ccRCC. However, the importance of these metabolic changes 
in tumour initiation remains unclear, since they could be a requirement for or a consequence of 
disease progression. Using the genetically engineered mouse models escribed above, we aimed 
to understand the impact of Hif1a-dependent metabolic alterations in regulating cellular 
behaviour and proliferation in culture and their consequences in vivo. 
6.3.6.2 HIFα in cell proliferation  
Although HIF1α and HIF2α ďiŶd to the saŵe ĐoŶseŶsus sequence on common target genes, an 
iŶĐƌeasiŶg aŵouŶt of data iŶdiĐates that theǇ haǀe opposiŶg effeĐts oŶ Đell pƌolifeƌatioŶ: HifϮα 
pƌoŵotes ǁhile Hifϭα ƌatheƌ ƌestƌaiŶs pƌolifeƌatioŶ. Tissue microarrays show that ccRCC 
eǆpƌessiŶg oŶlǇ HIFϮα, but not HIF1α, are significantly larger in volume and display a stronger 
staining for the proliferation marker Ki67 when compared to tumours expressing both HIF 
isoforms. Furthermore, HIF2α stabilization is associated with more advanced disease as HIF1α 
expression gradually decreases whereas HIF2α protein becomes more abundant during ccRCC 
progression (Mandriota et al. 2002). Consistently, loss of chromosome 14q which harbours the 
HIF1a allele is a frequent event ccRCC associated with poor disease outcome (Shen et al. 2011). 
Xenograft studies showed that silencing of HIFϮα iŶ RCC iŶĐƌeases gƌoǁth ƌates Đoŵpaƌed to 
control tumouƌs, ǁheƌeas HIFϭα decelerates cell growth (Biswas et al. 2010). Moreover, silencing 
of HIFϮα iŶ pVHL-deficient RCC cells is sufficient to suppress tumour formation (Kondo et al. 2002; 
Kondo et al. 2003). Intriguingly, most ccRCC cell lines exhibit a biallelic inactivation of HIF1a and 
ƌeiŶtƌoduĐtioŶ of Hifϭα iŵpaiƌs pƌolifeƌatioŶ in vitro. Consistently, doǁŶƌegulatioŶ of HIFϭα iŶ 
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RCCϰ Đells, a ĐĐRCC Đell liŶe eǆpƌessioŶ ďoth HIFα isofoƌŵs, pƌoŵotes Đell pƌolifeƌatioŶ in vitro 
and in vivo, as shown by the implantation of cells in the kidney of nude mice (Shen et al. 2011). 
The diffeƌeŶt effeĐts of HIFϭα aŶd HIFϮα oŶ pƌolifeƌatioŶ ŵaǇ at least paƌtlǇ ďe eǆplaiŶed ďǇ the 
opposiŶg effeĐts of HIFα isofoƌŵs oŶ the activity of the transcription factor MYC. Several studies 
have shown that HIFϭα aŶtagoŶizes MYC-depeŶdeŶt geŶe eǆpƌessioŶ, ǁhile HIFϮα pƌoŵotes 
MYC activity by several mechanisms. HIF2α eŶhaŶĐes MYC aĐtiǀitǇ ďǇ the staďilisatioŶ of the 
binding between MYC and its cofactor MAX, thereby augmenting the expression of genes 
involved in cell cycle progression such as cyclin D1 and D2 and inhibiting the synthesis of the cell 
cycle inhibitors p21 and p27 (Mack et al. 2005; Gordan et al. 2007). In contrast, HIF1α antagonizes 
MYC activity either by the direct binding to MYC itself or by the competitive binding to MAX and 
SP1, which is another MYC cofactor (Koshiji and Huang 2004; Koshiji et al. 2004). Moƌeoǀeƌ, HIFϭα 
stabilization promotes the proteasomal degradation of MYC and elevates the transcription of 
MX1-1, a MYC inhibitor (Zhang et al. 2007a). Concordantly, amplification of MYC on chromosome 
5c is another frequent event in ccRCC (Shen et al. 2011). While tuŵouƌs eǆpƌessiŶg oŶlǇ HIFϮα 
tend to display high levels of MYC expression and activation of MYC target genes, VHL wild type 
and HIFϭα/HIFϮα eǆpƌessiŶg ĐĐRCC shoǁ iŶĐƌeased aĐtiǀitǇ of MAP kiŶases aŶd TOR sigŶalliŶg 
pathways (Gordan et al. 2008). 
Taken together, these data suggest that a shift in the balance between HIF1α and HIF2α is a 
critical step in ccRCC formation and raise the hǇpothesis that the loss of HIFϭα aĐtiǀitǇ iŶ VHL-
deficient cells represents an oncogenic event (Gordan et al. 2008). However, most of these 
studies were performed in transformed cancer cell lines and it remains unclear whether the 
opposing effects of HIFϭα aŶd HIFϮα also play a role in the initial steps of ccRCC formation. 
Therefore, we aimed to dissect the different roles of HIFα isoforms on proliferation and 
transformation capacity in vivo.   
6.3.7 The tumour suppressor gene Trp53  
The transcription factor p53, encoded by the TP53 gene (Trp53 in mice), is mutated in 50% of all 
human cancers and controls various cancer-related processes as a tumour suppressor (Hollstein 
et al. 1994). The main regulator of p53 activity is the proto-oncogene Mdm2 (murine double 
minute 2), which acts as an E3 ubiquitin ligase, targeting p53 for degradation (Freedman and 
Levine 1999). Additionally, Mdm2 binds to p53 and prevents its transcriptional activity by 
interfering with the transcriptional machinery (Kubbutat et al. 1997; Thut et al. 1997). 
Intriguingly, Mdm2 itself is a transcriptional target of p53, enabling a fine-tuned balance between 
both proteins (Wu et al. 1993). Stress stimuli such as DNA damage, hypoxia, oncogene activation 
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or nutrient deprivation disturb the balance between Mdm2 and p53 and therefore activate a 
broad range of downstream processes including cell cycle arrest, apoptosis and genome stability. 
All these pathways are major mechanisms for tumour suppression, explaining the importance of 
p53 in tissue integrity. pVHL and hypoxia activate p53 signalling on several levels. For example, 
pVHL associates with p53 and thereby prevents the Mdm2-mediated ubiquitination and nuclear 
export of p53 (Roe et al. 2006). Further, studies in RCC cell lines demonstrated that inhibition of 
HIFϮα pƌoŵotes pϱϯ-depeŶdeŶt Đell death aŶd, iŶ ĐoŶtƌast to HIFϭα, eŶhaŶĐes the ƌespoŶse to 
radiotherapy, again underlying the pro-tuŵouƌigeŶiĐ aĐtiǀitǇ of HIFϮα (Bertout et al. 2009) 
(Roberts et al. 2009). One example for p53 downstream signalling is the regulation of cell cycle 
progression: DNA damage causes the p53-dependent expression of the cell cycle inhibitor p21 
(coded by Cdkn1a), which facilitates the accumulation of pRb and induces cell cycle arrest. If DNA 
repair is successful, p53 levels drop, allowing the entry into S-Phase. If not, p53 triggers apoptosis 
to prevent the establishment of oncogenic mutations (Sebastian et al. 2010). Similarly, the 
activation of oncogenes including RAS and MYC cause p53-dependent senescence or apoptosis 
(Sebastian et al. 2010). Recent findings also suggest a role of p53 in the regulation of cellular 
metabolism. Depending on oxygen and nutrient availability p53 modulates the expression of 
numerous of genes involved in glycolysis, oxidative phosphorylation, mitochondrial integrity, 
autophagy, mTOR signalling and other metabolic pathways (Jiang et al. 2011; Maddocks and 
Vousden 2011). Together, these changes promote the use of catabolic pathways to maintain 
energy production in periods of limited nutrients to ensure cell survival.  
Loss of p53 signalling activity or other cell cycle regulators disables the most important cellular 
self-protection mechanisms and facilitates the formation of cancers. To identify whether 
mutations in cell cycle regulators might represent another oncogenic event in the formation of 
ccRCC, we screened for pro-proliferative combinations in Vhl and Vhl/Hif1α negative primary 
kidney cells using a lentiviral based shRNA library targeting cell cycle regulators.  
6.3.8 Aim  
The goal of this thesis was to gain a better understanding of the initial events in the formation of 
ccRCC. ccRCC accounts for approximately 2.5 % of all adult malignancies and cannot be cured 
once it spreads beyond the kidney (Jonasch et al. 2012). Despite extensive research, the 
generation of suitable animal models has failed so far, indicating an insufficient knowledge about 
the molecular mechanism of the disease. Nevertheless, it has become clear over the last years 
that loss of function of the tumour suppressor pVHL is necessary but not sufficient to drive 
tumourigenesis in the renal epithelium. Furthermore, genetic profiling of human biopsies show 
that a high number of ccRCC tumours harbour a deletion of HIF1A, presumably promoting the 
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transformation of cancer cells (Monzon et al. 2011). We developed several mouse models 
harbouring specific deletions of Vhl, Hif1a or Hif2a and Trp53 either together or alone to 
investigate their cooperative effect in tumour initiation and progression in vivo. One of my main 
goals was to analyse the effects of the specific gene deletions in Vhl/Hif1a and Vhl/Hif1a/Trp53 
deficient mice. Primary cells from these mice also allowed us to further dissect the roles of Hif1α 
and Hif2α in the early stages of tumour formation, focusing on their effect on cell metabolism 
and cell transformation capacity. Moreover, we investigated whether the inactivation of specific 
cell cycle regulatory proteins, especially the deletion of the tumour suppressor Trp53 further 
transforms Vhl and Vhl/Hif1α negative cells, potentially representing another oncogenic event 
during cancer evolution.  
6.4 Hydronephrosis  
6.4.1 Prevalence and management of hydronephrosis 
Hydronephrosis is defined as an increase in the diameter of one or more components of the renal 
collecting duct (Thom and Rosenblum 2013). Antenatal ultrasound screening at 18-20 weeks 
gestation revealed congenital abnormalities in 1-2% of all pregnancies, whereas congenital 
hydronephrosis is with an overall prevalence of approximately 0.6% the most frequently detected 
abnormality (Livera et al. 1989; Dudley et al. 1997). In fifty percent of the patients both kidneys 
were affected (Dudley et al. 1997). Most cases of prenatally diagnosed hydronephrosis stabilize 
or even resolve spontaneously after birth or within the first two years of life (Woodward and 
Frank 2002). However, 10 – 25% of the cases show persistent severe dilatation and require 
medical or surgical intervention to prevent kidney insufficiency. Therefore, the decision for 
therapy is critical and the need for better treatment guidelines has been recently reported (Braga 
et al. 2014). In general, the likelihood of a patient for having significant postnatal abnormalities 
is proportional to the severity of the antenatally detected hydronephrosis (ANH) (Grignon et al. 
1986). In very rare cases hydronephrosis progresses significantly during pregnancy, requiring 
prenatal intervention to prevent further renal dysplasia (Yamacake and Nguyen 2013). In most 
cases conservative management of hydronephrosis is conducted, including antibiotic therapy to 
prevent urinary tract infections and regular ultrasound scans. However, progressive 
hydronephrosis, decreasing renal function and recurrent infection are clear indications for 
surgical intervention. Untreated hydronephrosis – or more precisely lack of treatment of the 
underlying etiology – leads to proteinuria, degeneration of nephrons, glomerulosclerosis and 
tubular atrophy, which eventually leads to chronic kidney insufficiency and end stage renal 
disease (Bailey et al. 1994; Rasouly and Lu 2013). Nevertheless, surgery for hydronephrosis 
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especially in neonates is technically challenging, leading to a high risk of complications and should 
therefore be considered carefully (Peters et al. 1989). Thanks to improved conservative 
management of urological conditions over the years only about 5% of patients with ANH will 
ultimately require surgery (Woodward and Frank 2002).   
In the literature, hydronephrosis is divided in an obstructive or a non-obstructive form. The most 
commonly used diagnostic tool to asses for obstruction is the diuretic renography using 
Mercaptoacetyltriglycine (Tc99m-MAG3) as radiolabelled agent (Hashim and Woodhouse 2012), 
where delayed MAG3 clearance is used as an indicator for obstruction (Kathel 1971). Although 
several disorders have been associated with the formation of congenital or acquired 
hydronephrosis, the underlying etiologies are often not fully understood and further research is 
required. We recently reported that specific deletion of the tumour suppressor Vhl in renal 
epithelial cells causes hydronephrosis in mice, however, the underlying mechanism remained 
unclear (Frew et al. 2008b). In the second part of this thesis, we aimed to identify these 
mechanisms by the investigation of possible molecular or obstructive causes. In the following 
sections, we present a review of the current literature on obstructive and non-obstructive 
hydronephrosis.  
6.4.2 Obstructive hydronephrosis 
6.4.2.1 Description 
Congenital anormalities of the ureter often cause impaired urine transport from the kidney to 
the bladder, causing urinary obstruction (blockage of urine transport by functional or physical 
obstruction) or vesicoureteral reflux (VUR) – the abnormal, retrograde flow of urine from bladder 
to the upper urinary tract (Gargollo and Diamond 2007). Both events increase the pressure in the 
ureter and renal pelvis eventually causing hydronephrosis and hydroureter, the dilation of the 
ureter (Rasouly and Lu 2013). Ureteropelvic junction obstruction (UJP) is the most common cause 
for marked hydronephrosis (renal pelvic diameter (RPD) > 10 mm), diagnosed in 10-30% of the 
cases (Podevin et al. 1996; Yamacake and Nguyen 2013). UJP is generally thought to be due to an 
abnormal development of the ureter just at the ureterojunction or proximal ureter (Peters 1995). 
In contrast, VUR is the most likely diagnosis in mild hydronephrosis (RPD = 5-9 mm) with a 
prevalence of 10-40% (Podevin et al. 1996; Yamacake and Nguyen 2013). Other causes of 
congenital hydronephrosis such as the obstruction of urterovesical junction (UVJ) (5-15%), 
multicystic dysplastic kidney (2-5%), posterior urethral valves (1-5%) and ureterocele (1-3%) are 
much less common (Yamacake and Nguyen 2013).  
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Mechanical obstructions caused by kidney stones, pregnancy or by tumours such as pelvic 
neuroblastoma can lead to hydronephrosis (Au et al. 1985; Woo et al. 2013). Interestingly, 
hydronephrosis can be observed in around 80% of all pregnancies, mostly caused by the 
mechanical compression of the ureter (Cheung and Lafayette 2013) (Au et al. 1985). Furthermore, 
hydronephrosis caused by obstructions due to impaired neuronal control of the upper urinary 
tract are a well-known complication of patients with spinal cord injury (Tsai et al. 2001; 
Vaidyanathan et al. 2009; Lai et al. 2014). 
The generation of non-genetic mouse models have enabled to study the effect of fetal 
obstructions of the urinary system, such as surgical induction of obstructions in guinea pigs 
(Chevalier and Kaiser 1984) or in fetal sheep. The latter is the most widely used model as the 
sheep kidney resembles the human kidney in terms of gestation time and pattern of renal 
development. These studies have shown that the surgical induction of partial or complete 
ureteral obstruction at different time points of gestation have profound effects on kidney 
function, such as decreased creatinine clearance and glomerular filtration rate, increased 
fractional excretion of sodium, and formation of hydronephrosis (Glick et al. 1983). Additionally, 
increased blastemal apoptosis leading to the formation of hydronephrosis was observed in a 
model of urinary bladder outflow obstruction. (Samnakay et al. 2006).  
6.4.2.2 Molecular mechanisms   
The genetic mechanisms causing obstructive uropathy are largely undefined. The generation of 
different mouse models and the investigation of human disorders have associated various 
pathways with urinary tract development including Wnt signalling (Yu et al. 2002; Trowe et al. 
2012), TGF-β sigŶalling (Miyazaki et al. 2000; Tripathi et al. 2012), Receptor tyrosine kinases (RTK) 
and the Hedgehog signalling pathway (Caubit et al. 2008).  Mutations in genes involved in these 
pathways potentially lead to malformations of the kidney, ureter or bladder (Rasouly and Lu 
2013), possibly resulting in obstructive or non-obstructive hydronephrosis. One example of a 
human disorder characterized by developmental abnormalities such as urethral obstruction and 
mesodermal developmental defects is the Prune-Belly Syndrome (PBS) (Manivel et al. 1989). 
Antenatal sonography of children with this syndrome revealed bilateral hydroureter and 
hydronephrosis, thin-walled bladder and a deficiency in amniotic fluid due to impaired kidney 
function (Woods and Brandon 2007; Chen et al. 2010). Although mutations in HNF1B (hepatocyte 
nuclear factor 1B) and CHRM3 (muscarinic cholineric receptor 3) have recently been associated 
with cases of familial PBS, the molecular mechanisms of the syndrome are widely unknown (Haeri 
et al. 2010; Hassett et al. 2012) (Weber et al. 2011). Moreover, defects in the ureteric budding, 
ureter differentiation and elongation, peristalsis, UVJ formation and bladder development have 
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been associated with vesicoureteral reflux (VUR), all being possible causes for obstructive 
hydronephrosis. Recently, mutations in several genes such as PAX2, Sox17 and Ret have been 
connected to the development of VUR (Rasouly and Lu 2013). 
6.4.3 Non-obstructive hydronephrosis 
6.4.3.1 Description 
Hydronephrosis can also occur without clinically significant obstruction and some studies report 
that the majority of cases are non-obstructive in nature (Woodward and Frank 2002; Thom and 
Rosenblum 2013). Excess urine production due to diverse underlying disorders can cause a back 
pressure on the kidney, leading to expansion of the renal pelvis and the collecting system. For 
instance, prolonged polyuria has been described as cause of bilateral non-obstructive 
hydronephrosis in cases of nephropathic diabetes insipidus (NDI), neurogenic diabetes insipidus, 
psǇĐhogeŶiĐ polǇdipsia aŶd the Batteƌ’s sǇŶdƌoŵe ;see ďeloǁͿ (Wheeler and Hanchey 1971; 
Harrison et al. 1979; Uribarri and Kaskas 1993). Furthermore, renal urine overload might also be 
the cause of some cases of antenatally diagnosed hydronephrosis. Fetal urine production is four 
to six times higher than after birth, possibly causing transient or persistent dilation of the renal 
pelvis (Walsh PC 2002; Thom and Rosenblum 2013). Finally, studies on rare human disorders such 
as the Pallistor-Hall Syndrome (PHS) revealed that congenital malformation of structures 
supporting the urinary tract can lead to non-obstructive hydronephrosis (Chang et al., 2004).  
6.4.3.2 Molecular mechanisms 
NDI is characterized by an impaired renal response to arginine vasopressin (AVP) stimulation and 
subsequent failure to regulate renal water reabsorption (Fujiwara, Morgan et al. 1995). In 
contrast, neurogenic diabetes insipidus is caused by an impaired production of vasopressin (AVP) 
in the brain (Di Iorgi et al. 2012). Genetic studies demonstrated that NDI is caused by mutations 
in the V2 type vasopressin receptor or in Aquaporin 2 (AQP2), an AVP-sensitive water channel 
(Pan et al. 1992; Moon et al. 2009). This notion is also supported by the generation of several 
mouse models with mutations in AQP2 or the Vasopressin receptor. Interestingly, 
hydronephrosis occurs only in a small subset of patients , whereas it is a common feature in 
mouse models for NDI (van Lieburg et al. 1999; Yun et al. 2000; McDill et al. 2006; Jin et al. 2009).  
Furthermore, decreased expression of AQP1, 2, 3 and 4 were observed in children with congenital 
hydronephrosis as well as in a spontaneous mutation model for hydronephrosis in mice 
(Ampawong et al. 2012). Although the degree of hydronephrosis correlates with the grade of AQP 
downregulation in humans, in both studies it remains unclear whether altered AQP expression is 
the cause for or a consequence of hydronephrosis. This question becomes relevant in the light of 
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a study of Li et al. in rats, where the authors surgically induced a bilateral ureteral obstruction 
(BUO) for 24h. Subsequent analysis of animals revealed the down regulation of AQP1, 2 and 3, 
which persisted up to 30 days after release of BUO. Moreover, these features correlated with 
polyuria and impaired urine concentration (Li et al. 2001).   
The Bartter syndrome is a group of rare autosomal-recessive disorders that are characterized by 
the severe reduction or lack of salt absorption by the thick ascending limb of Henle (TAL). Patients 
suffer from polyuria, renal salt wasting, hypokalemic metabolic alkalosis and elevated renin and 
aldosterone levels (Hebert 2003). So far, mutations in five genes have been identified in patients 
that lead to the classification of type I-IV Bartter syndrome. Three genes encode ion transporters 
(Type I-III): SLC12A (sodium-potassium chloride co-transporter NKCC2), KCNJ1 (renal outer 
medulla potassium channel, ROMK) and Clcnk (Cloride channel-K b, ClC-Kb). The other two genes 
identified are responsible for the regulation of TAL ion transporters (BSND and CaSR, type IV and 
V). Interestingly, patients with Type IV disease also suffer from sensorineuronal deafness since 
Barttin, the gene product of BSND, is required for the function of ClC-K channels in the inner ear 
(Jeck et al. 2001). Inactivation of NKCC2 and ROMK in the TAL enabled the generation of mouse 
ŵodels of Baƌtteƌ’s sǇŶdƌoŵe (Takahashi et al. 2000; Wagner et al. 2008; Yan et al. 2008). 
Wheƌeas hǇdƌoŶephƌosis is oŶlǇ oĐĐasioŶallǇ oďseƌǀed iŶ Batteƌ’s patieŶts, these ŵouse ŵodels 
exhibit a severe phenotype. Since the grade of polyuria correlates with the grade of 
hydronephrosis, the authors speculated that the back pressure produced by excess urine volume 
causes the hydronephrosis (Takahashi et al. 2000). Interspecies differences might be explained 
by differences in kidney structure or maturity after birth.  
As mentioned above, developmental malformation can also cause non-obstructive 
hydronephrosis. For example, Cain et al discovered a critical role of the Hedgehog signalling 
pathway in urogenital tract morphogenesis and function in a mouse model for the Pallister-Hall 
syndrome (PHS) (Cain et al. 2011). PHS, a rare disorder characterized by abnormalities of the 
kidney and other organs, is caused by mutations in the transcriptional repressor GLI3, a member 
of the Hedgehog pathway (Narumi et al. 2010). In mice, pathway inactivation by the deletion of 
Smoothened (Smo) in the renal pelvic and the upper ureteric mesenchyme resulted in non-
obstructive hydronephrosis and hydroureter, probably due to impaired unidirectional ureter 
peristalsis (Cain et al. 2011).   
6.4.4 Aim  
We recently reported that specific deletion of the tumour suppressor Vhl in renal epithelial cells 
causes hydronephrosis in mice, however, the underlying mechanism remained unclear (Frew et 
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al. 2008b). Vhl is a multipurpose protein involved in several pathways that are associated with 
the formation of hydronephrosis (see 6.3.5 for detailed discussion of pVhl function). For instance, 
numerous studies report interactions between Vhl activity and Wnt-β-catenin signalling 
presumably in a cell-specific manner, although the precise mechanism remains unclear (Berndt 
et al. 2009). For instance, Vhl decreases Wnt signalling by promoting the stabilization of Jade-1, 
an ubiquitinase responsible for the degƌadatioŶ of β-catenin (Zhou et al. 2004; Chitalia et al. 
2008). In contrast, Hifϭα haŵpeƌs the aĐtiǀatioŶ of β-catenin whereas Hif2a stimulates Wnt 
signalling (Lim et al. 2008; Choi et al. 2010). Furthermore, a recent study has shown that Vhl 
inhibits Hedgehog signalling by the direct interaction with Gli 1 (Cho et al. 2013). Finally, Abreu-
Rodriguez at al. showed that hypoxic stabilization of Hif1α increased Aqp1 expression in mouse 
hemangioendothelioma endothelial (EOMA) cells. This finding is supported by elevated Aqp1 
levels in brain and lung of mice exposed to hypoxia (Abreu-Rodriguez et al. 2011). Interestingly, 
decreased AQP1 abundance has also been described as a positive prognostic marker in ccRCC 
(Huang et al. 2009). A recent study directly links Hif1a with bladder outlet obstruction in rats. Six 
ǁeeks afteƌ suƌgiĐal ĐƌeatioŶ of oďstƌuĐtioŶ, iŶĐƌeased Hifα aďuŶdaŶĐe aŶd eǆpƌessioŶ of 
glycolytic enzymes were measured in the bladder. However no hydronephrosis was reported. 
The authors hypothesize that a switch to anaerobic glycolysis ensures maintained contractility 
and thereby upholds a normal micturition cycle (Ekman et al. 2014).  
In the second part of this thesis, we aim to understand the underlying mechanism of 
hydronephrosis in Vhl deficient mice. Hydronephrosis is a common complication in several 
human diseases and causes chronic kidney insufficiency and end stage renal disease when not or 
only insufficiently treated (Bailey et al. 1994; Rasouly and Lu 2013). Although several urinary tract 
malformations or genetic mutations have been associated with the formation of hydronephrosis, 
many questions remain unclear. For instance, little is known about the contribution of these 
malformations to chronic kidney disease and renal failure (Rasouly and Lu 2013). In this context, 
our mouse model is of special interest, since the mice display a normal life span and even aged 
kidneys show an intact morphology – except of the expanded renal pelvis. We therefore 
investigated possible molecular and obstructive causes potentially leading to hydronephrosis and 
its effect on kidney function.  
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7 Materials and Methods 
7.1 Materials 
7.1.1  General Chemicals  
Reagent Supplier 
30% Acrylamide/Bisacrylamide Solution Bio-Rad 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) Sigma-Aldrich 
Acetic acid (glacial) Merck 
Acetone Sigma-Aldrich 
Agar Sigma-Aldrich 
Agarose, D1 low EEO Conda 
Agarose, low melting point Sigma-Aldrich 
 Albumin from bovine serum Sigma-Aldrich 
Ammonium carbonate Sigma-Aldrich 
Ammonium chloride Fluka 
Boric acid Sigma-Aldrich 
Bovine serum albumin (BSA) Invitrogen 
Bromophenol blue Sigma-Aldrich 
Citric acid monohydrate Sigma-Aldrich 
Crystal violet Sigma-Aldrich 
CSA detection kit Dako 
Dimethylsulfoxide (DMSO) Sigma-Aldrich 
di-sodium hydrogen orthophosphate (Na2HPO4) Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Entellan Merck 
Eosin 1% (aqueous) BioSystems 
Ethanol AUL 
Ethidium bromide  Sigma-Aldrich 
Ethylenediamine tetra-acetic acid (EDTA) disodium salt dihydrate Sigma-Aldrich 
Formalin 10%, neutral buffered Sigma-Aldrich 
Glycerol Sigma-Aldrich 
HaeŵatoǆǇliŶ ;MaǇeƌ’sͿ J.T.Baker 
Hydrochloric acid, 32% Sigma-Aldrich 
Hydrogen peroxide Sigma-Aldrich 
Isopropanol AUL 
Lactate assay Kit II Biovision 
Magnesium chloride Sigma-Aldrich 
Magnesium sulfate Sigma-Aldrich 
Methanol AUL 
Mineral oil Sigma-Aldrich 
Mowiol  Sigma-Aldrich 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Bio-Rad 
N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) Sigma-Aldrich 
NP-40 Sigma-Aldrich 
NucleoBond Xtra Midi Macherey-Nagel 
NucleoSpin RNA kit Macherey-Nagel 
Paraformaldehyde Sigma-Aldrich 
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Reagent Supplier 
p-coumaric acid Sigma-Aldrich 
Phenyl-methyl-sulphonyl-fluoride (PMSF) Sigma-Aldrich 
Potassium acetate  
Potassium chloride Sigma-Aldrich 
Propidium iodide (PI) Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Protein assay Dye Reagent Bio-Rad 
Safflower oil Migros 
Sodium acetate Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Sodium dihydrogen orthophosphate (NaH2PO4) Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
Sulforhodamine B sodium salt (SRB) Sigma-Aldrich 
SYBR FAST Universal 2X qPCR Master Mix KapaBiosystems 
SYBR Green JumpStart Taq ReadyMix Sigma-Aldrich 
Trichloroacetic acid Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane (Tris base) Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl) Sigma-Aldrich 
Tri-Sodium citrate Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
Visipaque 270  GE Healthcare 
Xylene Thommen-Furler AG 
 
7.1.2  Drugs & tissue culture reagents 
Reagent  Supplier 
2Mercaptoethanol Bio-Rad 
2´,7´-dichlorodihydrofluorescein diacetate Invitrogen 
3,3,5 Triiodothyronine (T3) Sigma-Aldrich 
5-Bromo-2'-deoxyuridine (BrdU) Sigma-Aldrich 
Acridine Orange 10-nonyl bromide Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Apo-Transferrin (TF), human Sigma-Aldrich 
Calcium chloride Sigma-Aldrich 
Collagenase Type II Gibco 
Cycloheximid Sigma-Aldrich 
D-glucose Sigma-Aldrich 
DMEM without L-methionine, L-cystine Sigma-Aldrich 
DMEM/F12 Sigma-Aldrich 
DulďeĐĐo’s Modified Eagle Mediuŵ ;DMEMͿ Sigma-Aldrich 
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Reagent  Supplier 
Epidermal Growth factor (EGF), murine PeproTech 
Fetal Calf Serum (FCS) Biochrome AG 
G418 (geneticin) Sigma-Aldrich 
HBSS Gibco 
Hepatocyte Growth factor (HGF) PeproTech 
HEPES 1M Sigma-Aldrich 
Hydrocortisone (HC) Sigma-Aldrich 
Insulin, human Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
L-Glutamine Sigma-Aldrich 
Matrigel (growth factor reduced) Corning 
Met-[S35]-label (SCIS-103) Hartmann Analytics 
Penicillin/Streptomycin PAA 
Phosphate Buffered Saline (PBS) Biochrome Ag 
Polybrene (Hexadimethrine Bromide) Sigma-Aldrich 
Prostagladin E1 (PGE1) Sigma-Aldrich 
Puromycin InvivoGen 
Sodium bicarbonate Sigma-Aldrich 
Sodium Selenite (SS) Sigma-Aldrich 
Tamoxifen Sigma-Aldrich 
Trypsin EDTA Gibco 
Trypsin inhibitor, soybean Gibco 
 
  
  Materials and Methods 
44 
 
7.1.3  Kits 
Name $upplier 
ABC Kit (PK6100) Vectorstain 
Avidin/Biotin Blocking Kit (SP 2001) VectorLaboratories 
CellTiter-Glo Luminescent Cell Viability Assay Promega 
DAB Substrate Kit (SK-4100) VectorLaboratories 
GenElute Mammalian Genomic DNA Miniprep Kit Sigma-Aldrich 
Glucose assay Kit II Biovision 
Lactate assay Kit II Biovision 
NucleoBond Xtra Midi Macherey-Nagel 
NucleoSpin RNA kit Macherey-Nagel 
Ready-To-Go You-Prime First-Strand Beads GE Healthcare 
7.1.4 Antibodies  
Name Vendor Order 
number 
Source Dilution Applicati
on 
AE1 Gift from Wagner 
Lab 
- Rabbit 1:250 IF 
Alexa-488 Anti-
mouse 
Life technologies A11029 Goat 1:1000 IF 
Alexa-488 Anti-
rabbit 
Life technologies A11008 Goat 1:1000 IF 
Alexa-488 Anti-rat Life technologies A11006 Goat 1:1000 IF 
Alexa-568 Anti-
mouse 
Life technologies A11031 Goat 1:1000 IF 
Alexa-568 Anti-
rabbit 
Life technologies A11036 Goat 1:1000 IF 
Alexa-568 Anti-rat Life technologies A11077 Goat 1:1000 IF 
AMPKα ;FϲͿ Cell Signaling 
Technologies 
2793 
 
mouse 1:1000 WB 
Aquaporin 2 Gift from Loffing 
Lab 
- Rabbit 1:3500 IF 
ATP V1B1 Gift from Wagner 
Lab 
- Rabbit 1:250 IF 
BrdU Milipore MAP3510 Mouse  IF 
Glut1 Abcam Ab14683 Rabbit 1:500 WB/IF 
Hif1α  Novus 
Biotechnologies 
NB-100-479 Mouse 1:500 Wb 
Hif1α ;HϭαϲϳͿ Novus 
Biotechnologies 
NB-100-105 Mouse 1:20000 IHC 
Hif2α Pollard et al. 2007 PM8 rabbit 1:2500 IHC 
HRP anti-mouse ThermoScientific 31430 Goat 1:1000 IHC 
HRP anti-rabbit ThermoScientific 31460 Goat 1:1000 IHC 
LDH-A (N-14) Santa Cruz 
Biotechnology 
Sc-27230 
 
Goat 1:1000 WB 
NaPi2 Gift from Biber Lab - Rabbit 1:500 IF 
NCC Millipore AB3553 Rabbit 1:500 IF 
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NKCC2 Gift from Loffing 
Lab 
- Rabbit 1:250 IF 
p53 Leica 
Microsystems 
NCL-p53-
CM5p 
Rabbit 1:1000 WB 
PDK-1 Enzo Life Sciences ADI-KAP-
PK112-D 
Rabbit 1:1000 WB 
Pendrin Gift from Wagner 
Lab 
- Rabbit 1:250 IF 
Tamm Horsfall 
Protein (H-135) 
Santa Cruz 
Biotechnologies 
Sc-20631 Rabbit 1:250 IF 
Tubulin, acetylated Sigma-Aldrich T6793 Mouse 1:1000 IF 
Vhl (FL-181) Santa Cruz 
Biotechnologies 
Sc-5575 Rabbit 1:100 WB 
β-Actin (AC-74) Sigma-Aldrich A2228 Mouse 1:1000 WB 
7.1.5 Oligonucleotide sequences 
Name Sequence Application 
Control band cre fwd ATA ATG CCT TTC CTC AGT AAA CCA G Genotyping 
Control band cre rev GGA TCC CAT TAC AGA TGG TTG TG Genotyping 
Cre fwd AGG TTC GTG CAC TCA TGG A Genotyping 
Cre rev TCG ACC AGT TTA GTT ACC C Genotyping 
Hif1a fwd GGA GCT ATC TCT CTA GAC C Genotyping 
Hif1a rev GCA GTT AAG AGC ACT AGT TG Genotyping 
Hif2a fwd GAG AGC AGC TTC TCC TGG AA Genotyping 
Hif2a rev TGT AGG CAA GGA AAC CAA GG Genotyping 
p53 fwd GCC CTC TCT TAT CGC CAG AT Genotyping 
p53 rev GCT TAT GGG CTT CTC CAA ACT Genotyping 
Vhl fwd GGA GTA GGA TAA GTC AGC TG Genotyping 
Vhl rev GTA CAC CTG AGA GCG GCT TC Genotyping 
Aqp1 fwd AGG CTT CAA TTA CCC ACT GGA RT-qPCR 
Aqp1 rev GTG AGC ACC GCT GAT GTGA RT-qPCR 
Aqp11 fwd TGG GGC TAA TGC TGC TGT TC RT-qPCR 
Aqp11 rev CAC CCA TTT CGG GG GAC ATA RT-qPCR 
Aqp2 fwd ATG TGG GAA CTC CGG TCC ATA RT-qPCR 
Aqp2 rev ACG GCA ATC TGG AGC ACAG RT-qPCR 
Aqp3 fwd GCT TTT GGC TTC GCT GTCAC RT-qPCR 
Aqp3 rev TAG ATG GGC AGC TTG ATC CAG RT-qPCR 
Aqp4 fwd CTTT CTG GAA GGC AGT CTC AG RT-qPCR 
Aqp4 rev CCA CAC CGA GCA AAA CAAA GAT RT-qPCR 
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Aqp6 fwd GTG TAG CAG GGC TTA CCT TCT RT-qPCR 
Aqp6 rev GAT GGC GAT CTG GAG CAC A RT-qPCR 
Aqp7 fwd AAT ATG GTG CGA GAG TTT CTG G RT-qPCR 
Aqp7 rev ACC CAA GTT GAC ACC GAG ATA RT-qPCR 
Atp6v1b1 fwd AAG TTT GCC CAG TAT GCT GAG RT-qPCR 
Atp6v1b1r rec GCA GGA TGT CCC CTG TGA A RT-qPCR 
Chd1 fwd CAG CCT TCT TTT CGG AAG ACT RT-qPCR 
Chd1 rev TTA CAG CTA CCT GCC ACT TTT C RT-qPCR 
Cubulin fwd CAC TTT AGG TTG TGG TGG AAC A RT-qPCR 
Cubulin rev TTG CTG TCA AAG CTA ATC TCC C RT-qPCR 
Epo fwd ACT CTC CTT GCT ACT GAT TCC T RT-qPCR 
Epo rev ATC GTG ACA TTT TCT GCC TCC RT-qPCR 
Hif1a fwd TGC TCAT CAG TTG CCA CTT C RT-qPCR 
Hif1a rev CCT CAT GGT CAC ATG GAT GA RT-qPCR 
Hif2a fwd CTG ATG GCC AGG CGC ATG ATG RT-qPCR 
Hif2a rev CTG ATG GCC AGG CGC ATG ATG RT-qPCR 
Ldh-a fwd TGG CTT TCC CAA AAA CCG AGT  RT-qPCR 
Ldh-a rev CCA TCA GGT AAC GGA ACC GC RT-qPCR 
Lkb1 fwd TTG GGC CTT TTC TCC GAG G  RT-qPCR 
Lkb1 rev CAG GTC CCC CAT CAG GTA CT RT-qPCR 
p53 fwd GCG TAA ACG CTT CGA GAT GTT RT-qPCR 
p53 rev TTT TTA TGG CGG GAA GTA GAC TG RT-qPCR 
Pdk1 fwd AGG ATC AGA AAC CGG CAC AAT RT-qPCR 
Pdk1 rev GTG CTG GTT GAG TAG CAT TCT A RT-qPCR 
Pfkfb3 fwd CAA CTC CCC AAC CGT GAT TGT  RT-qPCR 
Pfkfb3 rev TGA GGT AGC GAG TCA GCT TCT RT-qPCR 
Pgk1 fwd TGG AGC CAA CTC CGT TGT C RT-qPCR 
Pgk1 rev CAG GCA TTC TCG ACT TCT GGG RT-qPCR 
Pk-m1 fwd TTG TGC GAG CCT CCA GTC RT-qPCR 
Pk-m1 rev ACT CCG TGA GAA CTA TCA AAG C RT-qPCR 
Pk-m2 fwd TCG AGG AAC TCC GCC GCC TG  RT-qPCR 
Pk-m2 rev CCA CGG CAC CCA CGG CGG CA RT-qPCR 
S12 fwd GAA GCT GCC AAA GCC TTA GA  RT-qPCR 
S12 rev AAC TGC AAC CAA CCA CCT TC RT-qPCR 
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Slc12a1 (NKCC2) fwd TGG GTT GTC AAC TTC TGC AAT RT-qPCR 
Slc12a1 (NKCC2) rev CCG GGA AAT CAG GTA GTA GGC RT-qPCR 
Slc12a3 (NCC) fwd ACA CGG CAG CAC CTT ATA CAT RT-qPCR 
Slc12a3 (NCC) rev GAG GAA TGA ATG CAG GTCA GC RT-qPCR 
Slc26a4 (Pendrin) fwd AAG AGA GCC TTT GGT GTG GTA RT-qPCR 
Slc26a4 (Pendrin) rev CAG GGC ATA AGC CAT CCC TTG RT-qPCR 
Slc34a1 (NaPi-IIa) fwd TGC CTC TGA TGC TGG CTTT C RT-qPCR 
Slc34a1 (NaPi-IIa) fwd TTG TGG GTT GCC AAC ATG ATG RT-qPCR 
Slc34a1 (NaPi-IIa) rev GATA GGA TGG CAT TGT CCTT GAA RT-qPCR 
Slc34a1 (NaPi-IIa) rev CCA GCT TGG TAG GTA GTG GGT RT-qPCR 
Slc4a1 (AE1) fwd AGA TCC CAG ATC GAG ACA GC RT-qPCR 
Slc4a1 (AE1) rev GCT CCA CAT AGA CCT GAC CG RT-qPCR 
SLC5A1 (SGLT1) fwd ATG CGG CTG ACA TCT CAG TC RT-qPCR 
SLC5A1 (SGLT1) rev ACC AAG GCG TTC CAT TCA AAG RT-qPCR 
Umod (THP) fwd CCT GGG ACA TGC AGG AAC AC RT-qPCR 
Umod (THP) rev GTA GGA GAC CAC TCT GAG CCT RT-qPCR 
VEGF-A fwd CTT GTT CAG AGC GGA GAA AGC RT-qPCR 
VEGF-A rev ACA TCT GCA AGT ACG TTC GTT RT-qPCR 
Vhl fwd CAG CTA CCG AGG TCA TCT TTG RT-qPCR 
Vhl rev CTG TCC ATC GAC ATT GAG GGA  RT-qPCR 
Vim fwd GCG GCT GCG AGA GAA ATT GCA RT-qPCR 
Vim rev CCG TTC AAG GTC AAG ACG TGC CA RT-qPCR 
Self-made Adapter  rev #1 CAAGCAGAAGACGGCATACGAGATACCTAG
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTCTGCCATTTGTCTCGAG 
Deep-Sequening 
Self-made Adapter  rev #2 CAAGCAGAAGACGGCATACGAGATTGGTAC
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTCTGCCATTTGTCTCGAG 
Deep-Sequening 
Self-made Adapter rev  #3 CAAGCAGAAGACGGCATACGAGATAACGTG
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTCTGCCATTTGTCTCGAG 
Deep-Sequening 
TruSeq Adapter fwd AATGATACGGCGACCACCGAGATCTACACTC
TTTCCCTACACGACGCTCTTCCGATCTATCTTG
TGGAAAGGACGA 
Deep-Sequening 
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TruSeq Adapter rev  #1 CAAGCAGAAGACGGCATACGAGATTCAAGT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTCTGCCATTTGTCTCGAG 
Deep-Sequening 
TruSeq Adapter rev  #2 CAAGCAGAAGACGGCATACGAGATCTGATC
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCT CTGCCATTTGTCTCGAG 
Deep-Sequening 
TruSeq Adapter rev  #3 CAAGCAGAAGACGGCATACGAGATAAGCTA
GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTCTGCCATTTGTCTCGAG 
Deep-Sequening 
7.1.6 Plasmids 
Vector Reference Vendor 
Adeno-Cre-GFP 1700 Vector Biolabs 
Adeno-GFP 1060 Vector Biolabs 
shCdkn1a TRCN0000042583 Sigma-Aldrich 
shCdkn1a TRCN0000042585 Sigma-Aldrich 
shCdkn1a TRCN0000042586 Sigma-Aldrich 
shCdkn1a TRCN0000042587 Sigma-Aldrich 
shCdkn1a TRCN0000054898 Sigma-Aldrich 
shCdkn1a TRCN0000054901 Sigma-Aldrich 
shCdkn1a TRCN0000054902 Sigma-Aldrich 
shCdkn1a TRCN0000042584 Sigma-Aldrich 
shCdkn1a TRCN0000054899 Sigma-Aldrich 
shCdkn1a TRCN0000054900 Sigma-Aldrich 
shCdkn1b TRCN0000071063 Sigma-Aldrich 
shCdkn1b TRCN0000071064 Sigma-Aldrich 
shCdkn1b TRCN0000071066 Sigma-Aldrich 
shCdkn1b TRCN0000071067 Sigma-Aldrich 
shCdkn1b TRCN0000071065 Sigma-Aldrich 
shCdkn1c TRCN0000042588 Sigma-Aldrich 
shCdkn1c TRCN0000042589 Sigma-Aldrich 
shCdkn1c TRCN0000042590 Sigma-Aldrich 
shCdkn1c TRCN0000042592 Sigma-Aldrich 
shCdkn1c TRCN0000042591 Sigma-Aldrich 
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shCdkn2a TRCN0000077815 Sigma-Aldrich 
shCdkn2a TRCN0000077816 Sigma-Aldrich 
shCdkn2a TRCN0000231227 Sigma-Aldrich 
shCdkn2a TRCN0000231228 Sigma-Aldrich 
shCdkn2a TRCN0000231226 Sigma-Aldrich 
shCdkn2a TRCN0000231225 Sigma-Aldrich 
shCdkn2a TRCN0000257162 Sigma-Aldrich 
shCdkn2a TRCN0000222729 Sigma-Aldrich 
shCdkn2a TRCN0000222730 Sigma-Aldrich 
shCdkn2a TRCN0000222731 Sigma-Aldrich 
shCdkn2b TRCN0000042598 Sigma-Aldrich 
shCdkn2b TRCN0000042599 Sigma-Aldrich 
shCdkn2b TRCN0000042600 Sigma-Aldrich 
shCdkn2b TRCN0000042601 Sigma-Aldrich 
shCdkn2b TRCN0000042602 Sigma-Aldrich 
shCdkn2b TRCN0000085033 Sigma-Aldrich 
shCdkn2b TRCN0000085034 Sigma-Aldrich 
shCdkn2b TRCN0000085036 Sigma-Aldrich 
shCdkn2b TRCN0000085037 Sigma-Aldrich 
shCdkn2d TRCN0000085088 Sigma-Aldrich 
shCdkn2d TRCN0000085089 Sigma-Aldrich 
shCdkn2d TRCN0000085090 Sigma-Aldrich 
shCdkn2d TRCN0000085091 Sigma-Aldrich 
shCdkn2d TRCN0000085092 Sigma-Aldrich 
Env-IRES-puro Morita et. al (Morita et al. 2000)  
shHif1a TRCN0000232222 Sigma-Aldrich 
shHif1a TRCN0000232220 Sigma-Aldrich 
shHif1a TRCN0000232223 Sigma-Aldrich 
shLdh-a TRCN0000308636 Sigma-Aldrich 
shLdh-a TRCN0000308638 Sigma-Aldrich 
shLdh-a TRCN0000041743 Sigma-Aldrich 
shLdh-a TRCN0000041744 Sigma-Aldrich 
shLdh-a TRCN0000308704 Sigma-Aldrich 
shPdk1 TRCN0000078810 Sigma-Aldrich 
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shPdk1 TRCN0000078812 Sigma-Aldrich 
pLKO.1 ns 10879 Addgene 
pMD2.G 12259 Addgene 
psPAX2 12260 Addgene 
shRb1 TRCN0000042546 Sigma-Aldrich 
shRb1 TRCN0000042547 Sigma-Aldrich 
shRb1 TRCN0000055378 Sigma-Aldrich 
shRb1 TRCN0000055379 Sigma-Aldrich 
shRb1 TRCN0000055380 Sigma-Aldrich 
shRb1 TRCN0000055382 Sigma-Aldrich 
shRb1 TRCN0000235830 Sigma-Aldrich 
shRb1 TRCN0000235829 Sigma-Aldrich 
shRb1 TRCN0000235831 Sigma-Aldrich 
shRb1 TRCN0000218613 Sigma-Aldrich 
shRb1 TRCN0000218099 Sigma-Aldrich 
shRb1 TRCN0000042545 Sigma-Aldrich 
shRb1 TRCN0000042543 Sigma-Aldrich 
shRb1 TRCN0000042544 Sigma-Aldrich 
shRb1 TRCN0000055381 Sigma-Aldrich 
shRbl1 TRCN0000088103 Sigma-Aldrich 
shRbl1 TRCN0000088104 Sigma-Aldrich 
shRbl1 TRCN0000088105 Sigma-Aldrich 
shRbl1 TRCN0000088106 Sigma-Aldrich 
shRbl1 TRCN0000088107 Sigma-Aldrich 
shRbl1 TRCN0000234086 Sigma-Aldrich 
shRbl1 TRCN0000234087 Sigma-Aldrich 
shRbl1 TRCN0000234088 Sigma-Aldrich 
shRbl1 TRCN0000218550 Sigma-Aldrich 
shRbl2  TRCN0000071273 Sigma-Aldrich 
shRbl2 TRCN0000071274 Sigma-Aldrich 
shRbl2  TRCN0000071275 Sigma-Aldrich 
shRbl2  TRCN0000071276 Sigma-Aldrich 
shRbl2  TRCN0000071277 Sigma-Aldrich 
SV40 large T-Antigen pBSSVD2005 Addgene 
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shTrp53 TRCN0000012358 Sigma-Aldrich 
shTrp53 TRCN0000012359 Sigma-Aldrich 
shTrp53 TRCN0000012360 Sigma-Aldrich 
shTrp53 TRCN0000012361 Sigma-Aldrich 
shTrp53 TRCN0000012362 Sigma-Aldrich 
shTrp53 TRCN0000054548 Sigma-Aldrich 
shTrp53 TRCN0000054550 Sigma-Aldrich 
shTrp53 TRCN0000054551 Sigma-Aldrich 
shTrp53 TRCN0000054552 Sigma-Aldrich 
shTrp53 TRCN0000054549 Sigma-Aldrich 
shTrp53 TRCN0000174221 Sigma-Aldrich 
shTrp53 TRCN0000204876 Sigma-Aldrich 
shTrp63 TRCN0000012749 Sigma-Aldrich 
shTrp63 TRCN0000012750 Sigma-Aldrich 
shTrp63 TRCN0000012751 Sigma-Aldrich 
shTrp63 TRCN0000012752 Sigma-Aldrich 
shTrp63 TRCN0000012748 Sigma-Aldrich 
shTrp73 TRCN0000012753 Sigma-Aldrich 
shTrp73 TRCN0000012754 Sigma-Aldrich 
shTrp73 TRCN0000012755 Sigma-Aldrich 
shTrp73 TRCN0000012756 Sigma-Aldrich 
shTrp73 TRCN0000012757 Sigma-Aldrich 
7.2 Virus production  
7.2.1 Bacterial strains and media 
Plasmid DNA was grown in the bacterial strain Mach1-T1R (Invitrogen). S.O.B. medium 
(Invitrogen) and Luria Bertani Bouillon medium (Fluka Analytical) was used for growth of bacteria. 
7.2.2 Transformation 
The plasmid DNA was added to an aliquot of chemically competent bacteria thawed on ice. The 
DNA/cell mix was incubated on ice for 30 minutes and heat shock was induced for 30 seconds at 
42℃ without shaking. Cells were placed on ice for 2 minutes followed by addition of room 
temperature S.O.C. medium. Cells were incubated at 37℃ for 1 hour at 300 rpm in a shaking 
incubator (Thermomixer Comfort, Eppendorf). Finally, transformation mix was plated onto pre-
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warmed agar plates containing appropriate antibiotic (100 µg/ml ampicillin or 50 µg/ml 
kanamycin), and incubated at 37oC overnight. 
7.2.3 Plasmid isolation 
For small-scale preparations, 2 ml of an overnight bacterial culture was centrifuged at 12 000 g 
for 5 minutes. DNA was isolated using GenElute Plasmid Miniprep Kit (Sigma) according to the 
ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtions. For large-scale preparations, 200 ml of an overnight bacterial culture 
was centrifuged at 4500 g for 10 minutes. DNA was isolated using Macherey-Nagel NucleoBond 
Xtra Midi Kit according to manufacturer's instructions. Following resuspension in TE (10 mM Tris, 
1 mM EDTA, pH 8), DNA concentration was determined by absorbance at 260 nm.  
7.2.4 Production of adenovirus particles 
Adenoviruses - Type 5 (dE1/E3) expressing Cre recombinase + GFP (Ad-Cre-GFP) or GFP only (Ad-
CMV-GFP) were amplified in HEK-293 cells, cultured in DMEM mix (10 % fetal calf serum (FCS), 
2mM glutamine, 10 kU/ml penicillin, 10 mg/ml streptomycin) at atmospheric oxygen levels at 
37°C. Cells were infected with adenoviral stocks (7.1.6) at 50 - 80% confluency. Adenovirus-
containing cells were harvested 2-3 days after infection when 80-90% of the cells were de-
attached and centrifuged at 300 g for 5 minutes. Cell pellets were suspended in PBS, placed for 5 
min in liquid nitrogen for thorough freezing, followed by thawing through incubation in a 37℃ 
water bath. Freezing and thawing cycles were repeated twice. Cell lysate was centrifuged at 2900 
g for 15 minutes at room temperature to pellet the cell debris. The supernatant containing viral 
particles was stored in aliquots at -20℃. 
7.2.5 Production of lentivirus particles 
Lentiviral vectors (7.1.6) were produced using calcium phosphate-mediated transfection of HEK-
293T cells Transfection was performed when the plate was 50-70% confluent. The medium was 
replaced with fresh DMEM (14 ml / 15 cm dish) two hours before transfection. The following 
transfection mix for one 15 cm dish was prepared in a 50 ml conical tube: 25 µg transfer vector 
plasmid, 14.5 µg packaging plasmid (psPAX2), 8 µg amphotropic VSV-G envelope (pMD2.G)  or 9 
µg ecotropic envelope (Env-IRES-puror), 660 µl of  0.1X TE, 180.5 µl of H2O and 282.5 µl of 1M 
CaCl2. 1.5 ml of 2xHEBS was added drop wise under constant agitation. The precipitate was left 
at room temperature for 15 minutes and then added drop wise to the cells, followed by 
incubation at 37℃ for 16 hours. The medium was aspirated and 14 ml of fresh DMEM was slowly 
added. The medium containing lentiviral particles was harvested twice every 24 h hours. The 
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supernatants were cleared by centrifugation at 500 g for 5 minutes, filtered using a 0.45 µm filter 
unit and stored in aliquots at -80℃. 
7.2.6 Determination of viral titer 
For titration for lentivirus 5x104 cells were seeded per 6-well plate the day before infection. The 
next day the virus was diluted in DMEM 1:103, 1:104 and 1:105 and added to the cells together 
with polybrene (4 µg/ml). 24 hours later the viral supernatant was removed and cells were split 
1:4 in triplicates on 6-well plates. Two days after infection, puromycin selection (2 µg/ml) was 
performed for 7-10 days. To visualize colony growth, the plates were stained with crystal violet 
(0.3% crystal violet in 70% methanol) at room temperature. After 1 hour, cells were washed in 
tap water and air dried. The viral titer corresponds to the number of colonies present at the 
highest dilution containing colonies, multiplied by the dilution factor and by two, to account for 
the twofold increase of cells during the transduction period and the 1:4 splitting. 
7.3 Cell culture assays 
7.3.1 Isolation and culturing of mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were isolated from embryos of relevant floxed strains at 
E13.5. After dissecting away the head, internal organs and spinal cord, the remaining tissue was 
minced with a razorblade, incubated for 15 minutes at 37°C in trypsin EDTA, re-suspended in 
growth media (DMEM supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 10 kU/ml 
penicillin, 10 mg/ml streptomycin and 200 µM -mercaptoethanol) and plated on a 10 cm dish. 
Cells were split 2-3 days later into two 15 cm dishes and 2-3 days later frozen at passage two. 
Cells were cultured in conventional cell culture incubators at 5% oxygen. For low oxygen 
concentrations (1% oxygen) cells were cultured in an oxygen glove-box incubator (INVIVO2 400, 
Ruskinn).  
7.3.2  Isolation and culturing of epithelial kidney cells (PKCs) 
Kidneys were dissected from 2 month-old floxed mice. After removing the capsule under sterile 
conditions, kidneys were mashed with a razor blade on ice and digested in collagenase II solution 
at 37°C and 5% oxygen for 30 min. The cell suspension was filtered through a 70 µm cell strainer 
and washed in HBSS + 5% FCS. Erythrocytes were lysed for 1 min using standard ACK buffer. Cells 
were re-suspended in complete K-1 culture medium (Dulbecco's modified Eagle's medium 
(DMEM) and Hams F12 mixed 1:1, supplemented with 0.5% fetal calf serum, 2 mM glutamine, 10 
kU/ml penicillin, 10 mg/ml streptomycin, hormone mix (5 µg/ml insulin, 1.25 ng/ml prostaglandin 
E1 (PGE1), 34 pg/ml triiodothyronine, 5 µg/ml transferrin, 1.73 ng/ml sodium selenite, and 18 
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ng/ml of hydrocortisone and 25 ng/ml epidermal growth factor (EGF)). Cells were counted and 
seeded at a density of 1x106 cells on standard 10 cm plastic tissue culture plates. After 5-6 days 
in culture, cells were infected with adenoviruses expressing GFP or Cre-GFP or lentivirus, 
respectively (see 7.3.3).  
7.3.3 Cell infection 
A confluent 10 cm dish of pMEFs was split 1:3, treated with polybrene (4 µg/ml) and infected 
with an appropriate amount of lentivirus for 24 h. 48 h after infection, cells were selected with 
puromycin (4 µg/ml) and adenovirus infection was performed identically. PKCs were treated with 
polybrene at a density of 50% and simultaneously infected with lentivirus and adenovirus. 
Puromycin selection (2 µg/ml) was performed for three days 24 h after infection.  
7.3.4 Cell immortalization 
Wild type and Vhlfl/fl MEFs were transformed by transfection with a plasmid expressing SV40 large 
T-Antigen and pools of cells forming colonies after plating at low density were harvested for 
generation of cell lines. Vhlfl/fl Hif1afl/fl cells were immortalized by transfection with the plasmid 
described above, followed by six passages of serial low density splitting (1:10) (Harding Revised 
11/5/2003).  
7.4 Cellular and biochemical analysis 
7.4.1 Real time PCR-analysis 
Total RNA was prepared from cultured cells or from powdered tissue of whole kidneys using 
NucleoSpin RNA kit and cDNA synthesis was done with random hexadeoxynucleotide primers and 
Ready-To-Go You-Prime First-Strand Beads. The real-time PCR analysis of cDNA was performed 
with SYBR Green JumpStart Taq ReadyMix and used primers listed above (7.1.5). 
7.4.2 Western blotting 
Protein extracts from cultured cells were prepared by washing the cells twice with cold PBS and 
lysing in RIPA buffer (50 mM Tris–HCl at pH 7.5, 150 mM sodium chloride, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, 2mM EDTA, 1 mM sodium fluoride, 1 mM Na3VO4, 1 mM PMSF, 1 mM 
dithiothreitol, 1:100 Protease Inhibitor Cocktail).  
To assess Hifα protein levels, nuclear extracts were prepared. Cells were washed once in ice cold 
PBS and subsequently incubated for 20 minutes on ice in lysis buffer (10 mM HEPES, KOH pH 7.9, 
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 mM PMSF) 
followed by adding addition of NP-40 to a final concentration of 0.1%, vortexing and centrifuging 
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at 5000 rpm. The nuclear pellet was extracted and incubated for 5 min on ice and frozen over 
night at - 80 °C in protein extraction buffer (400 mM NaCl, 20 mM HEPES, KOH pH 7.9, 1 mM 
EDTA, 1mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 mM PMSF). To remove insoluble 
material the lysates were at 14000 g and 4°C for 10 minutes. Using the Bradford protein assay 
cleared protein lysates were quantitated using bovine serum albumin as a standard. Prior to use, 
samples were boiled for 5 minutes at 95°C. Proteins were run on 6–15% acrylamide gels, 
transferred to nitrocellulose membranes and visualized by semi-dry immunoblotting with 
antibodies described above (7.1.4). The signal was detected using the Fujifilm Luminescent Image 
Analyzer LAS4000 mini. 
7.4.3 Proliferation assays 
For MEF proliferation assays, cells were seeded at densities of either 2x105 or 3x105 cells per 6 
cm dish in triplicates and counted after 3 days before reseeding at the same density for the next 
passage. Proliferation assays shown in all figures are representative of at least 3 independent 
experiments. 
 
For primary kidney cells, a Sulforhodamine B (SRB) colometric assay was performed (Vichai and 
Kirtikara 2006). Cells were cultured in K-1 medium containing 10% fetal calf serum for 2 days 
before seeding for the SRB assay. 2x103 cells per well were seeded and fixed with 5% (wt/vol) 
trichloroacetic acid at the indicated time points, followed by staining with 0.057% (wt/vol) SRB 
solution and air drying. SRB was solubilized by incubation in 10 mM Tris base solution (pH 10.5) 
and OD was measured at 540 nm in a microplate reader (Anthos Lucy 3). 
7.4.4 Transformation assays  
For low density assays, 5000 cells were seeded per 10 cm plate. After ten days, cells were washed 
with PBS and stained with crystal violet (0.3% crystal violet in 70% methanol) at room 
temperature. After 1 h, cells were washed with tap water and air dried.   
 
For soft agar assays, 2% low melting temperature agarose was dissolved in ddH2O and mixed 1:1 
with 2x DMEM mix (20% FCS, 4 mM glutamine, 20 kU/ml penicillin, 20 mg/ml streptomycin, pH 
7.4). 1 ml solution was distributed per well of a 12-well plate and allowed to set at room 
temperature. For the middle layer, 0.8% low melting agarose was dissolved in ddH2O and mixed 
1:1 with 2x DMEM mix containing 1x105 cells per genotype. Subsequently, 1 ml cell suspension 
was distributed in triplicates (final cell number: 2.5x104 per well), and allowed to set for 30 min 
at room temperature. Finally, the layers were covered with 0.5 ml normal medium to prevent 
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dehydration.  
For primary kidney cells, 2x K-1 medium (31.2 g/l DMEM/F12, 2.4 g/l sodium bicarbonate, 20% 
FCS, 20 kU/ml penicillin, 20 mg/ml streptomycin, 5 µg/ml insulin, 1.25 ng/ml prostaglandin E1 
(PGE1), 34 pg/ml triiodothyronine, 5 µg/ml transferrin, 1.73 ng/ml sodium selenite, and 18 ng/ml 
of hydrocortisone, pH 7.4) was used instead of 2x DMEM mix.   
For anchorage-independent growth assay, 1x105 cells were seeded in untreated polystyrene 
plates to reduce cell attachment. Medium was changed by filtering the cells in cell strainers (pore 
size 40 – ϭϬϬ μŵͿ. 
7.4.5 ATP measurements 
Cells were trypsinized, counted (Beckman counter Vi-Cell XR and Z2) and 1.5x105 cells were re-
suspeŶded iŶ ϳϱ μl PB“ aŶd ϳϱ μl ďuffeƌ ;CellTiteƌ-Glo Luminescent Cell Viability Assay, Promega). 
Cells were lysed for 10 min at room temperature and distributed as technical triplicates in an 
opaque 96-well plate. Luminescence signal was detected with a microplate reader (Anthos Lucy 
ϯͿ. “tudeŶt’s t-test was performed for statistical analysis (P-values: * <0.05, ** <0.01, *** <0.001).  
7.4.6 Gain of representation assay 
To create a shRNA library for cell cycle regulatory genes, twelve genes of interest were chosen 
(Cdkn1a, Cdkn1b, Cdkn2a, Cdkn2b, Cdkn2c, Cdkn2d, Rb1, Rbl1, Rbl2, Trp53, Trp63, Trp73) and 
each gene was represented by 3-14 hairpins (see 7.1.6). Virus was produced in gene batches as 
described earlier (7.2) and viruses were mixed including a non-silencing (ns) control. Vhlfl/fl and 
Vhlfl/fl Hif1afl/fl primary kidney cells were isolated (7.3.2) and cultured in K-1 medium 
(supplemented with 0.5% FCS). At a confluency of 50%, cells were treated with polybrene (4 
µg/ml) and simultaneously infected with adenovirus (Adeno-GFP or Adeno-Cre-GFP) and 
lentivirus (cell cycle shRNA library, MOI=0.1). Medium was changed to K-1 containing 10% FCS 
the following day. Two days after infection, puromycin selection (2 µg/ml) was performed for one 
week. When plates were confluent, 5000 cells per 10 cm plate were seeded for synthetic 
proliferation screen (6 plates, T1), western blot analysis (1 plate) and crystal violet staining (1 
plate). For T0 and Western blot analysis, remaining cells were seeded in two 10 cm plates. Three 
days later, genomic DNA was isolated using the GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma-Aldrich) aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶ aŶd ŶuĐleaƌ extracts were harvested as 
described earlier (7.4.2).   
To visualize colony growth, one plate per genotype was stained with crystal violet 10 days after 
seeding.  For synthetic proliferation screen, colonies were harvested when plates were confluent 
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and genomic DNA was isolated. shRNA hairpins were amplified and sequencing adapters were 
added using the primers described in 7.1.5. Primers with different barcode sequences (marked 
in yellow) were used to distinguish different genotypes. Deep sequencing was performed on an 
Illumina HiSeq 2000 by the Functional Genomic Centre Zurich (FGCZ).  
Foƌ the isolatioŶ of Hifα pƌoteiŶ leǀels ŶuĐleaƌ eǆtƌaĐts ǁeƌe pƌepaƌed. Cells were washed once 
in ice cold PBS and subsequently incubated for 20 minutes on ice in lysis buffer (10 mM HEPES, 
KOH pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 
mM PMSF) followed by addition of NP-40 to a final concentration of 0.1%, vortexing and spinning 
at 5000 g. The nuclear pellet was extracted and incubated for 5 min on ice and frozen over night 
at - 80 °C in protein extraction buffer (400 mM NaCl, 20 mM HEPES, KOH pH 7.9, 1 mM EDTA, 
1mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 mM PMSF). To remove insoluble material 
the lysates were centrifuged at 14 000 g at 4°C for 10 minutes. Using the Bradford protein assay 
cleared protein lysates were quantitated using bovine serum albumin as a standard. Prior to use, 
samples were boiled for 5 minutes at 95°C. Proteins were run on 6–15% acrylamide gels, 
transferred to nitrocellulose membranes and visualized by semi-dry immunoblotting with 
antibodies described above (7.1.4). The signal was detected using the Fujifilm Luminescent Image 
Analyzer LAS4000 mini. 
7.5 Mouse manipulations 
7.5.1 Mouse maintenance 
Mice were maintained in a specific pathogen-free environment on a 12 hour day/night cycles. 
Food and water was freely available. Breeding pairs were set up using animals of minimum age 7 
weeks and pups were weaned at approximately 3 weeks of age. 
7.5.2 Mouse strains  
Hif1afl/fl(Ryan et al. 2000), Vhlfl/fl (Haase et al. 2001), Trp53fl/fl (Jonkers et al. 2001) and  Hif2afl/fl 
(Gruber et al. 2007) mice were crossed with Ksp1.3-Cre/+ (Shao et al. 2002a; Patel et al. 
2008)(Patel, Li et al. 2008)(Patel, Li et al. 2008) mice to generate the following mouse lines: 
Ksp1.3-Cre/+; Hif1afl/f,  Ksp1.3-Cre/+; Hif2afl/f, Ksp1.3-Cre/+; Vhlfl/fl; Hif1afl/fl, Ksp1.3-Cre/+; Vhlfl/fl; 
Hif2afl/f,  Vhlfl/fl; Hif1afl/fl; Trp53fl/fl Previously described Ksp1.3-Cre/+; Vhlfl/fl (Frew et al. 2008b) and 
Ksp1.3-Cre/+; Trp53fl/fl (Wild et al. 2012) mouse strains were interbred to generate Ksp1.3-Cre/+; 
Vhlfl/fl; Trp53fl/fl mice. Ksp1.3-Cre/ERT2 mice (Patel et al. 2008) was used to generate Ksp1.3-
Cre/ERT2; Vhlfl/fl mice. Non-Cre transgenic littermate mice served as controls for all cohorts. 
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SCID/Beige mice (C.B-17/IcrHsd-Prkdcscid Lystbg-J were obtained from Harlan Laboratories (USA).  
Wild type cells were isolated from C57BL/6 embryos (Janvier Labs (USA)).  
7.5.3 Genotyping 
Ear biopsies were digested for 15 min at 95°C in lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH 12) 
and thereafter neutralised afterwards with the same amount of neutralisation buffer (40 mM 
Tris-HCl, pH 5). The PCR reaction was carried out according to standard procedures using 
JumpStart Taq DNA polymerase and the primers shown in 7.1.5. The DNA was analyzed on 1.5% 
agarose gels in SBE buffer (5 mM NaOH bufferd with boric acid, pH 8.5). 
7.5.4 Tamoxifen treatment 
Ksp1.3-Cre/ERT2 transgenic mice were administered tamoxifen for induction of Cre/loxP 
recombination. The tamoxifen was dissolved in 100% ethanol and diluted 1:10 in corn oil to a 
final concentration of 20 mg/ml. Mice were injected intraperitoneal (I.P) with tamoxifen (4 mg/40 
g body weight) at the age of 8 weeks. Non-Cre transgenic littermate mice served as controls for 
all cohorts. 
7.5.5 Xenograft assay  
3-5x106 cells were detached with Trypsin or Accutase and re-suspeŶded iŶ ϳϬ μl DMEM. Cells 
were placed in a pre-cooled 30 gauge syringe and mixed with 70 μl ice cold matrigel. Syringes 
were kept on ice to avoid hardening of matrigel. SCID/Beige mice were anaesthetized by 
inhalation of 2% isofluorane using oxygen as carrier gas, shaved at both flanks and cells were 
slowly injected subcutaneously. Mice were euthanized the latest when xenograft size reached a 
size of 1 cm3. The xenograft was fixed in 10% formalin and processed as described below (7.5.6) 
7.5.6 Tissue collection and procedure  
Mouse tissues were snap-frozen in liquid nitrogen (protein and mRNA analysis) and stored at -
80°C or immersion-fixed in 10% formalin at 4°C overnight and stored in 70% ethanol. After 
dehydration in serial dilutions (3 h 70% EtOH, 2 h 80% EtOH, 2 h 90% EtOH, 2 h 96% EtOH, 2 h 
100% EtOH, 2 h xylene, 3 h paraffin at 65°C), organs were embedded in paraffin and cut into 5 
μŵ seĐtioŶs aŶd fiǆed oŶ polǇsiŶe microscope adhesion slides (VWR). 
7.5.7  Measurement of feeding parameters in metabolic cages 
Single animals were adapted to the metabolic cage (Tecniplast 3600M021) for two days, followed 
by five measurements every 24 h. Mice were housed on a 12 h day/night cycle and provided with 
pulverized normal chow and water ad libitum. To avoid evaporation, urine collection trays were 
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covered with mineral oil. Collected urine was centrifuged for 13 000 g at 4°C and the supernatant 
was frozen at -20°C. 
7.5.8 Water restriction test 
Single mice were adapted to the metabolic cage and the first measurement was performed for 
24 h as described above (see 7.5.7). During water restriction, mice were provided with 50% 
powder chow in water and the experiment was stopped when a single mouse showed signs of 
dehydration. Mice were again provided with water and the third measurement was performed 
for 24 h.   
7.5.9 Urine analysis 
24 h urine was collected as described above (see 7.5.7). Samples were diluted 1:10 in ddH2O and 
osmolality was determined by freezing point osmometry (Osmometer, Roebling). Urine ion levels 
and urinary creatinine were analyzed with the UniCel® DxC 800 Synchron® Clinical System in 
cooperation with the ZIRP (University of Zürich). pH was measured with a pH meter from fresh 
urine (Seven easy, Mettler Toledo). 
7.5.10 Blood collection and analysis 
Animals were anaesthetized and blood was terminally collected from the vena cava or by 
puncturing the heart and treated with sodium-heparin. Analysis of hemoglobin and electrolyte 
levels, blood pH and blood gas values were performed immediately with the ABL825Flex. 
Hematocrit levels were determined by capillary centrifugation (5 min at 8000 rpm) and the ratio 
was determined manually. Blood plasma was stored at – 80°C for further analysis. Creatinine, 
blood urea nitrogen (BUN), albumin and phosphorus were determined using the UniCel® DxC 800 
Synchron® Clinical System in cooperation with the ZIRP (University of Zurich).  
7.5.11 Micro-computed Tomography (µCT) 
Animals were anaesthetized and Visipaque 270 was injected i.v. at 8 µl/g bodyweight (Almajdub 
et al. 2008) as contrast agent. µCT images were recorded with a Quantum FX microCT (Perkin 
Elmer) with the following settings: 100 µA, 90 kV, respiratory gating and fine scanning. µCT data 
were exported as DICOM images to be analyzed in the Quantum FX data format for overview X-
ray picture and the CaliperAnalyze 11.0 software was used for for 3D reconstruction. 
7.5.12 High-resolution respirometric analysis  
Animals were euthanized with CO2 and dissected immediately. One mm3 biopsies were taken 
from cortex and medulla under the microscope and transferred to ice cold PBS. Wet weight was 
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determined after drying the tissue on a Whatman paper. Biopsies were transferred to modified 
mitochondrial respiration medium (MiROS, 5 mM MgCl2, 5 mM KHPO4-, 10 mM HEPES, 70 mM 
sucrose, 220 M mannitol, 1 mg/ml fatty acid free BSA, pH 7.4) and oxygen consumption was 
measured using a OROBOROS Oxygraph-2k (ORBOROS INSTRUMENTS  Corp, Innsbruck, Austria) 
according to the following procedure: Leak respiration (LN), representing resting oxygen 
consumption of an unaltered system, was induced by the addition of malate (2 mM) and octanoyl 
carnitine (0.2 mM). Adenosine diphosphate (ADP, 5 mM) was added for determination of the 
maximal electron flow through the electron-transferring flavoprotein (ETF) and fatty acid 
oxidative capacity (PETF). PCI (respiratory capacity specific to complex I) was induced by the 
addition of glutamate (10mM) and pyruvate (5 mM). Maximal state 3 respiration (oxidative 
phosphorylation capacity P) was measured subsequently to the addition of succinate (10 mM). 
Finally, complex I was inhibited by rotenone (0.5 µM) to asses maximal state 3 respiration specific 
to complex II (PCII). Finally, mitochondrial respiration was abrogated by blocking complex III with 
2.5 µM antimycin A, allowing the correction of residual O2. Cytochrome C oxidase activity 
(complex IV) was assessed by the addition of tetramethylphenylenediamine (TMPD, 0.5 mM) and 
Ascorbate (2 mM). Values were calculated using the DatLab OROboros 5.1 softare and presented 
as means ± standard deviation. P-ǀalues: * ч Ϭ.Ϭϱ. N=ϲ. EǆpeƌiŵeŶt ǁas ĐoŶduĐted ďǇ MiĐhal 
Rajski, Robert A. Jacobs and Stine Lundby. 
7.6 Histological analysis  
7.6.1 Haematoxylin and Eosin (H&E) staining   
Tissue sections were de-waxed for 3 min in xylene and hydrated for 2 min each in serial dilutions 
of ethanol washes (100%, 95%, 70%). Nuclei were stained for 4 min in haematoxylin and dipped 
3 times in 0.3% acid alcohol (70 % EtOH in ddH2O acidified with 0.3% HCl 32%) for differentiation. 
Proteins were stained for 8 min in 1% eosin solution. Finally, specimen were dehydrated for 2 
min in serial ethanol dilutions (70%, 95%, 100%) and xylene (3 min) and mounted in entellan. 
7.6.2 Immunohistochemistry 
Tissue sections were de-waxed in xylene and hydrated in series of ethanol washes ( 10 min xylene, 
10 min 100 % EtOH, 10 min 95% EtOH, 5 min in 70% EtOH) and washed for 5 min in PBS-T  (137 
mM NaCl, 2.7 mM KCl, 19 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.4, 0.3% Triton x-100). For antigen 
retrieval, slides were cooked for 5 min at 110°C in 0.1 M citrate buffer (pH 6) using a standardized 
pressure cooker (HistosPro, Milestone). Next, specimens were incubated in peroxidase blocking 
solution (3% H2O2  in 10% methanol) for 30 min, circled with a hydrophobic pen and incubated in 
protein blocking solution (PBS, supplemented with 10% goat serum, 0.3% Triton, 1 drop avadin 
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per 250 µl solution). Primary antibodies were diluted in PBS, containing 10% goat serum, 0.3% 
Triton and 1 drop biotin solution per 250 µl blocking buffer) and sections were incubated 
overnight at 4°C. Biotinylated secondary antibodies were diluted (10% goat serum in PBS) and 
applied for 1 h at room temperature. Sections were washed and subsequently incubated in TBS 
for 10 min. For complex formation,  1 drop Avadin DH and and 1 drop biotinylated horseradish 
peroxidase were mixed in 2.5 ml TBS (50mM Tris, 150 mM NaCl, pH 7.5) 30 min prior to use, and 
solution was applied for 1 h at room temperature. Next, specimen were washed in TBS and 
incubated in 50 mM Tris (pH 7.6). ϯ,ϯ’-diaminobenzidine (DAB) was used as a chromogen 
aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. FiŶallǇ, the speĐiŵeŶs ǁeƌe counterstained with 
hematoxylin solution for 30 s, dehydrated in serial ethanol dilutions (1 min 70% EtOH, 2 min 95% 
EtOH, 2 min 100% EtOH, 3 min in Xylene) and mounted in entellan. All incubations were 
performed in a humidified chamber. Between incubations, sections were washed three times for 
5 min in PBS, unless otherwise stated.  
Immunohistochemistry taƌgetiŶg Hifα pƌoteiŶs ǁas peƌfoƌŵed usiŶg the Dako CatalǇzed “igŶal 
AŵplifiĐatioŶ ;C“AͿ kit aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶ. The folloǁiŶg ĐhaŶges ǁeƌe 
included in the protocol: After peroxidase block, specimen were incubated for 15 min in avadin 
solution (TBS, supplemented with 1% BSA, 0.1% Tween, 2 drops avadin solution per 250 µl 
solution), followed by 15 min biotin solution (TBS, containing 1% BSA, 0.1% Tween 20 and 2 drops 
biotin solution per 250 µl solution). For washing, standard TBS-T (50 mM Tris, 150 mM NaCl, 0.1% 
Tween 20) was used before primary antibody incubation, whereas high salt TBS-T (0.05 M Tris-
HCl pH 7.6 containing 0.3 M NaCl and 0.1 % Tween 20) was used afterwards. Rehydration of 
sections, antigen retrieval and counterstaining was performed as described above. 
7.6.3 Immunofluorescent staining of tissues 
For immunofluorescence, specimens were processed as described above (7.6.1) without the 
avadin/biotin blocking step. After primary antibody incubation, sections were incubated with 
fluorophor-labelled secondary antibodies for 1 h. Subsequently, slides were washed with PBS and 
nuclei were stained for 10 min with DAPI (0.5 µg/ml in PBS containing 10% goat serum). After 
washing in PBS and ddH2O, sections were mounted in Mowiol. 
7.6.4 Immunocytochemistry 
Cells were cultured on round glass cover slips placed in a 6-well plate. After washing with PBS the 
cells were fixed in 4% PFA for 1 h at room temperature. Removal of PFA was followed by a 
washing step. The cover slips were incubated with blocking solution (10% goat serum/0.3% 
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Triton/PBS) for 1 h at room temperature. Incubation with antibodies was carried out as described 
in 7.6.3. 
7.6.5 Image acquisition and procession 
Brightfield and fluorescence microscopy was performed on either a Zeiss Scope. A1 microscope 
or an Axiovert 40 CRC microscope. Images were obtained with an Axiocam MRc5 camera using 
the Axiovision LE64 software and processed with Adobe Photoshop.  
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8 Results 
8.1 Combined mutation of Vhl and Trp53 causes cysts and tumours in mice 
 
During the initial part of my PhD work I participated in a project that investigated the cooperative 
effects of the deletion of Vhl and Trp53 in the epithelium of mouse kidneys and the genital-
urinary tract. This publication presented below forms the first result chapter of this thesis and 
several conclusions are relevant for the rationale and understanding of the results presented in 
chapter 8.2, which consists of a manuscript for publication and additional experiments 
iŶǀestigatiŶg the ƌole of Hifα tƌaŶsĐƌiptioŶ faĐtoƌs iŶ the eaƌlǇ phase of tuŵouƌ foƌŵatioŶ.  
Briefly, our studies demonstrated that in primary mouse fibroblasts senescence induced by loss 
of Vhl is largely independent of oxygen concentrations and is rescued by the deletion of Trp53. 
However, Vhl/Trp53 null MEFs still proliferate slower than Trp53 null cells, indicating that loss of 
Vhl exerts an anti-proliferative barrier even in immortalized cells.  Co-deletion of Vhl and Trp53 
in the renal epithelium causes the formation of simple cysts, atypical cysts and neoplasms in aged 
mice. Gene deletions in the  genital urinary tract caused dysplasia and tumour formation of the 
epididymis and uterus and malformation of the vesicular gland  (Albers et al. 2013). Furthermore, 
immunohistochemical analysis of human ccRCC samples demonstrated that TP53 is mutated in 
approximately 9% of human ccRCC, supporting the importance of loss of TP53 function in the 
formation of ccRCC. However, the late onset of the disease in mice indicates that additional 
oncogenic events have to occur to drive tumourigenesis in Vhl/Trp53 deficient epithelial cells. 
For this study, I analyzed the effect of loss of Vhl on the proliferation of large T antigen 
transfoƌŵed MEFs aŶd eǆaŵiŶed the eǆpƌessioŶ of Hifα iŶ Vhl/Trp53 deficient kidneys.  
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8.2 Hifϭα staďilization eǆerts anti-proliferative activities but is necessary for 
tumour formation 
8.2.1 Hifϭα reduces oǆidatiǀe phosphorǇlation, ATP levels and cellular proliferation but is 
necessary for initiation of renal cysts and tumours (Manuscript) 
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Abstract 
The von Hippel-Lindau (VHL) gene is biallelically inactivated in most cases of clear cell renal cell 
carcinoma (ccRCC). The protein product of the VHL locus, pVHL, possesses numerous potential 
tumor suppressor functions, including regulation of the HIF1α and HIF2α transcription factors. 
However, Vhl deletion in mice does not cause renal tumors. Allelic losses of HIF1A in VHL null 
ccRCC predict poor patient outcome and HIFϭα iŶhiďits, ǁhile HIFϮα pƌoŵotes the gƌoǁth of 
huŵaŶ ĐĐRCC ǆeŶogƌaft tuŵoƌs, suggestiŶg that HIFϭα ŵaǇ fuŶĐtioŶ as a tumor suppressor and 
HIFϮα as aŶ oŶĐogeŶe. CoŶsisteŶt ǁith this idea, ǁe shoǁ that staďilizatioŶ of Hifϭα, ďut Ŷot 
HifϮα, alteƌs gluĐose ŵetaďolisŵ ƌesultiŶg iŶ ƌeduĐed oǆǇgeŶ ĐoŶsuŵptioŶ aŶd ATP leǀels iŶ Vhl 
mutant primary fibroblasts and in mouse kidneys. Correlating with this energy deficiency, 
deletion of Vhl induces Hif1a-dependent, Hif2a-independent senescence in primary fibroblasts 
and inefficient proliferation in immortalized and transformed fibroblasts. However, renal 
epithelial-specific double deletion of Vhl/Hif1a or Vhl/Hif2a does not induce proliferative 
dysregulation or tumor formation in mouse kidneys. In contrast to its postulated tumor 
suppressor function, co-deletion of Hif1a prevents the formation of cysts and neoplasms in 
Vhl/Trp53 double mutant kidneys, showing that Hif1a is essential for the first stages of tumor 
foƌŵatioŶ. Thus, disƌuptioŶ of the ďalaŶĐe of Hifϭα aŶd HifϮα sigŶaliŶg togetheƌ ǁith loss of 
pVHL’s ŵaŶǇ putatiǀe tuŵoƌ suppƌessor functions are insufficient to induce ccRCC in mice. 
Ratheƌ, Hifϭα staďilizatioŶ is ŶeĐessaƌǇ foƌ the iŶitiatioŶ of tuŵoƌigeŶesis.  
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Introduction 
Clear cell renal cell carcinoma (ccRCC) is the most frequent subtype of renal cell carcinoma and 
up to 92% of ccRCC tumors harbor biallelic inactivation of the von Hippel-Lindau (VHL) tumor 
suppressor gene (Sato et al. 2013). Deep sequencing analyses of intratumoral genetic 
heterogeneity show that VHL mutations represent so-called trunk mutations, indicating that they 
occur at the earliest stage of tumor formation (Gerlinger et al. 2012; 2014). While studies of 
ccRCC cell lines grown as xenograft tumors have clearly demonstrated that the absence of pVHL 
function is necessary for the efficient growth of these fully transformed cell lines in this 
experimental setting (Iliopoulos et al. 1995; Gnarra et al. 1996), it is also apparent that losing VHL 
function alone is not sufficient to initiate tumor formation from a normal renal epithelial cell in 
the kidney. This idea is supported by detailed analyses of the relative frequencies of VHL mutant 
single cells in the context of normal kidney tubules compared to the number of ccRCC tumors in 
kidneys of familial VHL disease patients (Mandriota et al. 2002) and by numerous mouse genetic 
studies showing that deletion of Vhl in renal tubular epithelial cells does not cause tumor 
formation (Kleymenova 2003; Iguchi et al. 2008; Ma et al. 2003;Rankin et al. 2006;Mathia et al. 
2013; Schietke et al. 2012; Frew et al. 2008;Schley et al. 2011; Pritchett et al. 2014). ccRCC tumors 
frequently harbor mutations in numerous other genes that likely cooperate with loss of VHL 
function to induce tumor initiation and progression (Creighton et al. 2013; Sato et al. 2013). 
Consistent with this idea, the kidney epithelial cell-specific co-deletion of Vhl with Pten or Trp53, 
mouse homologs of tumor suppressor genes that are mutated or deleted in human ccRCC, caused 
the formation of cystic and/or neoplastic lesions that are similar to the lesions that are believed 
to represent the precursor lesions of ccRCC in human kidneys (Frew et al. 2008; Albers et al. 
2013). 
The protein encoded by the VHL gene, pVHL, controls many biological activities including 
regulation of the stability of the hypoxia-iŶduĐiďle tƌaŶsĐƌiptioŶ faĐtoƌs α ;HIFϭα aŶd HIFϮαͿ 
(Maxwell et al. 1999), ƌegulatioŶ of NFκB aĐtiǀitǇ (Yang et al. 2007), maintenance of the primary 
cilium (Thoma et al. 2007), activation of p53 (Roe et al. 2006),  secretion of extracellular matrix 
components (Kurban et al. 2008; Ohh et al. 1998), promotion of DNA double strand repair 
(Metcalf et al. 2013), regulation of the plane of cellular division (Thoma et al. 2009; Hell et al. 
2013) and suppression of aneuploidy (Thoma et al. 2009; Hell et al. 2014). It appears likely that 
the ĐoŵďiŶed loss of all oƌ ŵaŶǇ of pVHL’s fuŶĐtioŶs Đould ĐoŶtƌiďute to tuŵoƌ iŶitiatioŶ aŶd 
progression. Of these many potential tumor suppressor activities, the ďest uŶdeƌstood is pVHL’s 
function as the substrate recognition subunit of an E3-ubiquitin ligase complex comprising 
EloŶgiŶ B, EloŶgiŶ C, Rďǆϭ aŶd CulϮ, that taƌgets HIFϭα aŶd HIFϮα foƌ oǆǇgeŶ-dependent, 
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ubiquitin-mediated proteolytic degradation (Keith and Simon 2007; Keith et al. 2012; Wenger et 
al. 2005; Qing and Simon 2009). Loss of function mutations of VHL occur in ccRCC mutually 
exclusively to mutations in TCEB1, encoding Elongin C (Sato et al. 2013), and collectively these 
Đause ĐoŶstitutiǀe staďilizatioŶ of HIFϭα aŶd HIFϮα iŶ ϵϱ% of ĐĐRCC tuŵoƌs, iŵplǇiŶg that HIFα 
aĐtiǀatioŶ is a ŵajoƌ oŶĐogeŶiĐ dƌiǀiŶg foƌĐe iŶ ĐĐRCC. IŶdeed, HIFϮαis ŶeĐessaƌǇ foƌ the gƌoǁth 
of VHL-deficient ccRCC cell lines as xenografts (Kondo et al. 2003; Raval et al. 2005; Zimmer et al. 
2004). Several recent studies have suggested that HIFϭα aŶd HIFϮα plaǇ opposite ƌoles iŶ the 
ĐoŶteǆt of ĐĐRCC pƌogƌessioŶ. HIFϭα iŶhiďits, ǁheƌeas HIFϮα pƌoŵotes, the pƌolifeƌatioŶ of 
mouse embryo fibroblasts (Gordan et al. 2007), tumor formation in ccRCC xenografts (Kondo et 
al. 2003; Raval et al. 2005; Zimmer et al. 2004) and activity of the cell cycle promoting MYC 
oncoprotein (Gordan et al. 2007). CoŶsisteŶt ǁith the idea that the ďalaŶĐe of HIFϭα aŶd HIFϮα 
activities might control cellular proliferation of VHL null ccRCC tumors, early lesions in VHL patient 
kidŶeǇs pƌedoŵiŶaŶtlǇ eǆpƌess HIFϭα ǁheƌeas ŵoƌe adǀaŶĐed lesioŶs ofteŶ eǆpƌess higheƌ leǀels 
of HIFϮα (Raval et al. 2005). “poƌadiĐ ĐĐRCCs eǆpƌessiŶg HIFϭα aŶd HIFϮα eǆhiďit ƌeduĐed MYC 
aĐtiǀitǇ aŶd loǁeƌ pƌolifeƌatioŶ ƌates iŶ ĐoŵpaƌisoŶ to ĐĐRCC Đases eǆpƌessiŶg oŶlǇ HIFϮα (Gordan 
et al. 2008). This appaƌeŶt shift iŶ the HIFϭα/HIFϮα ďalaŶĐe duƌiŶg ĐĐRCC pƌogƌessioŶ ŵaǇ aƌise 
in some cases due to single copy loss of the chromosomal locus harboring the HIF1A gene which 
predicts poor patient outcome (Monzon et al. 2011). ccRCC cell lines frequently express only 
HIFϮα aŶd do Ŷot eǆpƌess fuŶĐtioŶal HIFϭα due to biallelic alterations of the HIF1A locus (Shen et 
al. 2011). The VHL ŵutaŶt RCCϰ Đell liŶe is oŶe eǆĐeptioŶ that eǆpƌesses ďoth ǁild tǇpe HIFϭα 
aŶd HIFϮα aŶd kŶoĐkdoǁŶ of HIF1A in these cells promotes xenograft tumor formation (Shen et 
al. 2011). ColleĐtiǀelǇ, these studies aƌgue that theƌe is a seleĐtioŶ agaiŶst HIFϭα eǆpƌessioŶ oƌ 
activitǇ duƌiŶg the pƌogƌessioŶ of ĐĐRCC aŶd that HIFϭα ŵaǇ aĐt to ƌestƌaiŶ ĐĐRCC pƌogƌessioŶ 
ǁheƌeas HIFϮα aĐtiǀitǇ is tuŵoƌ pƌoŵotiŶg. These studies hoǁeǀeƌ haǀe laƌgelǇ foĐused oŶ fullǇ 
transformed, genetically complex ccRCC cell lines derived from advanced tumors. It remains 
uŶĐleaƌ if aŶd hoǁ HIFϭα aŶd HIFϮα ĐoŶtƌiďute to the iŶitiatioŶ of ĐĐRCC fƌoŵ Đells that iŶitiallǇ 
harbor only mutations in the VHL gene. 
One of the earliest events following VHL mutation is likely to be a profound alteration of cellular 
ŵetaďoliĐ pathǁaǇs. Nuŵeƌous HIFϭα aŶd/oƌ HIFϮα-dependent metabolic changes have recently 
been reported in ccRCC cell lines, including elevated glucose uptake and conversion to lactate 
with a concomitant reduction in mitochondrial oxidation of pyruvate, reduced mitochondrial 
biogenesis, reduced mitochondrial complex I activity, altered cytochrome oxidase activity, 
increased pentose phosphate pathway flux, decreased oxidative glutaminolysis and increased 
lipogenesis through reductive glutamine metabolism (Iyer et al. 1998; Papandreou et al. 2006; 
Kim et al. 2006; Langbein et al. 2008; Luo et al. 2011; Zhang et al. 2007; Metallo et al. 2012; Chan 
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et al. 2011; Sun and Denko 2014; Tello et al. 2011; Fukuda et al. 2007). A potential confounding 
factor in the interpretation of these studies is that the ccRCC cell lines that were employed have 
complex genetic backgrounds that arose during tumor evolution. Some of these mutations 
potentially represent adaptive mechanisms that were selected because they allow cells to 
proliferate efficiently in the background of the numerous metabolic pathway constraints that 
appear to be imposed by constitutive HIFα aĐtiǀitǇ. Foƌ eǆaŵple, ĐĐRCCs fƌeƋueŶtlǇ haƌďoƌ 
activating mutations in the PI3K-mTORC1 pathway, inactivating TP53 mutations or exhibit high 
levels of MYC expression (Sato et al. 2013; Creighton et al. 2013), all of which are known to 
influence numerous cellular metabolic pathways (Vander Heiden et al. 2009; Levine and Puzio-
Kuter 2010). The contributions of metabolic alterations following VHL mutation, in otherwise 
genetically normal cells, to the earliest stages of tumor formation remain unknown. 
GiǀeŶ the appaƌeŶt iŵpoƌtaŶĐe of ĐoƌƌeĐt ƌegulatioŶ of HIFϭα aŶd HIFϮα aĐtiǀities iŶ the kidŶeǇ 
epithelium in the context of regulation of metabolism and development of ccRCC tumors, we 
undertook a systematic approach to genetically delete Hif1a or Hif2a, alone or together with Vhl 
iŶ ƌeŶal epithelial Đells iŶ ŵiĐe. We shoǁ that ǁhile Hifϭα aĐtiǀitǇ iŶduĐes ŵetaďoliĐ ĐhaŶges 
resulting in energy deficiency and inefficient proliferation of cultured primary cells, deletion of 
Hif1a together with Vhl is Ŷot suffiĐieŶt to Đause kidŶeǇ tuŵoƌ foƌŵatioŶ, aƌguiŶg that Hifϭα 
activity alone is not a barrier that prevents tumor formation by Vhl null kidney cells. In fact, in the 
tumor-prone Vhl/Trp53 mutant background, Hif1a co-deletion prevented the formation of cysts 
aŶd Ŷeoplasŵs, aƌguiŶg that staďilizatioŶ of Hifϭα is esseŶtial foƌ the iŶitial stages of tuŵoƌ 
formation in the kidney. 
Materials and Methods  
Mouse strains  
Hif1afl/fl (Ryan et al. 2000) and Hif2afl/fl (Gruber et al. 2007) mice were crossed with Ksp1.3-
Cre;Vhlfl/fl (Frew et al. 2008), Ksp1.3-Cre;Vhlfl/fl;Trp53fl/fl (Albers et al. 2013) or Ksp1.3-Cre/+ (Shao 
et al. 2002a; Patel et al. 2008)(Patel et al. 2008) mice to generate the following mouse lines: 
Ksp1.3-Cre/+;Hif1afl/fl,  Ksp1.3-Cre/+;Hif2afl/fl, Ksp1.3-Cre/+;Vhlfl/fl;Hif1afl/fl, Ksp1.3-
Cre/+;Vhlfl/fl;Hif2afl/fl and  Ksp1.3-Cre/+;Vhlfl/fl;Hif1afl/fl; Trp53fl/fl. Littermate mice that lacked the 
Cre transgene served as wild type controls. C57BL/6 mice were obtained from Janvier Labs.  
 
Mouse embryo fibroblasts (MEFs)  
MEFs were isolated from E13.5 embryos derived from intercrosses of relevant non-Cre expressing 
floxed mouse strains or C57BL/6 embryos (for wild type MEFs) and cultured in DMEM 
supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 10 kU/ml penicillin, 10 mg/ml 
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stƌeptoŵǇĐiŶ aŶd ϮϬϬ µM β-mercaptoethanol at 5% O2 and 5% CO2. WT, Vhlfl/fl and Vhlfl/fl Hif1afl/fl 
MEFs were transformed by transfection with a plasmid expressing SV40 large T-Antigen 
(Addgene, pBSSVD2005), followed by six passages of serial low density splitting (1:10). Cellular 
proliferation assays were performed according to a 3T3 protocol in which cells were plated at 3 
x 105 cells per 6 cm dish, counted after 3 days and re-plated at the same starting density. MEFs 
were infected with adenovirus expressing Cre recombinase and GFP (Ad-Cre-GFP, Vector Biolabs, 
#1700) or GFP only (Ad-CMV-GFP, Vector Biolabs #1060). Lentiviruses (LKO.1) expressing shRNAs 
against Hif1a (Sigma Mission shRNA, TRCN0000232222, TRCN0000232220) or a non-silencing 
sequence (Addgene, #10879) were titrated based on puromycin resistance after infection of 
NIH3T3 cells with serial viral dilutions and MEFs were infected using viruses at MOI of 1-3 in the 
presence of 4 µg/ml polybrene. 48 hours after infection, cells were selected for 2 days in the 
presence of 4 µg/mL puromycin.  
 
Metabolic assays of MEFs  
For ATP measurements, 1.5 x 105 tƌǇpsiŶised Đells ǁeƌe ƌesuspeŶded iŶ ϳϱ μl PB“ aŶd ϳϱ μl assaǇ 
buffer (CellTiter-Glo Luminescent Cell Viability Assay, Promega). Cells were lysed for 10 min at 
room temperature and distributed as technical triplicates in an opaque 96-well plate. 
Luminescence signal was detected with a microplate reader (Anthos Lucy 3). The Seahorse 
Bioscience XFe96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) was 
used for the measurement of mitochondrial oxygen consumption and extracellular acidification 
rate in MEFs. 5 x 104 cells were seeded per well in 12 wells of XFe 96-well cell culture microplates 
in 200 µl of DMEM and incubated for 16 h at 37°C in 20% O2. The next day the growth medium 
was replaced with 175 µl of bicarbonate-free DMEM (25 mM glucose, 110 mg/l sodium pyruvate, 
2 mM glutamine, pH 7.4) pre-warmed to 37°C. Before starting the assay procedure cells were 
preincubated at 37°C for 1 hour. For the measurement of oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) 5 cycles of mix/wait/measure times of 3/3/3 minutes were 
used. Protein abundance per well was determined via Bradford assay and used to normalize OCR 
and ECAR values. For measurement of glucose utilization and lactate production, 4 x 104 cells 
were plated per well of a 96 well plate, 8 hours later, medium was removed and replaced with 
ϭϬϬ μl DMEM supplemented with 10% FCS, 2 mM glutamine and 2 g/L glucose. Glucose and 
lactate concentrations in the medium after 50 h of culture were determined using Glucose Assay 
Kit II (Biovision) and Lactate Assay Kit II (Biovision).   
 
High-resolution respirometric analysis  
Animals were euthanized with CO2 and dissected immediately. 1 mm3 biopsies were taken from 
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cortex and medulla under the microscope and transferred to ice cold PBS. Wet weight was 
determined after drying the tissue on a Whatman paper. Biopsies were transferred to modified 
mitochondrial respiration medium (5 mM MgCl2, 5 mM KHPO4-, 10 mM HEPES, 70 mM sucrose, 
220 M mannitol, 1 mg/ml fatty acid free BSA, pH 7.4) and oxygen consumption was measured 
using a OROBOROS Oxygraph-2k (ORBOROS INSTRUMENTS  Corp, Innsbruck, Austria) according 
to the following procedure: Leak respiration (LN), representing resting oxygen consumption of an 
unaltered system, was induced by the addition of malate (2 mM) and octanoyl carnitine (0.2 mM). 
ADP (5 mM) was added for determination of the maximal electron flow through the electron-
transferring flavoprotein (ETF) and fatty acid oxidative capacity (PETF). PCI (respiratory capacity 
specific to complex I) was induced by the addition of glutamate (10mM) and pyruvate (5 mM). 
Maximal state 3 respiration (oxidative phosphorylation capacity P) was measured subsequently 
to the addition of succinate (10 mM). Finally, complex I was inhibited by rotenone (0.5 µM) to 
assess maximal state 3 respiration specific to complex II (PCII). Finally, mitochondrial respiration 
was abrogated by blocking complex III with 2.5 µM antimycin A, allowing the correction of 
residual O2. Cytochrome C oxidase activity (complex IV) was assessed by the addition of TMPD 
(0.5 mM) and Ascorbate (2 mM). Values were calculated using the DatLab OROboros 5.1 
software. 
 
Western blotting  
Protein extracts from cultured cells or powdered tissues were prepared using RIPA buffer (50 mM 
Tris–HCl at pH 7.5, 150 mM sodium chloride, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2mM 
EDTA, 1 mM sodium fluoride, 1 mM Na3VO4, 1 mM PMSF, 1 mM dithiothreitol, 1:100 Protease 
IŶhiďitoƌ CoĐktailͿ. Foƌ deteĐtioŶ of Hifϭα, ŶuĐleaƌ eǆtƌaĐts ǁeƌe pƌepaƌed ďǇ washing cells once 
in ice cold PBS, incubating for 20 minutes on ice in lysis buffer (10 mM HEPES, KOH pH 7.9, 10 
mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1:100 Protease Inhibitor Cocktail (Sigma-Aldrich), 1 mM 
PMSF) followed by addition of NP-40 to a final concentration of 0.1%, vortexing and centrifuging 
at 5000 rpm. The nuclear pellet was extracted and incubated for 5 min on ice in protein extraction 
buffer (400 mM NaCl, 20 mM HEPES, KOH pH 7.9, 1 mM EDTA, 1mM EGTA, 1:100 Protease 
Inhibitor Cocktail (Sigma-Aldrich 1 mM PMSF). To remove insoluble material all lysates were 
centrifuged at 14000 g and 4°C for 10 minutes. Western blotting was performed using the 
following antibodies: Actin (Sigma-AldƌiĐh, AϮϮϮϴͿ, HIFϭα ;Noǀus BiologiĐals, NBϭϬϬ-479), p53 
(Novocastra, NCL-p53-CM5p), pVHL (Santa Cruz, sc-5575), PDK1 (ENZO Life Science, ADI-KAP-
PK112-D) LDH-A (Santa Cruz Biotechnology, Sc27230), VDAC1 (Abcam, ab15895), FH (Abcam, 
ab95947).  
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Immunohistochemistry 
Immunohistochemistry of formalin fixed paraffin embedded tissues was performed as previously 
described (Albers et al. 2013; Frew et al. 2008) using the following antibodies: HIFϭα ;Noǀus 
Biologicals, NB100-ϭϬϱͿ, HIFϮα ;(Pollard et al. 2007), PM8) and Glut1 (Abcam, Ab14683).  
 
Mitochondrial mass  
After trypsinising, cells were washed twice in pre-warmed PBS and incubated for 30 minutes at 
37°C with 100 nM nonyl acridine orange (NAO) in PBS with 10% FCS. Samples were analysed by 
flow cytometry using a FACScanto II machine. 
Real time PCR-analysis 
Total RNA was prepared from cultured cells or from powdered tissue of whole kidneys using 
NucleoSpin RNA kit and cDNA synthesis was done with random hexadeoxynucleotide primers and 
Ready-To-Go You-Prime First-Strand Beads. The real-time PCR analysis of cDNA was performed 
with SYBR Green JumpStart Taq ReadyMix using primers listed in Supplementary Table 8.1.
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Results 
To begin to model the initial genetic events that occur in the progression of ccRCC we utilized 
primary mouse embryo fibroblasts (MEFs) as a genetically tractable cell culture system and 
focused on alterations in glucose metabolism. We derived MEFs from Vhlfl/fl, Vhlfl/fl;Hif1afl/fl, 
Vhlfl/fl;Hif2afl/fl and Vhlfl/fl;Hif1afl/fl;Hif2afl/fl embryos, infected them with adenoviruses expressing 
GFP (Adeno-GFP) or Cre (Adeno-Cre) and investigated the dependence of the expression of key 
genes that regulate glucose metabolism on Hif1a and Hif2a. The mRNA levels of Glut1, Pfkfb3, 
Pgk1, Ldha and Pdk1 were elevated in Vhl mutant cells in a Hif1a-dependent but Hif2a-
independent manner (Fig. 8.1A). Deletion of Vhl induces premature senescence that can be 
rescued by co-deletion of Trp53 (Albers et al. 2013). Vhl/Trp53 double null MEFs also exhibited 
higher mRNA abundance of these genes, indicating that the gene expression pattern is not a 
secondary consequence of senescence. The efficient deletion of all genes in the relevant floxed 
genotypes was confirmed by real time PCR (Supplementary Fig. 8.6). Since elevated expression 
of Ldh-a and Pdk1 is expected to promote the conversion of glucose-derived pyruvate into lactate 
at the expense of entry of pyruvate into the mitochondria for oxidative phosphorylation, we 
analysed cellular readouts of glycolytic flux. Modest increases in glucose utilization and 
extracellular acidification rate, as well as increases in the amount of lactate secreted by the cells, 
were observed in Vhl and Vhl/Trp53 null MEFs (Fig. 8.1B-D). In contrast to these relatively small 
increases, there was a large decrease in oxygen consumption in Vhl and Vhl/Trp53 null MEFs that 
was not attributable to reduced mitochondrial abundance, as assessed by NAO staining and 
protein abundance of the mitochondrial protein VDAC (Fig. 8.1E-G). These results suggest that 
Vhl deletion causes a small increase in glucose uptake and conversion to lactate but a large 
decrease in the entry of pyruvate into the mitochondrial TCA cycle, reflected by a lowered oxygen 
consumption rate. The reduced levels of oxidative phosphorylation that are not compensated by 
a large elevation in glucose flux to lactate suggested that cells may not be able to produce normal 
levels of ATP. Indeed, Vhl and Vhl/Trp53 deletion caused a decrease in cellular ATP levels that is 
dependent on Hif1a but independent of Hif2a, consistent with the transcriptional effects of these 
gene deletions on glycolytic regulatory genes (Fig. 8.1H-I). 
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Fig. 8.1 Loss of Vhl induces a Hif1a-dependent metabolic altereations in pMEFs. (A) Expression analysis 
of glycolytic genes in pMEFs following infecting with adenoviruses expressing GFP (GFP) or Cre-
recombinase (Cre).  (B-E) Measurements of glycolytic parameters in wild type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl 
Trp53fl/fl pMEFs: (B) glucose utilisation (C) extracellular acidification rate (ECAR), (D) relative lactate 
production, (E) oxygen consumption rate (OCR), (F) FACS analysis of Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl 
pMEFs using NAO as a dye for quantification of mitochondria, (G) Western blot analysis for VDAC and FH 
aďuŶdaŶĐe. IŵŵuŶoďlottiŶg usiŶg aŶ aŶtiďodǇ agaiŶst β-actin severed as a loading and transfer control, 
(H-I) relative intracellular ATP levels for wild type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl pMEFs (H) and Vhlfl/fl,  
Vhlfl/fl Hif1afl/f, Vhlfl/fl Hif2afl/fl and Vhlfl/fl Hif1afl/fl Hif2afl/fl pMEFs. 
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We reasoned that inefficient ATP production might lead to inefficient cellular proliferation. Vhl 
deletion is known to cause early senescence in MEFs (Welford et al. 2010; Young et al. 2008; 
Albers et al. 2013). Hif1a co-deletion, but not Hif2a co-deletion, completely rescued the 
proliferative defect that followed Vhl deletion (Fig. 8.2A). To our knowledge, this is the first form 
of senescence that has been shown to be genetically dependent on Hif1a. To determine whether 
Hifϭα staďilizatioŶ also iŵpaiƌed pƌolifeƌatioŶ of Vhl mutant cells that are unable to enter 
senescence we infected Vhlfl/fl;Trp53fl/fl MEFs with Adeno-GFP or Adeno-Cre as well as with 
lentiviral vectors expressing shRNA against Hif1a and performed proliferation assays. Gene 
deletion and knockdowns were confirmed by western blotting (Supplementary Fig. 8.7). 
Vhl/Trp53 null MEFs are immortalized but proliferate slower than Trp53 null MEFs (Albers et al. 
2013). At least paƌt of this pƌolifeƌatioŶ pheŶotǇpe is attƌiďutaďle to Hifϭα aĐtiǀitǇ siŶĐe tǁo 
independent shRNAs directed against Hif1a restored ATP levels to levels close to those in wild 
type cells and enhanced the proliferation rate of Vhl/Trp53 null MEFs (Fig. 8.2B). Consistently, 
loss of Hif1a in Vhl/Trp53 deficient pMEFs further increases the size of colonies formed when 
cells were grown at low density (Fig. 8.2C). Similarly, Vhl deletion in SV40 large T-Antigen 
transformed MEFs caused a reduction in ATP levels and slowed the rate of proliferation of these 
cells (Fig. 8.2E-F). Both of these effects were abolished when the same experiment was 
conducted in T-Antigen transformed Vhlfl/fl;Hif1afl/fl MEFs. Thus, Hifϭα staďilizatioŶ folloǁiŶg Vhl 
deletion leads to lowered ATP levels and exerts anti-proliferative effects in primary MEFs, 
immortalized MEFs and transformed MEFs. 
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Fig. 8.2 : Hifϭα staďilization folloǁing Vhl deletion exerts anti-proliferative effects in MEFs. (A) 
Proliferation assay of wild type, Vhlfl/fl, Vhlfl/fl Hif1afl/f, Vhlfl/fl Hif2afl/fl and Vhlfl/fl Hif1afl/fl Hif2afl/fl  following 
infection with adenoviruses expression GFP (GFP) or Cre-recombinase (Cre), (B) proliferation assay of Vhlfl/fl 
Trp53fl/fl pMEFs following co-infection with GFP or Cre and lentiviruses expressing non-silencing sequence 
(ns) or two different shRNA directed against Hif1a (shRNA-Hif1a #1 and shRNA-Hif1a #2), (C) cristal violet 
staining of cells from B after growing for 10 days at low density, (D) relative intracellular ATP levels of cells 
form B, (E) Proliferation assays of SV40-T-antigen transformed WT, Vhlfl/fl and Vhlfl/fl Hif1afl/fl following GFP 
or Cre infection, (F) relative ATP levels from cells in E. 
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To investigate whether similar metabolic changes also result from Vhl deletioŶ aŶd Hifϭα oƌ HifϮα 
dysregulation in renal tubular epithelial cells in vivo we generated Ksp1.3-Cre;Vhlfl/fl  (VhlΔ/Δ) (Frew 
et al. 2008), Ksp1.3-Cre;Hif1afl/fl (Hif1aΔ/Δ), Ksp1.3-Cre;Hif2afl/fl (Hif2aΔ/Δ), Ksp1.3-
Cre;Vhlfl/fl;Hif1afl/fl (VhlΔ/ΔHif1aΔ/Δ) and Ksp1.3-Cre;Vhlfl/fl;Hif2afl/fl (VhlΔ/ΔHif2aΔ/Δ) mice to obtain a 
panel of mice with different combinations of renal epithelial-specific loss or constitutive 
staďilizatioŶ of Hifϭα aŶd/oƌ HifϮα. IŵŵuŶohistoĐheŵiĐal staiŶiŶg ĐoŶfiƌŵed the eǆpeĐted 
staďilizatioŶ of eitheƌ oƌ ďoth Hifϭα aŶd HifϮα iŶ the relevant Vhl mutant genotypes (Fig. 8.3A). 
Elevated Glut1 protein expression was detected in VhlΔ/Δ and VhlΔ/ΔHif2aΔ/Δ renal tubules but not 
in renal tubules in VhlΔ/ΔHif1aΔ/Δ mice (Fig. 8.3B). mRNA abundance of Pfkfb3, Pgk1 and Ldha were 
similarly increased in whole kidney RNA isolations from VhlΔ/Δ and VhlΔ/ΔHif2aΔ/Δ mice but not 
VhlΔ/ΔHif1aΔ/Δ mice (Fig. 8.4A). These results demonstrate that elevated glycolytic gene expression 
in Vhl mutant renal tubular cells is dependent on Hif1a but not on Hif2a. We next developed a 
method to analyze mitochondrial oxygen consumption in biopsies of the renal cortex and medulla 
from mouse kidneys (Fig. 8.4B). Vhlfl/fl and VhlΔ/Δ mice were analysed, revealing that Vhl deletion 
in all renal nephron segments except for proximal tubules caused a decrease in total oxygen 
consumption in the medulla but not cortex of these mice, indicating decreased mitochondrial 
activity in the renal medulla of VhlΔ/Δ mice. This is consistent with the fact that the majority of 
tubules in the medulla are null for Vhl and the fact that Vhl wild type proximal tubular cells are 
the most abundant cell type in the cortex. We ĐoŶĐlude that Hifϭα-dependent metabolic 
alterations that lead to decreased mitochondrial activity and subsequent ATP deficiency in pMEFS 
also occur in Vhl mutant renal tubular cells in vivo. These alterations may therefore be potentially 
relevant at the earliest stages of tumor formation 
 
. 
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Fig. 8.3: Staďilization of Hifϭα, ďut not HifϮα, eleǀates Glutϭ protein eǆpression in renal tuďules. 
Generation of mice harboring specific deletions of Vhl, Hif1a and Hif2a in the renal epithelium using the 
Ksp1.3-Cre transgene. (A) Anti-Glut1 immunohistochemistry of depicted genotypes, (B) Anti-Hif1a and 
Anti-Hif2a immunohistochemistry, (C) hematoxilin and eosin (H&E) staining of kidneys of 6 month old mice:  
whole kidney (overview), renal cortex and renal medulla. Non-transgenic littermates were used as controls 
(WT). Scale bars: 1 mm (overview) and 100 µm (remaining pictures). 
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Fig. 8.4: Vhl deletion increases expression of glycolytic genes in kidneys and diminishes oxygen 
consumption rate in renal medulla. mRNA expression levels of glycolytic genes in whole kidney lysates of 
Ksp-Cre; Vhlfl/fl Ksp-Cre; Vhlfl/fl Hif1afl/fl and Ksp-Cre; Vhlfl/fl Hif2afl/fl. Non-transgenic littermates were used as 
controls (WT). Expression levels of S12 served for internal normalization. (B) High-resolution respirometry 
for Vhl-deficient kidneys (VhlΔ/Δ) and controls (Vhlfl/fl). Values are depicted for maximal state 3 respiration 
(total oxidative phosphorylation capacity, P), capacity for fatty acid oxidation (Lipid oxidation, PEFT), 
submaximal state 3 respiration through complex I (complex I, PCI), submaximal state 3 respiration through 
complex II (Complex II, PCII) and cytochrome C oxidase activity (complex IV, CIV). N=6. Experiment was 
conducted by Michal Rajski, Robert A. Jacobs and Stine Lundby.  
 
VhlΔ/Δ ŵiĐe eǆhiďit ĐoŶstitutiǀe staďilizatioŶ of ďoth Hifϭα aŶd HifϮα, ďut do Ŷot display 
hyperproliferative phenotypes and do not develop ccRCC precursor lesions or tumors (Frew et al. 
2008). “iŶĐe Hifϭα-mediated metabolic alterations causing ATP deficiency correlate with reduced 
proliferation in cell culture, we reasoned that Hifϭα ŵight aĐt as aŶ aŶti-proliferative factor that 
prevents tumor development following Vhl mutation. We therefore analysed cohorts of all of the 
above-described mutant mice at 6, 12 and 18 months of age. Neither Hif1a nor Hif2a deletion 
alone had any effect on the morphology of kidneys (Fig. 8.3C). Vhl/Hif1a double deletion, but not 
Vhl/Hif2a double deletion, fully rescued the previously-reported hydronephrosis phenotype 
caused by Vhl deletion (Frew et al. 2008). This phenotypic rescue will be described in detail 
elsewhere. Importantly, even when aged for up to 18 months, none of the genotypes exhibited 
cysts, dysplastic lesions or tumors (data not shown). We conclude that the combination of loss of 
the many putative tumor suppressor functions of pVHL plus constitutive expression of the 
putatiǀe oŶĐopƌoteiŶ HifϮα plus the aďseŶĐe of the putatiǀe tuŵoƌ suppƌessoƌ aĐtiǀitǇ of Hifϭα, 
does not affect epithelial homeostasis in the kidney.  
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While not sufficient to induce tumor formation, we reasoned that loss of Hif1a might nonetheless 
accelerate or enhance renal tumor formation in the Vhl/Trp53 double mutant tumor-prone 
genetic background (Albers et al. 2013). We generated Ksp1.3-Cre;Vhlfl/fl;Trp53fl/fl;Hif1afl/fl mice 
and analyzed cohorts of these mice at 3, 6 and 12 months of age. VhlΔ/ΔTrp53Δ/Δ mice display 
hydronephrosis, seminal vesicle developmental abnormalities, sub-fertility and sub-viability and 
by 12 months of age these mice develop simple and atypical kidney cysts, kidney neoplasms and 
benign epididymal tumors at high penetrance (Albers et al. 2013). About one third of these mice 
also develop a variety of genital-urinary tract carcinomas (Albers et al. 2013). All of these 
phenotypes were completely rescued in the VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ triple mutant background and 
mice developed no cysts or tumors in any organs (Fig. 8.5A-B). Thus, in contrast to our initial 
hǇpothesis, Hifϭα aĐtiǀitǇ is iŶdispeŶsaďle foƌ the iŶitiatioŶ of kidŶeǇ ĐǇst aŶd tuŵoƌ foƌŵatioŶ.  
 
Fig. 8.5: Deletion of Hif1a prevents tumor formation in Vhlfl/fl Trp53 fl/fl deficient mice. Generation of mice 
harboring specific deletions of Vhl, Trp53 and Hif1a in the renal epithelium using the Ksp1.3-Cre transgene 
((VhlΔ/Δ Trp53Δ/Δ Hif1aΔ/Δ) mice. (A) H&E staining and (B) anti-Hifϭα aŶd aŶti-HifϮα iŵŵuŶoĐheŵistƌǇ of 
kidneys, (B) H&E staining of uterus, vesicular gland and epididymis. Non-transgenic littermates were used 
as controls Vhlfl/fl Trp53fl/fl Hif1afl/fl) . Scale bar: 50 µm.    
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Discussion 
ccRCC is one of the few remaining major human cancer types for which there is no autochthonous 
mouse model, demonstrating that there are large gaps in our understanding of the molecular and 
cellular causes of this disease. A large body of correlative evidence in human ccRCC and functional 
geŶetiĐ eǀideŶĐe iŶ ĐĐRCC Đell liŶes has deŵoŶstƌated that HIFϭα staďilizatioŶ eǆeƌts a tuŵoƌ 
suppressor-like aĐtiǀitǇ ǁhile HIFϮα ďehaǀes oŶĐogeŶiĐallǇ iŶ the ĐoŶteǆt of pƌolifeƌatioŶ of 
tumor cells.  
In keeping with this idea, our studies of the metabolism of primary MEFs in cell culture revealed 
that Vhl deletioŶ Đauses Hifϭα-depeŶdeŶt aŶd HifϮα-independent induction of glycolytic genes, 
including Pdk1, that induce large decreases in mitochondrial oxygen consumption accompanied 
by relatively smaller increases in glucose uptake and metabolism to lactate, resulting in a 
deficiency of ATP production. Similar Hif1a-dependent and Hif2a-independent induction of 
glycolytic target genes and decreased mitochondrial oxygen consumption were observed 
following deletion of Vhl in renal epithelial cells in mouse kidneys. Many genes encoding glycolytic 
enzymes, including HK1, HK2, PGK1, PFKFB4, ALDOC, TPI1, ENO2, PDK1, and PDK3 have been 
demonstrated to be specific targets of HIF1A in ccRCC cell lines (Shen et al. 2011) and 
quantitatively similar VHL-dependent phenotypes in terms of glucose uptake, lactate secretion, 
oxygen consumption and ATP deficiencies have been observed in RCC4 cells which express 
fuŶĐtioŶal HIFϭα aŶd HIFϮα (Zhang et al. 2007; Chan et al. 2011). Thus, Vhl or VHL loss in mouse 
and human cells, respectively, causes a Warburg-like shift in glucose metabolism from oxidative 
phosphorylation to anaerobic glycolysis that results in a state of cellular energy deficiency. In 
primary Vhl mutant MEFs, this ATP deficiency correlates with the induction of cellular 
senescence. Both phenotypes are completely rescued by co-deletion of Hif1a but not of Hif2a. 
This result contradicts a previous account that senescence induced by loss of Vhl is independent 
of Hifα aĐtiǀitǇ (Young et al. 2008). One experimental difference that may account for these 
opposite conclusions is that our experiments were conducted at 5% O2 while the previous 
publication used 20% O2. It has been argued that culturing Vhl deficient MEFs under more 
physiologically relevant O2 concentrations (2-5%) is sufficient to rescue cellular senescence 
(Welford et al. 2010), however, in our hands, we observe only a partial rescue of proliferation 
under these conditions (Albers et al. 2013) and a full rescue of proliferative capacity is achieved 
only with the combination of 5% O2 and co-deletion of Hif1a. To the best of our knowledge this 
is the fiƌst deŵoŶstƌatioŶ of a foƌŵ of seŶesĐeŶĐe that is depeŶdeŶt oŶ Hifϭα.  
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The iŶhiďitoƌǇ effeĐts of Hifϭα staďilizatioŶ oŶ Đellulaƌ pƌolifeƌatioŶ aƌe paƌtiallǇ, ďut Ŷot fullǇ, 
rescued by co-deletion of Trp53 or transformation with SV40 large T-Antigen, since Vhl null cells 
in these genetic backgrounds were able to escape cellular senescence and proliferate in an 
immortalized manner (Albers et al. 2013), yet the proliferation rate of these cells was further 
enhanced by knockdown or knockout of Hif1a, which also rescued ATP levels. These results 
obtained in defined genetic backgrounds parallel previous results obtained using several VHL-
deficient ccRCC cell lines where knockdown of HIF1A enhanced the proliferation of cells that 
eǆpƌess fuŶĐtioŶal HIFϭα aŶd HIFϮα, ǁheƌeas HIF1A overexpression decreased the proliferation 
of HIF1A-ŵutaŶt Đells that eǆpƌess oŶlǇ fuŶĐtioŶal HIFϮα ďut did Ŷot deĐƌease the pƌolifeƌatioŶ 
of Đells eǆpƌessiŶg fuŶĐtioŶal HIFϭα aŶd HIFϮα. ColleĐtiǀelǇ, these ƌesults suggest that the MEF 
Vhl deletion model recapitulates many of the metabolic and proliferative features of ccRCC cell 
lines. 
“iŶĐe these fiŶdiŶgs added fuƌtheƌ eǀideŶĐe to the idea that Hifϭα staďilizatioŶ aĐts to iŵpaiƌ 
proliferation of Vhl mutant cells, we asked whether removing this putative barrier may allow 
hyperproliferation of Vhl mutant kidney epithelial cells in vivo, potentially allowing cysts or ccRCC 
tumors to form. However, even when aged for 1.5 years, VhlΔ/ΔHif1aΔ/Δ mice exhibited no renal 
proliferative abnormalities. Similar mouse models in which Vhl and Hif1a were deleted in renal 
epithelial cells under the control of different nephron segment-specific Cre transgenes also did 
not lead to tumor formation (Rankin et al. 2006; Pritchett et al. 2014). In the reverse experiment, 
VhlΔ/ΔHif2aΔ/Δ mice similarly did not develop renal proliferative phenotypes. Thus, despite the 
numerous putative tumor suppressor functions of Vhl, its deletion together with constitutive 
stabilization of HIFϭα aŶd HIFϮα aloŶe oƌ togetheƌ aƌe iŶsuffiĐieŶt foƌ ƌeŶal tuŵoƌ foƌŵatioŶ. 
Pƌeǀious studies also suppoƌt the idea that aĐtiǀatioŶ of the Hifα tƌaŶsĐƌiptioŶ faĐtoƌs aloŶe is Ŷot 
oncogenic. Combinatorial deletion of PHD1, PHD2 and PHD3 in mouse kidney epithelial cells 
ƌesults iŶ ĐoŶstitutiǀe HIFϭα aŶd HIFϮα staďilizatioŶ aŶd aĐtiǀatioŶ of HIFα taƌget geŶes ďut does 
not cause tumor formation (Adam et al. 2011) and transgenic expression of constitutively active, 
non-degƌadaďle ŵutaŶts of HIFϭα oƌ HIFϮα aloŶe, oƌ iŶ ĐoŵďiŶatioŶ, iŶ kidŶeǇ epithelial Đells also 
failed to induce tumor formation beyond the stage of simple cysts or small dysplastic lesions that 
could be envisaged as ccRCC precursor lesions (Schietke et al. 2012; Fu et al. 2011; 2013). While 
iŶsuffiĐieŶt foƌ tuŵoƌ foƌŵatioŶ, Hifϭα aŶd HifϮα aĐtiǀities ŵaǇ ŵodifǇ the pheŶotǇpe of tuŵoƌs 
that arise in other genetic backgrounds. Vhl/Trp53 deletion leads to the formation of Vhl mutant 
simple and atypical renal cysts, renal neoplasms as well as carcinomas in other organs of the 
genital tract (Albers et al. 2013). Based oŶ the eǀideŶĐe that Hifϭα suppƌesses Đellulaƌ 
proliferation, we anticipated that the tumor phenotype in these mice might be enhanced by Hif1a 
co-deletion. In fact, the opposite result was obtained and all phenotypes in these mice were 
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completely rescued. Insofar as the Vhl/Trp53 deletion model mimics the initial stages of evolution 
of ĐĐRCCs, these fiŶdiŶgs deŵoŶstƌate that Hifϭα staďilizatioŶ plaǇs aŶ esseŶtial oŶĐogeŶiĐ ƌole 
in tumor formation. 
Based on these findings we propose a new working model to explain ccRCC initiation and 
progression. Following biallelic inactivation of VHL, aĐtiǀatioŶ of HIFϭα oƌ HIFϮα aloŶe oƌ togetheƌ 
are insufficient for tumor formation, but likely provide an initial permissive environment that 
facilitates tumor formation once other cooperating genetic alterations arise, for example by 
inducing angiogenesis, promoting growth factor production and evading apoptotic responses. 
AdditioŶal HIFα-independent consequences of loss of pVHL function such as loss of planar cell 
division (Thoma et al. 2009; Hell et al. 2013) and sensitization to lose the primary cilium in 
response to extracellular signals (Thoma et al. 2007; Frew et al. 2008) may contribute to initial 
cellular dysplasia and cyst formation, while elevated levels of aneuploidy (Thoma et al. 2009; Hell 
et al. 2013) and inefficient repair of DNA damage (Metcalf et al. 2013) could lead to increased 
rates of generation of cooperating secondary mutations. In this context, it is likely that genetic 
alterations commonly found in ccRCCs that affect the PI3K-mTORC1 and p53 pathways, or the 
PBRM1, SETD2 or BAP1 tumor suppressors might act as cooperating mutations that initiate tumor 
formation (Creighton et al. 2013; Sato et al. 2013). HIFϭα aĐtiǀitǇ appeaƌs to ďe esseŶtial foƌ the 
emergence of ccRCC precursor lesions, at least in the background of cooperating TP53 mutations. 
Hoǁeǀeƌ, siŶĐe HIFϭα staďilizatioŶ also iŶduĐes ŵetaďoliĐ alteƌatioŶs that ƌesult iŶ loǁeƌed 
oxygen consumption and ATP levels and impaired cellular proliferation, it is likely there is a 
selection for tumor cells that can proliferate most efficiently in this genetic and metabolic 
background. One mechanism of evading these potential metabolic and proliferative constraints 
may be to select for functional losses of the HIF1A gene (Shen et al. 2011) or for other post-
tƌaŶsĐƌiptioŶal alteƌatioŶs that iŵpaiƌ HIFϭα staďilitǇ oƌ aĐtivity. Alternatively or additionally, 
mutations in other metabolism-regulating genes may act to further alter cellular metabolic 
pathways to achieve a balance of high rates of glycolytic flux and sufficient oxidative 
phosphorylation to provide the glycolytic and TCA cycle metabolic intermediates, as well as 
sufficient amounts of ATP, that are necessary to fuel efficient biosynthesis, cellular proliferation 
and tumor growth.  
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Supplement 
Gene (primer) Oligonucleotide sequence (5´-3´) 
Hif1a (fwd) TGC TCAT CAG TTG CCA CTT C 
Hif1a (rev) CCT CAT GGT CAC ATG GAT GA 
Hif2a (fwd) CTG ATG GCC AGG CGC ATG ATG 
Hif2a (rev) CTG ATG GCC AGG CGC ATG ATG 
Ldha (fwd) TGG CTT TCC CAA AAA CCG AGT  
Ldha (rev) CCA TCA GGT AAC GGA ACC GC 
  
  
Trp53 (fwd) GCG TAA ACG CTT CGA GAT GTT 
Trp53 (rev) TTT TTA TGG CGG GAA GTA GAC TG 
Pdk1 (fwd) AGG ATC AGA AAC CGG CAC AAT 
Pdk1 (rev) GTG CTG GTT GAG TAG CAT TCT A 
Pfkfb3 (fwd) CAA CTC CCC AAC CGT GAT TGT  
Pfkfb3 (rev) TGA GGT AGC GAG TCA GCT TCT 
Pgk1 (fwd) TGG AGC CAA CTC CGT TGT C 
Pgk1 (rev) CAG GCA TTC TCG ACT TCT GGG 
Pkm2 (fwd) TCG AGG AAC TCC GCC GCC TG  
Pkm2 (rev) CCA CGG CAC CCA CGG CGG CA 
S12 (fwd) GAA GCT GCC AAA GCC TTA GA  
S12 (rev) AAC TGC AAC CAA CCA CCT TC 
  
  
Vhl (fwd) CAG CTA CCG AGG TCA TCT TTG 
Vhl rev CTG TCC ATC GAC ATT GAG GGA  
Supplementary Table 8.1: 5`-3` sequences of primers used for real time PCR analyses 
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Supplementary Fig. 8.6: Efficient gene deletion in pMEFs from Fig. 8.1. RT-qPCR analysis of mRNA 
expression for Vhl, Hif1a, Hif2a and Trp53. S12 mRNA abundance was used for internal normalization. 
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Supplementary Fig. 8.7 Confirmation of efficient gene knockdowns and gene deletions from cells used in 
Fig. 8.2. (A) mRNA abundance of Vhl, Hif1a and Hif2a of depicted genotypes. Expression levels of S12 were 
used as for internal normalization (B-C) Western blot analysis using antibodies agaiŶst Hifϭα, pϱϯ aŶd pVhl. 
;DͿ WesteƌŶ ďlot aŶalǇsis usiŶg aŶtiďodies agaiŶst Hifϭα aŶd pVhl. Cell lǇsate ǁas haƌǀested at depiĐted 
tiŵe poiŶts. IŵŵuŶoďlottiŶg usiŶg aŶ aŶtiďodǇ agaiŶst β-actin severed as a loading and transfer control 
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8.2.2 Cooperative effects of loss of Vhl and Hif1a in primary kidney cells 
The work described in the manuscript above showed that the deletion of Hif1a in pMEFs rescues 
Vhl-dependent senescence and accelerates growth of Vhl/Trp53-deficient pMEFs. Next, we 
aimed to confirm these findings in a more disease-relevant cell type. We isolated primary 
epithelial kidney cells (PKCs) from mice harbouring floxed alleles of our genes of interest and 
induced gene deletion by the infection of cells with adenovirus expressing Cre recombinase or 
GFP as control. First, we measured the short term proliferation capacity by a sulforhodamine B 
colorimetric assay. Whereas loss of Vhl impairs growth as expected, this growth defect was not 
rescued by co-deletion of Hif1a, contradicting our observations in pMEFs (Fig. 8.8A-C). 
Furthermore, gene deletions did not cause immortalization of PKCs, as demonstrated by low 
density seeding of cells (Fig. 8.8B). Simultaneous deletion of Vhl and Trp53 in PKCs induces 
enhanced cell proliferation, which is not affected by silencing of Hif1a (Fig. 8.8D), in contrast to 
our findings with MEFs. These ƌesults iŶdiĐate that HIFϭα has Ŷo observable effect on the 
proliferation of primary kidney cells in these short term assays. In longer term low density colony 
forming and proliferation assays however, silencing of Hif1a in Vhl/Trp53 null PKCs apparently 
increases the rate of proliferation of immortalized cells as it resulted in the formation of more 
and bigger colonies (Fig. 8.8E). In contrast, loss of Hif1a does not induce immortalization in cells 
expressing wild type Trp53 (Fig. 8.8B). Another feature of cell transformation is the ability to 
proliferate in an anchorage-independent manner. We therefore seeded cells in unmodified 
polystyrene dishes, where cell attachment of wild type cells is prevented due to the hydrophobic 
nature of the plate. Interestingly, Vhl/Trp53 null PKCs frequently as floating spheres and are also 
able to attach to the bottom of the plate forming an epithelial monolayer. This phenotype was 
not altered by silencing of Hif1a (Fig. 8.8F). These results indicate that Vhl/Trp53 null transformed 
PKCs are capable to grow with no or only very little integrin interaction. To exclude any off-target 
effects, we validated these results using Vhl/p53/Hif1a triple floxed PKCs. Consistently, Cre but 
not GFP expressing cells are immortalized, proliferate faster and frequently form spheres in low-
attachment plates (Fig. 8.8H-J). Finally, we tested the tumour-forming capacity of Vhl/Trp53 
negative cells in vivo by the subcutaneous injection of cells into the flank of SCID mice. While 
Vhl/Trp53 null cells were not able to establish any tumours, one out of two Vhl/Trp53/Hif1a null 
ǆeŶogƌafts foƌŵed a tuŵouƌ afteƌ ϲ ŵoŶths, iŶdiĐatiŶg that loss of Hifϭα ŵight faǀouƌ tuŵouƌ 
growth in xenografts (Fig. 8.8K-L), however the fact that only one of two clones allowed a tumour 
to form and that this occurred at a very late timepoint, indicates that other modifying genetic 
events have presumably occurred in this tumourigenic clone. In contrast, Vhl/p53-deficient as 
well as Vhl/p53/ Hif1α-deficient pMEFs did not growth as xenografts (data not shown). 
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Fig. 8.8: Loss of Hif1a transforms Vhl/Trp53 deficient primary kidney cells. (A) Sulforhodamine B 
colorimetric proliferation assay (SRB) for Vhlfl/f and Vhlfl/f Hif1afl/fl primary kidney cells (PKCs) infected with 
adenoviruses expressing GFP or Cre recombinase, (B) low density assay for cells from A, (C) Western blot 
analysis for gene deletions from cells from A, (D) SRB assays for Vhlfl/flTrp53fl/fl PKCs infected with GFP or 
Cre and lentiviruses expressing a non-silencing sequence (shRNA-ns) or shRNA against Hif1a,(E) low density 
assay, (F) anchorage-independent growth assay and (G) western blot analysis for cells from D, (H) SRB assay 
for Vhlfl/fl Trp53fl/fl Hif1afl/fl PKCs expressing GFP or Cre. (I) Low density assay, (J) anchorage-independent 
growth, and (K) subcutaneous injection of xenografts with cells from H. (L) Confirmation of gene deletion 
for cells from H by RT-qPCR. Scale bars: 50 µm (F and J) and 1 cm (K).   
 
Despite extensive research, the origin of ccRCC is still under debate. Given that our primary cell 
culture system consists of a mix of renal epithelial cells, we speculated that a specific cell type 
might be more susceptible to oncogenic mutations than others. To address this question, we 
induced gene deletions in Vhl/Trp53/Hif1a floxed PKCs, isolated mRNA 3 days (T0) and 14 days 
(T1) after infection and quantified mRNA levels of markers for different tubular segments. mRNA 
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for NaPi-IIa (proximal tubules), Tamm-Horsfall protein (Thp, TAL) and Aqp2 (collecting ducts) 
were detectable at both time points, demonstrating that cells arising from different tubular 
segments are able to proliferate in culture (Fig. 8.9A-C). However, the relative population of Thp 
and Aqp2 expressing Vhl/Trp53/Hif1a negative cells doubled over time, whereas NaPi-IIa mRNA 
abundance slightly decreased. These results indicate that cells deriving from TAL and collecting 
duĐts haƌďouƌ a ŵild gƌoǁth adǀaŶtage oǀeƌ Đells deƌiǀiŶg fƌoŵ pƌoǆiŵal tuďules. As Hifϭα 
activity promotes epithelial to mesenchymal transition (EMT) (Luo et al. 2006; Higgins et al. 
2007), we also measured the expression levels of E-cadherin (marker for epithelial cells) and 
vimentin (mesenchymal cells) (Fig. 8.9D-E). E-cadherin mRNA levels decreased in GFP as well as 
Cre expressing cells whereas Vimentin abundance increased over time, either suggesting that 
epithelial cells undergo EMT or that mesenchymal cells proliferate faster than epithelial cells and 
therefore are enriched in the population. Gene deletions were confirmed by RT-qPCR (Fig. 8.9F-
H). To validate the knock out results, we repeated the experiment by silencing Hif1a in Vhl/Trp53 
null PKCs. Although we could confirm that all cells are able to growth in culture, the expression 
pattern of tubular and EMT markers were not reproducible (Fig. 8.9I-P). This difference might be 
due to ƌesidual Hifϭα leǀels oƌ iŶtƌaĐellulaƌ ĐhaŶges Đaused ďǇ leŶtiǀiƌal iŶtƌoduĐtioŶ of shRNA.  
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Fig. 8.9 Proliferating PKCs express markers for renal tubules and 
mesenchymal cells. (A-H) mRNA expression analysis of 
Vhlfl/flTrp53fl/flHif1afl/fl PKCs and (I-P) of Vhlfl/flTrp53fl/fl PKCs infected 
with GFP or Cre-recombinase expressing adenoviruses (GFP) and 
(Cre). Cells in I-P were infection in addition with lentiviruses   
 expressing non-silencing shRNA (shRNA-ns) or shRNA against Hif1a   
       (shRNA-Hif1a). 
 
The analysis of Vhl/Hif1a deficient mice demonstrated that deletion of Hif1a in Hif2a-expressing 
renal epithelial cells is not sufficient to induce tumourigenesis. To identify cooperative mutations 
that further increase the tumourigenic capacity of kidney epithelial cells, we performed a 
synthetic transformation genetic screen by silencing different cell cycle inhibitors in PKCs. We 
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simultaneously infected freshly isolated Vhl and Vhl/Hif1a floxed PKCs with adenovirus 
expressing GFP or Cre and a lentiviral based shRNA library harbouring 4-5 hairpins against each 
of 12 cell cycle regulatory genes (Cdkn1a, Cdkn1b, Cdkn1c, Cdkn2a, Cdkn2b, Cdkn2c, Cdkn2d, Rb1, 
Rbl1, Rbl2, Trp53, Trp63 and Trp73). Low density assays revealed that loss of function of cell cycle 
inhibitors can cause the immortalization of PKCs, which is fully abrogated by the loss of Vhl but 
restored by co-deletion of Vhl and Hif1a (Fig. 8.10A-B), consistent with the idea that Hif1a 
suppresses cellular transformation. To further investigate the transformation capacity of the 
cells, we tested the colony formation capacity in soft agar as well as the ability for anchorage-
independent growth. However, no colonies or spheres formation were observed in either Vhl or 
Vhl/Hif1a null populations infected with the shRNA library indicating that these genetic 
alterations are not sufficient to cause cellular transformation (Fig. 8.10C-D). To identify hairpins 
responsible for the immortalization of PKCs or those that provide a proliferative advantage to 
Vhl/Hif1a deficient PKC, we performed a population based gain-of-representation screen: 
genomic DNA of PKCs was harvested 3 days after infection with the lentiviral shRNA library (T0) 
and from colonies that formed when plated at low density for a further 10 days (T1) and the 
relative abundance of each of the integrated hairpins in the total population was assessed by 
deep sequencing. As at least one hairpin per target gene was present at T0 as well as at T1, 
indicating that inactivation of all cell cycle inhibitors represented in the library causes cell 
immortalization in wild type as well as in Vhl/Hif1a deficient PKC (Fig. 8.10E). Furthermore, we 
found that 10 hairpins targeting 5 different genes are enriched at T1 compared to T0 in Cre 
expressing but not in GFP expressing cells (5 hairpins targeting Cdkn1a, 2 targeting Trp53 and one 
each against Rb1, Rbl1 and Trp63), suggesting that the inactivation of these genes causes a 
proliferation advantage in a Vhl/Hif1a deficient context. These results demonstrate that loss of 
Vhl in renal epithelial cells causes a Hif1a-dependent proliferation barrier, which cannot be 
overcome by mutations of the cell cycle inhibitors chosen for the screen. Furthermore, loss of 
Cdkn1a, Trp53, Trp63, Rb1 and Rbl1 enhance the proliferation of Vhl/Hif1a null kidney cells and 
might represent other oncogenic hits during tumour evolution.  
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Fig. 8.10 Loss of Vhl causes a Hif1a-dependent proliferation barrier. Vhlfl/fl and Vhlfl/flHif1afl/fl PKCs were co-
infected with adenovirus expressing Cre-recombinase (Cre) or GFP (GFP) and a lentivirus-based library 
containing shRNA hairpins targeting different cell cycle inhibitors (Cdkn1a, Cdkn1b, Cdkn1c, Cdkn2a, Cdkn2b, 
Cdkn2c, Cdkn2d, Rb1, Rbl1, Rbl2, Trp53, Trp63). (A) Crystal violet staining of cells growing 14 days at low density 
seeding,  (B) Confirmation of gene deletions, (C) soft agar assay, (D) anchorage-independent growth assay, 
(E) gain of representation screen with cells from A-D: Deep-sequencing of starting population 3 days after 
infection (T0) and of colonies growing at low density (T1). 
 
8.2.3 Discussion 
To confirm the findings from our studies performed in pMEFS in a more disease-relevant cell 
type, we established a new culturing system for primary epithelial kidney cells (PKCs) that were 
freshly isolated from different transgenic mice. Gene expression analyses and antibody stainings 
for nephron markers revealed a mixed population of cells arising from different nephron 
segments, which express E-cadherin for several days of culturing and confirm the epithelial 
nature of PKCs (results from Holger Lehmann and Michal Rajski). Therefore, our culturing system 
enables us to target cells from all nephron segments that have been shown give rise to ccRCC 
(Droz et al. 1990; Motzer et al. 1996; Paraf et al. 2000; Mandriota et al. 2002; Straube et al. 2011).  
Our studies show that loss of Vhl impairs growth of PKCs, which is not rescued by the deletion of 
Hif1a, contrasting our previous findings in pMEFS (Fig. 8.8A and Fig. 8.2A). The observed 
difference between these 2 cell types might be due to the very low proliferation rate of PKCs 
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which is barely above background levels obscuring the detection of significant differences in 
growth. Loss of Trp53 in Vhl-deficient PKCs, however, accelerates proliferation and enables cell 
growth at low density, a feature of immortalized cells. Interestingly, although there is no effect 
on the measurable short term proliferation rate of PKCs, loss of Hif1a in Vhl/Trp53 deficient PKCs 
further increased the size of colonies formed when cells were grown at low density (Fig. 8.1D-F). 
Moreover, we found that loss of Vhl prevents the immortalization of PKCs caused by the 
inactivation of cell cycle inhibitors. Loss of Hif1a enables the overcoming of this barrier and 
enables the formation of colonies in low density assays (Fig. 8.10A). In line with our observations 
in pMEFs, these observations suggest that loss of Hif1a promotes the aggressiveness of cancer 
cells, presumably contributing to the bad prognosis of patients with loss of chromosome 14q 
(Monzon et al. 2011).  
Gene expression profiling of PKCs performed by Michal Rajski demonstrated an increased 
expression of glycolytic genes in Vhl-deficient PKCs, which is abrogated by the deletion of Hif1a 
as well as of Hif2a. It remains to be investigated whether these changes also result in restricted 
availability of ATP, as observed in pMEFS. To finally prove our hypothesis that the reprogramming 
of the cellular metabolism is responsible for the impaired proliferation of PKCs and pMEFS, we 
aim to mimic the effects of loss of Hif1a by the downregulation of Pdk1 in Vhl and Vhl/Trp53 cells, 
again enabling the entry of pyruvate into the TCA cycle (Fig. 6.5). We expect that loss of Pdk1 
activity enables again the re-entry of pyruvate into the TCA cycle, increasing the production of 
ATP and subsequently facilitates cell proliferation. However, given that other Hif1α targets are 
also likely to contribute to the reduced ATP levels upon loss of Vhl, loss of Pdk1 might only cause 
a partial rescue of the phenotype. For instance, expression of LON and NDUFA4L2 have been 
shown to attenuate mitochondrial activity, probably further diminishing ATP production (Fukuda 
et al. 2007; Tello et al. 2011).  
Contradictory to our finding in mouse kidneys, where Hif1a is necessary for the initiation of 
Vhl/Trp53 negative tumours, one out of two subcutaneous injections of Vhl/Trp53/Hif1a-
deficient PKCs lead to the formation of a tumour (Fig. 8.8K). We hǇpothesized eaƌlieƌ that Hifϭα 
activity is needed to establish a pro-tumorigenic environment in the kidney. Given that xenograft 
assays in immunosuppressed mice represent a rather artificial system with very distinct 
environmental conditions compared to the mouse kidney, it is plausible that Hif1a is not 
necessary to establish a niche for xenograft growth. Furthermore, additional mutations might 
have occurred in these lines of Vhl/Trp53/Hif1-deficient cells, since the deletion of Vhl and Trp53 
are not sufficient to drive xenograft growth (data not shown). A plausible oncogenic event might 
be the activation of c-myc, concordantly with other studies performed in our lab where 
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overexpression of c-myc in Trp53 negative PKCs enables xenograft growth, irrespectively of Vhl 
activity (Tomas Hejhal, oral communication).  
To find potential driver mutations in Vhl/Hif1a negative cells, we performed a gain of 
representation screen in PKCs. We found that deletion of Cdkn1a, Trp53, Trp63, Rb1 and Rbl1 
enhances the proliferation of Vhl/Hif1a deficient cells, potentially representing other oncogenic 
hits during tumour evolution (Fig. 8.10E).  Mutations in cell cycle regulatory genes frequently 
occur in human cancers and several mouse tumour models have been generated by the 
inactivation of cell cycle kinases (Sotillo et al. 2001; Ko et al. 2005; Sotillo et al. 2005; Malumbres 
and Barbacid 2009). In ccRCC, the TCGA study identified mutations in cell cycle control genes in 
18% of the cases. The genes showing up in our screen were only mutated in 4% (Cerami et al. 
2012; Gao et al. 2013). Although the percentage is rather low, it is likely that mutations in these 
genes or in upstream or downstream targets can exert important driver functions in a subset of 
ccRCC. The significance of Rb mutations is supported by work from our lab performed by Sabine 
Harlander, which demonstrates that deletion of Rb1 rescues the loss of Vhl-dependent 
senescence phenotype in pMEFs. Furthermore, VhlΔ/Δ Trp53Δ/Δ Rb1Δ/Δ mice develop renal lesions 
already after 3 months. Given that other studies report higher frequencies of mutations in RB1 
and also in TP53 in ccRCC biopsies, it is possible that the number of mutations in Rb, Trp53 and 
potentially also in other cell cycle regulators is underestimated in the study mentioned above 
(Shuin et al. 1995; Albers et al. 2013). Therefore, it would be valuable to further validate these 
genes in different cell culture systems, for instance in a colony-forming assay. Finally, it would be 
interesting to induce the inactivation of these genes in the kidney of Vhl/Hif1a deficient mice, for 
instance by a lentiviral-based approach and monitor the formation of potential tumours in vivo. 
Based on our finding that Hif1a is crucial for tumour initiation in the mouse kidney it might be 
necessary to develop a model that allows the time-delayed inactivation of genes to identify 
additional driver mutations in ccRCC.  
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8.3 Renal Hifϭα staďilization iŵpairs renal ǁater reaďsorption and causes 
hydronephrosis 
8.3.1 Introduction 
Hydronephrosis is characterized by the expansion of the renal pelvis and the collecting system 
and is the most frequently diagnosed prenatal abnormality, occurring in approximately 1% of all 
pregnancies (Dudley et al. 1997; Thom and Rosenblum 2013). Most cases show stabilization or 
even a normalization of kidney morphology within the first two years after birth; however 10 – 
25% of the young patients show persistent severe dilatation and require medical or surgical 
intervention to prevent kidney insufficiency (Woodward and Frank 2002). The underlying 
mechanism often remains unclear, however possible causes are obstructions of the urogenital 
tract or excess urine production. Conversely, hydronephrosis is also a common symptom in renal 
disorders that are caused by reduced renal ion transport or aquaporin expression therefore 
impairing renal urine reabsorption (Gargollo and Diamond 2007; Moon et al. 2009). Furthermore, 
kidney stones, pelvic neuroblastoma, pregnancy or impaired ureteral peristaltic activity can cause 
hydronephrosis in adults and therefore is a common complication in a broad range of human 
diseases (Au et al. 1985; Woo et al. 2013). Untreated hydronephrosis causes chronic kidney 
insufficiency and end stage renal disease, however, the precise mechanism is not yet fully 
understood (Rasouly and Lu 2013). 
We previously published that epithelial deletion of Vhl causes hydronephrosis in mice, however 
the underlying mechanism remained unclear (Frew et al., 2008). Importantly, in contrast to other 
published mouse models for hydronephrosis, Vhl-deficient mice display a normal life span and 
also kidneys from older mice are largely morphologically intact – except for the expanded renal 
pelvis, which leads to a partial thinning of the renal cortex. These observations indicate a new 
potential mechanism for the formation of hydronephrosis at least in mice. Therefore, in the 
second part of the thesis, we investigated the effect of loss of Vhl on kidney function more closely, 
aiming to understand the underlying etiologies of the hydronephrosis phenotype. 
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8.3.2 Results 
As shown in the first part of this thesis, Vhl-deficient kidneys display a bilateral hydronephrosis 
that is rescued in Vhl/Hif1a-deficient, but not in Vhl/Hif2a-deficient mice (Fig. 8.3C). 
Hydronephrosis is defined by the increased diameter of one or more components of the renal 
collecting system (Thom and Rosenblum 2013). Sectioning of Vhl-deficient kidneys in different 
planes confirmed the expansion of the renal pelvis and a thinning of the renal medulla when 
compared to Vhlfl/fl control kidneys (Fig. 8.11).  
 
Fig. 8.11: Loss of Vhl causes hydronephrosis. H&E staining of different section planes of adult Ksp-Cre; 
Vhlfl/fl kidneys (VhlΔ/Δ) and controls (+/+, Vhlflfl). N=2, Scalebar = 1 mm.  
Given that hydronephrosis is often caused by an obstruction or dysplasia of the ureter (Peters 
1995; Thom and Rosenblum 2013), we visualized the morphology of the urinary system by micro-
computed tomography (µCT) (Fig. 8.12A). VhlΔ/Δ kidneys display a clearly changed morphology 
with an expanded renal pelvis and almost no medullary structures. Furthermore, the cortical 
structures displayed a much weaker signal from the contrast agent when compared to the cortex 
of wild type kidneys, suggesting changes in urine flow or renal filtration. However, we did not 
notice any obvious delay in renal clearance of the contrast agent and 3-D rendering of the kidney 
volume, ureter and bladder did not show any urinary obstruction or development of hydroureter, 
a dilation of the ureter (Shopfner 1966). Interestingly, measurement of kidney size in vivo 
demonstrated an increase in renal diameter by approximately 20%, possibly compensating for 
space lost by the expansion of the pelvis (Fig. 8.12B and C).  
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Fig. 8.12:  Hydronephrosis is not caused by kidney obstruction. (A) Three-dimensional reconstruction of 
kidney, ureter and bladder. (B) Coronal view of a two-dimensional image of control (Vhlfl/fl) and Vhl-
deficient kidneys (VhlΔ/Δ), (C) Measurement of kidney diameter in vivo. Caliper µCT analysis. Contrast agent: 
Visipaque.   
 
Fetal kidneys produce four to six times more urine before than after birth (Walsh PC 2002). A 
common hypothesis for the development of congenital non-obstructive hydronephrosis is a 
dilation of the renal pelvis caused by increased urine volume (Thom and Rosenblum 2013). To 
investigate whether an overproduction of urine might cause hydronephrosis, we subjected single 
VhlΔ/Δ mice to 24h urine collection for several consecutive days. Indeed, measurement of water 
consumption and urine output revealed severe polyuria and polydipsia, with 24h urine 
production being increased by a factor of 10 in VhlΔ/Δ mice (Fig. 8.13A-B). Furthermore, urine 
osmolality was decreased by almost 90% (Fig. 8.13G), whereas food consumption and feces 
production remain unchanged (Fig. 8.13C-D). No difference in mouse bodyweight was observed 
in either genotype (Fig. 8.13E). Whilst Vhl/Hif2a-deficient mice display a similar phenotype, co-
deletion of Vhl and Hif1a does not disturb water homeostasis in mice, again indicating a Hif1a-
dependent phenotype. Loss of both Hifa isoforms alone had no impact on kidney function. 
Fuƌtheƌ uƌiŶe aŶalǇsis deŵoŶstƌated that staďilizatioŶ of Hifϭα ďut Ŷot of HifϮα iŶĐƌeases uƌiŶe 
pH, presumably either due to impaired renal pH regulation or the dilution of protons due to 
polyuria (Fig. 8.13F). Since blood pH is normal (see below), the second reason appears to be the 
most likely explanation.  Taken together, we hypothesize that the excess of urine production in 
Vhl-deficient mice exceeds the ability of the ureter to remove the urine, subsequently building 
up a back pressure on the kidney, causing a slow expansion of the renal pelvis and collecting 
system and finally leading to the development of hydronephrosis.  
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Fig. 8.13: Loss of Vhl causes Hif1a-dependent polyuria 
and decreased urine osmolality. (A-D) Metabolic 
parameters achieved by single housing of control (fl/fl) 
and gene-deficient mice (Δ/Δ) in metabolic cages, (E) Body 
weight of different cohorts, (F) Urine pH, (G) Urine 
osmolality. Age of mice: 2-3 months. Males and females, 
N=6. Analyses of Hif2afl/fl and Vhlfl/fl Hif2afl/fl mice were 
conducted by Michal Rajski.  
 
Since progressive hydronephrosis and polyuria can lead to glomerular sclerosis, interstitial 
inflammation and tubular atrophy (Takahashi, Chernavvsky et al. 2000, Ampawong, Klincomhum 
et al. 2012, Mesrobian and Mirza 2012), we next investigated the effect of Hifϭα dǇsƌegulatioŶ 
and subsequent occurrence of hydronephrosis and polyuria on kidney function. Analysis of blood 
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samples showed that loss of Vhl alone or together with a deletion of Hif1a or Hif2a does not alter 
kidney parameters such as blood creatinine, blood urea nitrogen (BUN) and electrolytes levels, 
indicating fully functional kidneys (Fig. 8.14A and B). Nevertheless, loss of Hif1a decreases blood 
phosphate concentration, whereas Hif2aΔ/Δ mice display elevated potassium levels. Importantly, 
despite observed Hif1a-dependent increase in urine pH (Fig. 8.13F), blood pH levels remain 
unchanged, indicating intact renal pH regulation.  
 
 
Fig. 8.14: VhlΔ/Δ mice display intact kidney function. (A) 
Blood parameters of transgenic control mice (fl/fl) and gene-
deficient mice (Δ/Δ), (B) Kidney function parameters. Age of 
mice: 2-3 months. Males and females, N=6. Analyses of 
Hif2afl/fl and Vhlfl/fl HIf2afl/fl mice were conducted by Michal 
Rajski.   
 
 
 
Although VhlΔ/Δ mice display a normal life span, we speculated that excessive urine production 
could harm the kidney over time, leading to kidney insufficiency in aged mice. We therefore 
repeated all metabolic experiments with ten to twelve month old mice. Surprisingly, we could 
not detect any significant changes in urine output or water consumption upon loss of Vhl (Fig. 
8.15A). Closer examination of Vhl-deficient animals revealed that only two out of four mice 
displaǇed hǇdƌoŶephƌosis, although all kidŶeǇs staiŶed positiǀelǇ foƌ Hifϭα aŶd HifϮα. TakiŶg oŶlǇ 
hydronephrotic animals in consideration, we could confirm the occurrence of polyuria and 
decreased osmolality in these mice. Blood analysis demonstrated a slight increase in blood urea 
nitrogen, but no change in creatinine or electrolyte levels was detected, indicating intact kidney 
function (Fig. 8.15B-C).  
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Fig. 8.15: Aged Vhl-deficient mice exhibit slight kidney insufficiency. (A) Metabolic parameters and urine 
analysis from control (Vhlfl/fl) and Vhl-deficient mice (VhlΔ/Δ) and mice with hydronephrosis, (B) Blood kidney 
function parameters: creatinine (Crea) and blood urea nitrogen (BUN), (C) Blood electrolyte levels. Mixed 
gender, N=4, Significant values are highlighted in red.   
 
Polyuria has been described as a symptom of several genetic disorders in humans. In the 
following sections we investigate whether similar mechanisms may contribute to the polyuria 
phenotype observed in Vhl-deficient mice. For instance, excess urine production is a common 
feature of nephrogenic diabetes insipidus (NDI) (Robertson 1988). NDI is characterized by an 
impaired renal response to arginine vasopressin (AVP) stimulation, consequently causing a failure 
in renal water reabsorption (Fujiwara et al. 1995). To investigate the urine concentration capacity 
of Vhl-deficient kidneys, we performed a water restriction test. After two days adaptation in the 
metabolic cage, we provided mice with food and water for 24 hours ad libitum (Fig. 8.16A). Next, 
we restricted the mice from drinking water, however providing them with an equal mix of water 
and food to attenuate the effect of dehydration. After 5.5 h of water restriction Vhl-deficient 
mice showed signs of dehydration and the experiment was aborted. Analysis of the urine 
demonstrated that VhlΔ/Δ mice produced 5 times more urine than control mice, whereas the urine 
concentration was 4x lower (Fig. 8.16B). During water restriction, urine of control mice was more 
diluted when compared to the 24 h measurement at day 1, probably due to lack of sleep during 
the measurement period. Interestingly, absence of drinking water was not compensated by 
increased wet food consumption in dehydrated mice (Fig. 8.16B). Kidney values returned to 
normal again when mice were provided with sufficient water (Fig. 8.16C). These results 
demonstrate that Vhl-deficient mice are not able to concentrate urine, even when challenged by 
water restriction. Immunofluorescent detection of renal AQP2 expression showed increased 
apical staining of the vasopressin-sensitive water channel AQP2 even in unchallenged mice, 
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suggesting functional vesicle trafficking and vasopressin stimulation (Fig 8.17). Taken together, 
these results indicate that loss of Vhl causes polyuria, which cannot be overcome by the 
activation of the AVP system.  
 
 
Fig. 8.16: Vhl-deficient mice fail to concentrate urine under water deprivation. Mice were housed in 
metabolic cages for three consecutive measurements. (A) Water ad libitum for 24 h (day 1), (B) Water 
restriction (day 2, mice provided with wet food for 5.5 h), (C) Water ad libitum for 24 h (day 3). 
Values are depicted for urine volume, urine osmolality and food intake. Age of mice: 2-3 months. 
Males and females, N=4. 
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Fig 8.17: Increased apical localization of Aqp2 
in collecting ducts of Vhl-deficient in 
unchallenged Vhl-deficient mice. 
Immunofluorescence staining of Aqp2 
expression in 14 day old kidneys. N=10. Scale 
bar = 25 µm. 
 
 
 
Examination of polyuric patients and the generation of several mouse models uncovered that 
mutations in renal aquaporins (Aqp) can cause polyuria and hydronephrosis (Ampawong et al. 
2012; Li et al. 2012), hence we analyzed the expression of aquaporins in the kidney. Gene 
expression analysis of kidneys of adult mice revealed decreased abundance of Aqp1, Aqp2, Aqp3 
and Aqp7 mRNA (Fig. 8.18A). Decreased renal protein levels of Aqp2 could be confirmed by 
Western blot analysis (Fig. 8.18C). Consistently, immunofluorescent staining exhibits less Aqp1 
and Aqp2 staining in the renal medulla of young VhlΔ/Δ kidneys when compared to controls (Fig. 
8.18B). Taken together, these results indicate that epithelial loss of Vhl reduces renal abundance 
of Aqp, potentially decreasing the rate of renal urine reabsorption and finally causing polyuria. 
However, studies show that Aqp expression in mice can also decrease in response to ureter 
obstruction induced by the mechanical clamping, mimicking the situation in obstructive 
hydronephrosis. Therefore, we cannot rule out the possibility that decreased Aqp expression in 
Vhl-deficient kidneys is rather a secondary effect than a cause (Li et al. 2012). 
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Fig. 8.18: Deletion of Vhl causes decreased expression of several aquaporins in the adult kidney. (A) Gene 
expression analysis, S12 was used as internal standard, N=6, (B) Immunofluorescence staining of Aqp1 and 
Aqp2 levels in 14 day old kidneys, N=10, Scale bar = 200 µm. (C) Protein expression level for Aqp2 in adult 
kidneys.  
 
Another possible cause of polyuria is an impaired function or expression of renal ion transporters 
(Takahashi et al. 2000). We therefore performed immunofluorescence staining on kidneys of 
young Vhl-deficient mice for specific renal ion transporters along the nephron, confirming the 
expression of transporters in the proximal tubules (NaPi-IIa, ATPV1B1), thick ascending limb of 
Henle (THP, NKCC2) and distal tubules (NCC). However, it remained unclear whether expression 
levels were changed upon loss of Vhl (Fig. 8.19A). Gene expression analysis in adult mice revealed 
decreased mRNA abundance of Slc34a1 (NaPi-II), Atp6v1b1 (ATPV1B1) and Slc26a4 (Pendrin, 
proximal tubules and cortical collecting ducts), but not of Umod (THP) and Slc12a1 (NKCC2) (Fig. 
8.19B). Consistently, Western blot analysis showed similar protein levels for NCC and NKCC2 in 
VhlΔ/Δ and control animals. However, decreased Slc34a1 transcript levels did not translate into 
decreased protein abundance for NaPi-IIa (Fig. 8.19 C).  
 
We did not expect any changes in proximal tubule gene expression since the Ksp.1.3 promoter is 
oŶlǇ ǀeƌǇ ǁeaklǇ eǆpƌessed iŶ the pƌoǆiŵal tuďules, ĐausiŶg Hifα staďilizatioŶ oŶlǇ iŶ ƌaƌe Đells iŶ 
this nephron segment. To further investigate the down regulation of Slc34a1 expression, we 
examined renal mRNA levels of two additional markers for proximal tubules, Slc5a1 (Sglt1) and 
Cubn (Cublin). Abundance of both markers was reduced. Given that the apparent reductions in 
markers of different tubule segments occur in both Vhl wild type and Vhl null nephron segments, 
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the most likely explanation is that there is progressive damage of the kidney caused by 
permanent hydronephrosis, leading to a moderate loss of nephrons in adult mice (Fig. 8.19A).  
 
Fig. 8.19: Decreased expression of renal ion transporters in upon loss of Vhl. (A) Immunofluorescence 
staining of depicted renal ion transporter abundance in kidneys of 14 days old mice, N=10, Scale bar = 200 
µm. (A) Gene expression analysis of transporter expression in adult kidneys: Slc34a1 (NaPi-II), Slc5a1 
(SGLT1), Cubn (Cublin), Umod (THP), Slc12a1 (NKCC2), Slc12a3 (NCC), Atp6v1b1 (ATPV1B1) and Slc26a4 
(Pendrin), S12 was used as internal standard, N=6, (C) Protein expression level in kidneys of adult mice.  
 
Next, we investigated whether changes in transporter expression impairs renal ion reabsorption. 
Urine analysis revealed that VhlΔ/Δ mice excrete 1.5- to 2-fold more salt within 24 h than control 
mice (Fig. 8.20A). However, it is likely that the total amount of salt excretion in VhlΔ/Δ mice is 
overestimated compared to wild type animals, as urine recovery from the metabolic cages is 
more efficient in mice with polyuria, since a smaller fraction of urine is lost on the wires and 
tubes.  A more precise method to assess deregulated renal reabsorption is the calculation of the 
fractional excretion rate (FE), which expresses the amount of salt excreted in the urine compared 
to the amount filtered by the glomeruli (Espinel 1976). We could not detect any difference in FE 
for sodium, potassium or calcium, indicating intact renal ion reabsorption (Fig. 8.20B). 
Considering the normal electrolytes levels in the blood of Vhl-deficient mice, these results argue 
against a failure of ion transporter expression or activity as a cause of polyuria. Nevertheless, we 
could only calculate the fractional excretion rate for 2 out of 6 animals since urine creatinine level 
was below detection range. Therefore, we cannot rule out the possibility that FE is changed in 
these mice.  
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Fig. 8.20: Loss of Vhl does not disturb renal ion reabsorption in mice.  Urine was collected from mice 
housed in metabolic cages. (A) Urine ion excretion within 24h, N=6 (B) Fractional excretion rate (FE) = 
([Na]urine/[Na]plasma) ([Cre]urine/[Cre]plasma) of depicted electrolytes, Creatinine levels were determined in  
Fig. 8.14B, N=2. Significant values are highlighted in red.  
 
Another possible mechanism for the development of hydronephrosis is a defect in kidney 
development. To investigate in which age the phenotype first occurs we analyzed the 
morphology of kidneys at different time points. Fetal kidneys dissected at day E18.5 as well as 
from newborns (day 1-7) display normal morphology. However, kidneys from mice aged 14 days 
display an expanded renal pelvis, indicating the development of hydronephrosis between day 7 
and 14 after birth (Fig. 8.21). In rodents, nephrogenesis continues after birth for another 10 to 
14 days, until nephron maturation and vascularization are completed (Song and Yosypiv 2012). 
Our results suggest that a defect in late renal development or the increase in renal work load 
cause polyuria and hydronephrosis in Vhl-deficient mice. 
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Fig. 8.21: Hydronephrosis in Vhl-deficient mice develops between postnatal day 7 and 14. Hematoxilin and 
Eosin (H&E) staining of cytoplasma (pink) and nuclei (blue) of kidney sections at depicted timepoints 
(Embryonal day 18.5, postnatal day P1-P14), N=2-10). Scale bar = 500 µm. 
 
Given that loss of Vhl causes impaired growth in pMEFs we hypothesized that deletion of Vhl in 
renal tubules might cause the cells to proliferate more slowly during development, presumably 
causing shorter renal nephrons, which might reduce the concentrating power of the kidney, 
leading to diluted urine. An established assay to address tissue proliferation is the 
immunohistochemical staining for Ki67, a protein that is expressed in all non-quiescent cells 
(Gerdes et al. 1984). Although Vhl-deficient kidneys exhibit more cells that are positive for Ki67 
staining, particularly in the inner medulla, closer examination indicated that many positive cells 
were peritubular cells and therefore not part of the renal nephron (Fig. 8.22). We therefore 
conducted further experiments to directly determine whether loss of Vhl alters tubular cell 
proliferation capacity.  
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Fig. 8.22: Vhl-deficient kidneys display increased staining for non-quiescent cells. Ki67 
immunohistochemical staining of kidney sections of 14 days old Vhl-deficient or corresponding control 
mice. Scale bars: overview 200 µm, cortical and medullar sections:  50 µm. N=10. 
 
A more direct method to assay for cell proliferation is the Bromodeoxyuridine (BrdU) 
incorporation assay. The nucleotide analog is injected into mice and incorporated in the DNA of 
proliferating cells during S-Phase, where it can be later visualized by antibody staining. We 
injected BrdU in 7 and 14 day old mice two hours prior to dissection. Co-staining of BrdU and 
specific markers of different nephron segments revealed that there were no differences between 
wild type and Vhl mutant kidneys in the percentage of proliferating cells in proximal tubules, in 
the thick ascending loops of Henle (TAL) and the collecting ducts (Fig. 8.23A-D).  
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Fig. 8.23: Loss of Vhl does not alter proliferation capacity of renal tubular cells at day 7 and 14. (A) BrdU 
was injected in neonatal mice 2 h prior to dissection at postnatal day 7 (B) Quantification from A. Data was 
collected from 500-1000 positive cells per tubular marker. N=3. (C) BrdU injection 48 h before dissection 
at day 12, (D) Quantification from 1500 – 2500 positive cells per marker from D. N=4. Co-staining of DAPI, 
BrdU, and NaPi-Iia (proximal tubules), THP (thick ascending limb of Henle) or AQP2 (collecting ducts). 
Respective colors are depicted in the figure. Scale bar = 50 µm. 
 
Next, we hypothesized that increased peritubular Ki67 staining in Vhl-deficient kidneys might be 
due to increased tissue vascularization, since Hifϭα ƌegulates the eǆpƌessioŶ of ǀasĐulaƌ epithelial 
growth factor (VEGF), a major molecular mediator of angiogenesis (Connolly et al. 1989). 
Therefore, we measured Vegf-a transcript levels in kidneys of transgenic mice, demonstrating 
that adult Vhl-deficient mice exhibit elevated renal Vegf-a expression (Fig. 8.24D). Whereas loss 
Hif1a clearly abrogates the Vhl-dependent increase in Vegf-a expression, Vhl/Hif2a-deficient 
mice display a clear but not significant increase of transcripts, possibly because of tissue loss due 
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to more severe hydronephrosis in these mice. Visualization of renal blood vessels by 
immunohistochemial staining for von Willebrand factor (vWF) and CD31, two established 
markers of endothelial cells, confirmed a Hif1a-dependent regulation of kidney vascularization 
(Fig. 8.24A-C). Whereas we could not detect any difference in vWF expression in the renal cortex, 
staďilizatioŶ of Hifϭα, ďut Ŷot of HifϮα ŵassiǀelǇ iŶĐƌeases the deŶsitǇ of eŶdothelial ǀessels iŶ 
the renal medulla (Fig. 8.24A, compare upper row for cortex and lower row for medulla). This 
observation could be confirmed by vWF and CD31 staining in young Vhl-deficient mice (Fig. 8.24B-
C). 
 
 
 
Fig. 8.24: Loss of Vhl indiuces a Hif1a-dependent increase in renal Vegf-a 
expression and kidney vascularization. (A) Immunohistochemical 
visualization of endothelial cell marker von Willebrand factor (vWF) in adult 
transgenic kidneys (cortical and medular sections), N=4-6. Scalebar 50 µm. 
(B) Staining of endothelial markers vWF and (C) CD31 in 14 day old Vhl-  
 deficient kidneys, N=10. Scale bars: overview 200 µm, cortical and   
   medullary section:  50 µm.  
 
As the kidney is important for the regulation of the hematopoietic system in adults, we next 
tested whether changes in renal vascularization have an impact on blood homeostasis. Under 
low oxygen levels renal interstitial fibroblasts secrete erythropoietin (EPO), thereby promoting 
the production of red blood cells (Wenger and Hoogewijs 2010). Although the precise mechanism 
of oxygen-sensing in the kidney is still controversial, it is known that EPO expression is controlled 
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ďǇ HifϮα. As shoǁŶ iŶ Fig. 8.25A, loss of Vhl causes a Hif1a-dependent decrease in hemoglobin 
concentration in adult mice. Diminished hematocrit levels could be confirmed by an independent 
method in VhlΔ/Δ and VhlΔ/ΔHif2a Δ/Δ animals (data not shown). Interestingly, the difference is more 
pronounced in males than in females (Fig. 8.25B). Reduced hemoglobin levels were also shown 
in aged VhlΔ/Δ mice (Fig. 8.25C). Given that the Ksp.1.3 promoter drives Cre expression only in 
epithelial but not in interstitial cells, decreased hemoglobin and hematocrit levels probably 
reflect a secondary adaption to Vhl deletion in the nephron due to increases in renal 
vascularization. However, changes in Epo gene expression could not be detected by RT-qPCR (Fig. 
8.25D) 
 
 
 
Fig. 8.25: Expression of Hif1a decreases hemoglobin and hematocrit levels. 
(A) Analysis of hemoglobin values of transgenic mice, N=6 (B) hematocrit level 
of Vhl-deficient females and males, (C) hemoglobin values of aged mice, N=4, 
8-12 months, (D) Gene expression analysis of Epo levels in Vhl-deficient 
kidneys. N=6.  
 
 
TakeŶ togetheƌ, ǁe shoǁed that staďilizatioŶ of Hifϭα iŶĐƌeases ƌeŶal ǀasĐulaƌizatioŶ iŶ Vhl-
deficient kidneys. We hypothesize that changes in medullary blood flow disrupts the osmotic 
gradient, essentially washing out salt from the renal interstitium and thereby preventing urinary 
concentration and urine reabsorption. The excess production of urine causes a back pressure on 
the kidney, leading to the expansion of the renal pelvis. To test this idea, we generated Vhl floxed 
mice harboring a tamoxifen-inducible Cre-recombinase (Ksp1.3-CreERT2; Vhlfl/fl) allowing the 
speĐifiĐ aĐtiǀatioŶ of Hifα iŶ the adult kidŶeǇ aŶd theƌeďǇ ĐiƌĐuŵǀeŶtiŶg poteŶtial effeĐts of Vhl 
deletioŶ duƌiŶg ƌeŶal deǀelopŵeŶt. μCT aŶalǇsis aŶd uƌiŶe aŶalǇsis did Ŷot shoǁ aŶǇ sigŶifiĐaŶt 
changes in urine production or kidney morphology in vivo more than six months after tamoxifen 
induction, contradicting to our hypothesis (Fig. 8.26A-D). However, immunohistochemical 
analysis of Hifα pƌoteiŶ eǆpƌessioŶ ƌeǀealed ǀeƌǇ feǁ Hifα positiǀe ŶuĐlei, iŶdiĐatiŶg loǁ 
D 
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recombination efficiency (Fig. 8.26E). It is therefore very likely that renal eǆpƌessioŶ of Hifϭα ǁas 
not sufficient to induce vascularization of the renal medulla and impair renal urine absorption.  
 
 
 
 
 
 
Fig. 8.26: Deletion of Vhl in adult mice does not change 
kidney function or morphology. Gene recombination 
was induced in Ksp-Cre-ERT2; Vhlfl/fl mice by tamoxifen at 
the age of eight weeks. (A) Food intake, Feces output, 
water intake and urine output achieved by housing of 
control (fl/fl) and gene-deficient mice (Δ/Δ) in metabolic 
cages, (B) Urine pH, (C) Hematocrit (D) H&E staining of 
kidŶeǇ seĐtioŶs, ;EͿ Hifα iŵŵuŶohistoĐheŵistƌǇ. N=ϰ. 
Age of mice: 2-3 months. Males and females, N=6. 
  
8.3.3 Discussion 
We previously published that epithelial deletion of Vhl causes bilateral hydronephrosis in mice, 
however the underlying mechanism remains unclear (Frew et al. 2008a). In this study, we aimed 
to identify the ethology of hydronephrosis in VhlΔ/Δ  mice and its consequence on kidney function. 
We could show that 24h urine production of VhlΔ/Δ mice is increased by a factor of 10 when 
compared to non-transgenic litter mates, accompanied by a massively reduced urine osmolality 
(Fig. 8.13A-B, G), pointing towards a non-obstructive cause for the formation of hydronephrosis. 
This notion is further supported by µCT-based visualization of the urogenital tract, which revealed 
no obvious delay in renal clearance of the contrast agent and an intact morphology of the ureter 
and the bladder in VhlΔ/Δ mice (Fig. 8.12A-B). These data demonstrate that Vhl deficient mice do 
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not suffer from any malformation or obstructions of the urogenital tract in contrast to several 
mouse models for hydronephrosis (Cain et al. 2011; Ekman et al. 2014). Consistently, 
hydronephrosis appears between postnatal day 10 and 14, further excluding an impairment of 
early renal development. Instead, excess urine production in Vhl-deficient mice most likely 
exceeds the ability of the ureter to remove the urine, subsequently building up pressure on the 
kidney and slowly expanding the renal pelvis and the collecting system. Consistently, µCT imaging 
revealed a weaker signal of the contrast agent from the cortex of VhlΔ/Δ  mice compared to Vhlfl/fl 
mice, presumably due to changes in urine flow or renal filtration rate.  
Non-obstructive hydronephrosis represents the majority of cases diagnosed in humans and 
several human disorders are associated with polyuria and subsequent formation of non-
obstructive hydronephrosis (Woodward and Frank 2002; Hebert 2003; Jin et al. 2009; Moon et 
al. 2009). To find the underlying cause of polyuria in Vhl-deficient mice we investigated several 
potential mechanisms that are known to impair renal water absorption in human disorders or 
corresponding mouse models. For instance, nephrogenic diabetes insipidus (NDI) is caused by a 
failure of the recruitment of the arginine vasopressin (AVP)-sensitive water transporters AQP2 to 
the apical membrane of collecting ducts, thereby impairing concentration of urine (Fujiwara et 
al. 1995). In VhlΔ/Δ mice, AQP2 staining is predominantly localized to the apical membrane of 
collecting ducts, indicating that these cells are sensitive to AVP stimulation (Fig 8.17). In clinics, 
NDI is commonly diagnosed by the lack of response to desmopressin injections, an AVP analogue 
(Fenske and Allolio 2012). Therefore, AVP-sensitivity in Vhl-deficient mice could be further 
confirmed by desmopressin injections. However, given that the recruitment of AQP2 to the cell 
membrane was already observed under unchallenged conditions, we speculate that VhlΔ/Δ mice 
already exhibit a maximal activation of the AVP system to prevent dehydration and thereby 
would not respond to an additional stimulation with desmopressin. This hypothesis also provides 
an explanation for the inability of Vhl-deficient mice to respond to water restriction despite 
functional AQP2 recruitment (Fig. 8.16B). Consequently, we would expect an even more 
pronounced polyuria when mice were treated with an AVP V2-receptor antagonist such as 
tolvapan (Yamamura et al. 1998).  
Not only the loss of function of AQP2 but also deletions of AQP1, 3 and 4 are associated with 
polyuria in mice (Yang et al. 2001; McDill et al. 2006; Ampawong et al. 2012). Examination of AQP 
gene expression in VhlΔ/Δ kidneys revealed a decreased abundance of AQP1, 2, 3 and 7, proposing 
that lower levels of water channels in VhlΔ/Δ mice might at least partially contribute to the 
phenotype (Fig. 8.18A,C). Together with the concomitant decrease in gene expression of different 
segment markers such as NaPi-IIa (proximal tubules), NCC (distal tubules) and Pendrin (proximal 
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tubules and cortical collecting ducts), these data indicate a general shortening of the renal 
nephron, presumably as a consequence of the expansion of the renal pelvis (Fig. 8.19B). This 
notion is supported by the antibody staining to label specific renal segments which are 
particularly reduced in the renal medulla (Fig. 8.18B and Fig. 8.19A). To circumvent any secondary 
effects of changes in renal morphology, we aim to further investigate the expression of renal 
transporters in neonatal mice. 
In the kidney the Na-K-ATPase consumes the majority of ATP produced in the cell to transport 
solutes though the membrane (Soltoff 1986). Given that loss of Vhl recues cellular ATP production 
in MEFs, it is appealing to speculate that low ATP levels in the renal epithelium might impair the 
maintenance of renal ion gradients, which are necessary for the efficient reabsorption of water. 
However, we found normal plasma levels for various electrolytes and similar renal reabsorption 
rates for sodium, potassium and calcium in Vhl-deficient mice compared to wild type mice, 
arguing against a problem with renal ion transport (Fig. 8.20B and Fig. 8.14A). Furthermore, VhlΔ/Δ 
mice exhibit normal blood levels of creatinine and blood urea nitrogen (BUN), further indicating 
unaffected kidney function. Consistently, aged mice exhibit a largely preserved renal function and 
histology (Fig. 8.15A-C). This is in strong contrast to most other published mouse models with 
polyuria, which suffer from kidney insufficiency and severe renal damage. For instance, mice 
suffering from NDI show progressive hydronephrosis, kidney insufficiency, growth retardation 
and reduced survival (Yang et al. 2001; McDill et al. 2006). Mouse models for Bartter syndrome, 
a group of genetic disorders caused by mutations in renal ion transporters, display an even more 
severe phenotype as they exhibit an imbalance in electrolytes in addition to the other symptoms 
(Takahashi et al. 2000; Yan et al. 2008). We therefore speculate that loss of pVhl in the renal 
epithelium provides a new model for non-obstructive hydronephrosis in mice.  
The investigation of Vhl/Hif1a and Vhl/Hif2a-deficient mice revealed that the deletion of Hif1a, 
but not Hif2a, fully restoƌes ƌeŶal ŵoƌphologǇ aŶd fuŶĐtioŶ, deŵoŶstƌatiŶg a Hifϭα depeŶdeŶt 
ŵeĐhaŶisŵ. Although the staďilizatioŶ of Hifϭα iŵpaiƌs Đell pƌolifeƌatioŶ in vitro (Fig. 8.2A) nwe 
did not detect any difference in the proliferation of tubular cells of VhlΔ/Δ mice compared to 
controls at day 7 and 14 (Fig. 8.23A-D). Similarly, initial experiments at day 14 also did not show 
any difference in apoptosis of tubular cells (data not shown). It remains to be tested whether 
increased apoptosis at an earlier time point might contribute to the formation of hydronephrosis.  
Loss of Vhl causes an elevated expression of Vegf-a in the kidney, which is abrogated by co-
deletion of Hif1a but not Hif2a (Fig. 8.24D). Vegf-a is a known Hif1a target gene and serves as 
major mediator of angiogenesis (Connolly et al. 1989). Staining for two independent endothelial 
cell markers confirmed that the increased renal abundance of Vegf-a mRNA is translated into an 
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increased vascularization of renal medulla of VhlΔ/Δ and VhlΔ/Hif2aΔ/Δ mice (Fig. 8.24A-C). Although 
it has earlier been shown that co-expression of Vegf and Hif1a induces the formation of mature 
vessels in the skin, we aim to confirm the functionality of the vasculature by the generation of 
vascular erosion casts of VhlΔ/Δ kidneys and investigate the architecture of the medullary 
capillaries by electron microscopy (Elson et al. 2001). In mice, the maturation of the renal 
vasculature continues until approximately 10 days after birth (Machura 2007). Therefore, we 
hypothesize that an increased medullary blood flow (MBF) in Vhl-deficient kidneys during this 
time period allows a more efficient absorption of salts from the renal interstitium, thereby 
disrupting the osmotic gradient which is the driving force for urine concentration. Therefore, the 
lower osmolality of the interstitium prevents efficient uptake of water in the renal tubules, 
resulting in an excess production of urine. This urine subsequently induces a back pressure on 
the kidney, causing an expansion of the renal pelvis. Several other studies confirm that renal 
blood flow is a central mediator of ion and water absorption in the kidney (Lu et al. 1992; Zou et 
al. 2001). For instance, selective infusion of vasodilators in the renal medulla of rats increases 
MBF, accompanied by diuresis and natriuresis (Mattson and Cowley 1993). In contrast, 
vasoconstrictors decreased MBF and lowered the excretion of water and sodium (Rajapakse and 
Mattson 2011). Therefore, it would be interesting to test whether local inhibition of Vegf-a and 
subsequent reduction of medullary capillary abundance restores normal urine output in VhlΔ/Δ 
mice. Intriguingly, hydronephrosis has not been reported in any other model of Vhl-deletion in 
the renal epithelium, although an increase in renal vasculature and Vegf production has also been 
observed in some cases (Ma et al. 2003; Rankin et al. 2006; Schley et al. 2011; Mathia et al. 2013; 
Pritchett et al. 2014). Given that these mice seem to exhibit a milder increase in renal 
vascularization compared to our mouse model it is feasible that a moderate increase in renal 
blood flow is not sufficient to disturb the renal osmotic gradient.  
Polyuria appears to have opposing effects on haematocrit levels in mice, probably depending on 
the underlying cause and the severity of the phenotype. Loss of Vhl lowers haemoglobin and 
haematocrit levels in mice, similar to mice suffering from prenatal hydronephrosis (Fig. 8.25A-C) 
(Wu et al. 2009). In contrast, polyuria in other mouse models has either no effect or even 
increases Hct levels, presumably due to dehydration (Takahashi et al. 2000; Schley et al. 2011). 
We speculate that in VhlΔ/Δ mice increased renal vascularization improves the oxygenation of the 
tissue, which in turn lowers renal Epo production and subsequently diminishes erythropoiesis. 
An alternative – or additional – explanation for reduced erythropoiesis could be a change in renal 
oxygen consumption. As shown in figure 8.4B, loss of Vhl in the nephron decreases mitochondrial 
respiration in the tissue due to Hif1a-dependent changes in cellular energy metabolism and 
mitochondrial activity. These changes possibly lead to a higher oxygen concentration in the tissue 
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leading to decreased renal Epo production. Although, Epo mRNA abundance did not change in 
the kidney, serum Epo levels remain to be tested (Fig. 8.25D).   
Increased renal vascularization might also provide an explanation for the milder effect of polyuria 
on kidney function compared to other mouse models with polyuria. Administration of VEGF has 
been shown to enhance capillary repair and improve renal function in renal disorders or after 
injury (Kim et al. 2000; Kang et al. 2001). Furthermore, diminished Vegf-a expression and capillary 
density in patients with diabetic nephropathy is associated with disease progression 
(Lindenmeyer et al. 2007). Therefore, we speculate that the pressure-induced expansion of the 
renal pelvis might damage the renal capillaries, promoting renal destruction. In contrast, 
increased VEGF expression in Vhl-deficient mice improves renal blood flow and thereby prevents 
kidney damage. Conversely, however, other studies report a deleterious role of VEGF 
overproduction in several renal pathologies or mouse models (Kang and Johnson 2003). It is likely 
that the expression of other Hifα taƌget geŶes also eǆeƌt ƌeŶopƌoteĐtiǀe effeĐts, foƌ iŶstaŶĐe ďǇ 
the decreased production of reactive oxygen species (ROS) or promoting cell survival (Haase 
2013). CoŶsisteŶtlǇ, geŶetiĐ aĐtiǀatioŶ of Hifα has ďeeŶ shoǁŶ to pƌoteĐt the kidŶeǇ duƌiŶg aĐute 
ischemic injuries (Manotham et al. 2005; Schley et al. 2011). 
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Tumours evolve through the accumulation of driver mutations and other genetic alterations that 
provide a proliferation and survival advantage to the cell.  Epidemiologic studies suggest that 
solid tumours require fiǀe to eight of these ͞ hits͟ foƌ theiƌ development (Armitage and Doll 1954). 
However, cells also gather a large number of passenger mutations over time that have no impact 
on tumour growth. During recent years, large whole genome profiling studies revealed a broad 
range of genetic alterations in established tumours such as ccRCC. However, it remains unclear 
which mutations or combinations of mutations are driving tumourigenesis, as well as in which 
order they have to occur. One aim of this thesis was to investigate the cooperative effects of four 
commonly mutated genes in ccRCC (Vhl, Hif1α, Hif2α and Trp53) and their relevance in tumour 
initiation. We found that loss of Hif1a in a Vhl/Trp53 negative background provides a proliferation 
advantage to cells in culture, however Hif1a is crucial for tumour initiation in vivo. To test whether 
loss of Hif1a is beneficial for tumour growth in already established lesions, it would be necessary 
to develop animal models that allow staggered inactivation of genes to model the physiological 
process of tumour evolution. One possibility would be to combine different inducible systems to 
mediate gene deletions in vivo, such as the Cre/LoxP and the Flp/FRT systems (Sauer and 
Henderson 1989; O'Gorman et al. 1991). However, since the generation of classical conditional 
mouse models is a time-consuming process that requires a lot of personnel and financial 
resources, new approaches are desirable. Our lab recently developed a promising lentiviral-based 
vector system called MuLE (Multiple Lentiviral expression), which allows the simultaneous 
introduction of multiple genetic alterations into mammalian cells in vivo and in vitro (Albers et al. 
2014, unpublished data). This system enables the generation of polycistronic lentiviruses which 
can be directly injected in the kidney or other organs of interest to induce gene overexpressions 
or deletions. At the same time, fluorescent (e.g. iRFP, tdTomato, mCherry) or enzymatic reporters 
(luciferase, lacZ) can be expressed to monitor tumour growth in vivo. For instance, it would be 
interesting to produce lentivirus particles expressing Cre recombinase, luciferase and an 
inducible shRNA targeting Hif1a (e.g. isopropyl-b-D-thio-galactoside (IPTG)-inducible shRNA, 
Sigma-Aldrich), inject them into the kidney of Vhlfl/flTrp53fl/fl mice and monitor the formation of 
renal lesions by in vivo imaging. Subsequently, the effect of loss of Hif1a on these lesions can be 
examined by the induction of the shRNA hairpin expression. Similarly, it would be possible to 
screen for other driver mutations or oncogenic gene combinations in vivo. Promising candidate 
genes would be the genes found in our gain of representation screen (Cdkn1a, Trp53, Trp63, Rb1 
and Rbl1) or PBRM1, BAP1, SETD2 and members of the TOR pathway as they have recently been 
shown to be commonly mutated in ccRCC (Sato et al. 2013). Importantly, due to the broad range 
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of cells that can be infected by lentiviruses the MuLE system allows targeting of not only epithelial 
cells but also other cell types that might contribute to tumour formations, such as renal stem 
cells (Funke et al. 2008; Axelson and Johansson 2013). 
To identify additional candidates, it would be interesting to repeat our gain of representation 
screen with an shRNA library targeting a larger number of commonly mutated genes or even the 
whole kinome or genome and additionally test cooperative effects in different backgrounds such 
as in Vhl/Trp53 or Vhl/Cdkn2a null PKCs. Additionally, it would be possible to use other gene 
libraries based on the RNA-guided CRISPR-Cas9 nuclease system that allows the generation of 
gene knockouts in mammalian cells (Ran et al. 2013). Another approach to identify potential 
driver mutations in ccRCC is the whole genome sequencing of micro-dissected lesions that arise 
in Vhl/Trp53 mice. Given that tumour growth is initiated almost a year after the deletion of Vhl 
and Trp53, we speculate that additional oncogenic alterations occur in the already tumour prone 
Vhl/Trp53 null epithelial cells to drive proliferation. Therefore, these mutations represent a key 
step in tumour evolution and might provide promising targets for future treatment approaches.  
The mouse models generated by the approaches discussed above would provide new insights 
into the molecular mechanisms underlying the formation of ccRCC that are necessary for the 
development of efficient treatments for advanced ccRCC. For instance, cell lines generated from 
lesions at different stages could be used to screen different chemical libraries for potential new 
drug targets. Eventually, new drugs could be validated in these mouse models by assessing 
tumour response over time by in vivo imaging. 
In the second part of this thesis we identified a new mechanism that leads to the formation of 
hydronephrosis in mice, which might help to understand so far unexplainable cases of 
hydronephrosis in humans and especially in children. The most intriguing finding was that in 
contrast to other polyuric mouse models, the kidneys of Vhl-deficient mice do not suffer from 
ƌeŶal iŶsuffiĐieŶĐǇ oƌ ƌeŶal daŵage. The fiŶdiŶg that staďilizatioŶ of Hifϭα eǆhiďits ƌeŶopƌoteĐtiǀe 
functions provides new perspectives for the treatment of patients suffering from hydronephrosis 
or chronic kidneys diseases. Therefore, it would be interesting to test whether the stabilization 
of Hifϭα Đould pƌeǀeŶt oƌ atteŶuate ƌeŶal daŵage also iŶ otheƌ ŵouse ŵodels ǁith polǇuƌia, foƌ 
instance by the phaƌŵaĐologiĐal aĐtiǀatioŶ of speĐifiĐ Hifϭα taƌgets iŶ the kidŶeǇ, suĐh as the 
stimulation of renal angiogenesis or by reducing ROS production. Of special interest could be the 
treatment of mice with a mutation in AQP2, a model for NDI (McDill et al. 2006). Although 
primary NDI is a rather rare syndrome, secondary NDI is a common complication of other genetic 
disoƌdeƌs ;e.g. Baƌtteƌ’s sǇŶdƌoŵeͿ oƌ as side effeĐt of phaƌŵaĐologiĐal iŶteƌǀeŶtioŶs ;e.g. lithiuŵ 
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treatment), thereby affecting a large number of patients worldwide (Bockenhauer and Bichet 
2013).  
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